<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04BB5F2A-93D1-42AE-808E-6E2EBC56CEFE">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-19 21:46:48 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E02A39E-C080-4AA5-A578-0D1CA3F8E035</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F2D0330-3621-43B4-80AB-6403B37102F4"/>
    <pav:createdOn>2014-03-19 21:46:48 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:409A0EC3-91FB-4548-B12E-4379B334BE2A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DF6DF930-17C8-4F3C-AEAB-082C82AC5C3B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:507CDC9F-5FEC-4C22-94E1-C7A68D90D932</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3ABF75A8-203E-4006-B94D-B6F3CF1F8F59"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CBCABF1-CAF5-41E9-9F27-45D414074DC8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25ACCDE7-5C34-4230-8A3E-0AFC060AB38A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4646369-10DC-4A89-8B69-EE04FF739B14"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:30D75678-130E-4213-AED7-CD08EE0D8776"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:584B8C60-BD97-4F4F-A18E-5CA90F22705B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0C086E4-1554-493D-B74C-4A9ADBA7551F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C4A5A7E-62C0-4D2C-8BB1-1F2C4357C0D5">
    <ao:body rdf:resource="urn:linkedspls:uuid:6EF7612E-50D2-45C2-BABB-AEE63C4D5E6F"/>
    <pav:createdOn>2014-03-23 23:45:23 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:44B18BB4-6F45-47F5-9C2C-BBFD4EC22E1F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:84DD1FD1-E42A-43C2-9D8E-6E9C37BD8261"/>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:12275577-E2AA-4E41-8B90-7B1D504B3D24"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E337973D-3AB5-4417-9730-A6C83967B719"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C906A701-35C0-4912-BDF3-E8D9DB230149"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1CE401E-2FEC-468E-8713-3215ED06F8B0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA336BCA-2F02-4355-9BAF-B08795A43735">
    <ao:body rdf:resource="urn:linkedspls:uuid:FDFC650A-05C3-4B52-A481-22A004FB3C2D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:639FE7BF-F5B9-4ADA-8B80-F40A39C4B192"/>
    <pav:previousVersion>urn:domeoserver:annotationset:089C517C-E8B9-4C53-AE05-4CE6156DA7F3</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A71CDBA-2F99-4E8A-9209-A304EB4E9DE4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE6F9C06-B63E-417E-ACD0-A59B0522D2D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2BF08F4-7DEA-497B-B8E6-824C0106DFAE"/>
    <pav:lastSavedOn>2014-03-23 23:32:43 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-23 23:32:56 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBD2DEAB-C642-434F-B4B6-E048FEEA0230">
    <ao:prefix>* 2, TPMT * 3A and TPMT * 3C . </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBD2DEAB-C642-434F-B4B6-E048FEEA0230"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-23 23:17:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>DBD2DEAB-C642-434F-B4B6-E048FEEA0230</domeo:uuid>
    <ao:exact>Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D5BBD6A-3F65-42E1-9D71-195831BDCF29">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E800EF0-7C91-462C-92A5-E6C7AE789A1E">
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3FFC358-5556-4074-B21C-8F1378BDF2FC">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-23 23:33:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:0DC53070-C143-49C8-9EF1-DE9255CB3490"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A2E3C16-B3B7-4460-ABBF-BF584D1BD2FE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <pav:lastSavedOn>2014-03-23 23:33:26 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DCD89AF2-B008-4C18-9D5A-D61B8AEE8758"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:509249B5-D139-492E-850E-CBD78DD46246"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4F7452CE-6182-4F3B-AD28-A04F1E3D4178"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E08C79A-1A2F-4A83-B5C1-DB65814982C6"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7A5BC104-9FE6-456C-A15B-911E5DC00024</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:03C78464-2B72-4920-AEEE-1547B53F8EC8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D1B480A-CB2B-4B21-98E0-4D42777E9274">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E08C79A-1A2F-4A83-B5C1-DB65814982C6">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFCA1EBA-DD22-42C9-BA19-79E64C5DF664">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E80D92C-B10C-4D27-B476-44F857D79289">
    <ao:body rdf:resource="urn:linkedspls:uuid:8063BEAE-A3F9-454B-8BEA-B26256A49C16"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E91D15EB-EAE8-44C3-8EC2-57447FB7B83B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D287D6D4-7617-42AE-A23C-D17A2C4C821B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B05CC1B2-9885-4107-96E6-FC90975D9704"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:A6313A70-75F3-4B32-8CA0-24D47A750641</pav:lineageUri>
    <pav:createdOn>2014-03-30 16:14:23 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:14AB543E-C90A-4554-8E9D-F595B526BA8C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:855C17ED-28CA-446A-9861-15DAAAB40AD4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:031E69A8-B922-4126-B5FA-55509D1E3847"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3ADA8F27-4AE2-420C-A0CC-4262BA73508E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-30 16:14:30 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23B63723-8C3A-4EF0-9623-C5B97D720696">
    <ao:body rdf:resource="urn:linkedspls:uuid:E1B62F6D-4BAD-43EC-AA3E-9CDB6BE4974F"/>
    <pav:previousVersion>urn:domeoserver:annotationset:AA262104-B74A-4CF7-8B58-106D00160F45</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B83BEC0-9ABD-44DA-8D0A-26030CBADF97"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0780ADEF-2787-4415-BDFB-28378B861EF8"/>
    <pav:lastSavedOn>2014-03-12 21:45:24 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C31AAB9-8A63-4151-AC01-1F670DA758B2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B734427-24D9-47B2-A3A5-D32C1ED4EE27"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-12 21:45:18 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD3F6ECA-B488-48BE-B3C6-EF23440E5B29"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:93BEAA66-B763-46A2-A2A1-F9EEB01B5E34"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:12DED5C6-4B22-4FD5-9B97-AA962F2D3E68"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0478553F-57CD-4BF9-B84A-398A94154BD7">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C198E9AB-C699-4935-B849-980310B35971">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN </ao:suffix>
    <pav:createdOn>2014-03-23 22:41:41 -0400</pav:createdOn>
    <domeo:uuid>C198E9AB-C699-4935-B849-980310B35971</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C198E9AB-C699-4935-B849-980310B35971"/>
    <ao:exact>Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1C739DE-B62B-4646-A3A9-45C59E793972">
    <ao:context rdf:resource="urn:domeoclient:uuid:657A455D-D51A-42C3-8D72-544D57C642B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7745A9CF-9213-4A18-B669-937847EED031"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B45AE9C-9219-48E0-AE3B-B0BDC28794C5"/>
    <pav:lastSavedOn>2014-03-23 23:10:57 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F286ADB-3EE6-4F26-93F8-8E4FF4BE424F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6608012D-FFE0-43FE-9B53-D87FF742DA15"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91C4E519-31DB-49C9-9076-973C0E6E730D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2522303D-646C-4F04-A668-FD71235C52A8"/>
    <pav:createdOn>2014-03-23 23:07:23 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:54C198C9-35F0-4172-9CD4-BE50467C98EC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:92E7F224-2A00-4CD6-B754-F6BEE04EB74A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:622DD8C0-8911-4956-9076-01A4DB828FA9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B825C73B-E13F-4830-BB16-F900606C110C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D89E8B4-53B7-4A25-98F9-DE460FCCE099">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6633FDEF-079F-449E-979D-584ECAF63B28">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F29FBDD8-75F6-46D5-A55F-79977C70936B">
    <ao:body rdf:resource="urn:linkedspls:uuid:71AC6136-3775-476F-B9DC-5EDE88B06C69"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:lastSavedOn>2014-03-12 22:18:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-12 22:18:19 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:647C844F-254B-48AF-A0AA-0ECEA2853B25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9188E11F-53F9-44AB-B734-844806C40192"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2083735-0499-4324-BD13-EBC3F7678685"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:85B0CEE8-721A-4417-B809-CE3F5FF624B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E451B2B0-3965-44FB-ACC3-9E1A4D507002"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E1566EE7-9321-4FAA-A247-AEF404479CA9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:29581B62-80D1-413A-B32F-0006250DAE69</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6DAFA0F-668E-4B88-8228-5995DD84BE45"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2911EA05-CD45-4AF8-ADA7-42A011B8C6D0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:84762B3A-A12D-46B4-98BE-4A75E451729E"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A99C9B5-B169-4344-83C9-569C10A54723">
    <dailymed:pharmgxDrug>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#undefined</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65FD2F35-26FC-4759-B2D5-2BCC06B7C081">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:0FA01E16-C6B6-48C5-921F-D8B7A4E05BD8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F87F4BB0-EE86-4394-AE4D-534856B88728"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D09554F-BACB-4D55-A9CF-D49A2D143AA6"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:68363CB8-A508-4F81-92E7-54EAB5EED24A"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:F1FF055A-9CBD-46F1-B19C-8C7FE6AF23A8</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N5cf05de4e75a49b7a97c9a4a82f928bd"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D83D91EF-C509-4483-8A0C-EF81CE93FF1E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6E04BC7-676E-4E8D-A02A-FA9131F20B55"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C854BE2C-87F1-404D-BA2F-B94E48A71323"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA8156F2-5244-4396-8F3D-6AFED5F1971C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA6592B8-4262-481A-B5B9-C5A70C98C18C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F29FBDD8-75F6-46D5-A55F-79977C70936B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:ADA3E8BB-56D3-4C42-B892-4E019DB266FE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6149E72F-574F-4685-9C85-0BB06DCDCE24"/>
    <pav:createdOn>2014-03-12 21:33:09 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3470463F-AC84-496A-A953-1CA3A5A7E3E8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:62264B8B-1D55-4BF4-81DD-C1160D65CF53"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:110BAA20-1916-4570-9902-EBECD0FBD556"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23B63723-8C3A-4EF0-9623-C5B97D720696"/>
    <pav:lastSavedOn>2014-03-12 22:41:26 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:1E38AAC3-F5C6-4B40-B0AF-398DC3604757"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:947CC237-B3E0-4A0E-9449-3B442B171949"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDAED30A-05DF-4A56-9F8E-6DD05281B994"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:48AEF407-1141-45D6-A133-68BBEB8BA436"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97FBC6B0-D570-4F49-906E-DEA55D7EF1E7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:8917C3BF-0373-4E59-A1A1-490C0745828E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B0D29515-01BF-47A0-9735-FF49CA55FCD7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BBB30D8-A408-4FAA-A670-0860D0EFFF2A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50E09AB9-8A5F-4184-ADE1-24562F02DEA6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E31860F8-637D-427E-9017-5FE78F4A4999"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D292616A-93A0-47B6-BB1A-767C4E112C50">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>SJS/TEN</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E202F594-3D04-48CD-BA4F-2C8F8B884E31">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E202F594-3D04-48CD-BA4F-2C8F8B884E31"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-23 23:35:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:513D3C96-1A62-4B0D-A959-66B184641C3E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7824CDF8-8A94-4F90-A1C9-6FFA824306EC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:66A3173F-9D44-4C07-BFB7-EDDA29107205"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:778B723C-CA30-4BEE-83B7-80E367D33A16"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:966C255B-C6F3-40EA-8BE9-1A329E583ED6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CCDC9ECA-E44E-42DF-AF7F-E5411C16DC2A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2014-03-23 22:49:49 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:779A75BC-3578-4F79-AFEC-3C7B452E7702"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E56DC4D7-A132-43DC-B9A3-0721BFA976B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FBB31F9-83CD-4E77-9073-35E840CAFCDF"/>
    <pav:createdOn>2014-03-23 22:50:00 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:E88042A5-290E-4A79-BB1B-56DA0D058DE0</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:647C844F-254B-48AF-A0AA-0ECEA2853B25">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1FD229B-39CC-4BAB-8D93-ECB99A7C3810">
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:6FF595AE-67B8-49FC-9B25-8FB5728E46BE</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B8DF96B-B8D5-4EA2-8036-D03F02D2355B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9340C2C9-029B-4D12-868B-3B2F725F4E9B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA0A95C1-EEC6-42D7-90A0-41E65CD09812"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D29BBA81-587C-4066-A8FA-C57C38744BA3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-31 00:34:18 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-31 00:34:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BB86830-58D0-4AF1-97C7-936B5CC2947C">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79C08A64-F2E5-491B-806A-9EE2DE8F4CA9">
    <ao:body rdf:resource="urn:linkedspls:uuid:0478553F-57CD-4BF9-B84A-398A94154BD7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-23 23:02:13 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3368ED4-4551-49AF-9456-74CC54095451"/>
    <pav:lastSavedOn>2014-03-23 23:02:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6A185B5-0BD2-45EC-B5F6-C88D9FCD80F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B3B18A4-18BF-446F-A539-E1646A195DD3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3A7D4FE-DF36-4022-AF9F-8E239EA508B5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE224250-659D-4170-907A-8D249877F63C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A55FEF1E-F69C-4CE2-8851-7519EEC89FC9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:712048D1-3527-4C08-89DB-15C5DC87C2C9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:894068D7-91D1-4766-9BF8-B43068180349"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9279AC9-3248-423F-A0F7-23743468123E">
    <poc:MedicalCondition>myselosuppression</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6ECDB828-24C6-4DDD-B929-485E9A52DDD6">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35CD8A1E-7116-4119-B4B4-608CF77B37A6">
    <pav:lineageUri>urn:domeoserver:annotation:A43E68FB-4A1E-4A81-8CC6-D8CB67A1437E</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE6FEF91-5B7E-47AA-9A22-83043D872EDF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E6CFABA-58A9-4A7D-A950-377ED1252E26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFA0A017-B8C1-4C7D-813C-C4D6120AE197"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0100E1EA-4B4A-49F7-8DB7-CE39B674E1E2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-23 23:46:11 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDB38A36-093D-4F67-A73F-6746B5B82DB4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:056EC7EF-FF16-45FE-B8BE-C0169E49A180"/>
    <pav:createdOn>2014-03-23 23:44:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:367D3C7E-D6C0-4E7A-BE56-534577280FC9">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B750723B-8ABA-4370-B0BF-790B249D2FBC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D0EA308-186E-432B-990C-BCA90E55B4A1">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA6592B8-4262-481A-B5B9-C5A70C98C18C">
    <ao:body rdf:resource="urn:linkedspls:uuid:D6AF04C1-87E4-4116-91BF-11F4F6030CA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61FE1D19-7E15-4A5C-908C-9EBCD9D99A5C"/>
    <pav:lastSavedOn>2014-03-12 22:06:01 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3469BC10-36DD-43F6-98E3-436A610D618E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:926949F0-4D54-4C5E-9A18-E99423856F63"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:47D3BDC7-54EA-4C97-B28C-679F896B082C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7749190C-16B5-4A6B-8A34-DAD000CE4E93"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:81EA2F09-6A53-4EFF-9949-C78B44593AF3"/>
    <pav:createdOn>2014-03-12 22:06:01 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4A1B9CE-C76A-44B2-AF56-2BFE56C2DC18"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0C27D59-B65D-48F1-942E-AEA6623FDFBF</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0046B31A-AA6E-4C31-963B-68B292488255"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8916D64D-9A5F-4535-9083-31E3FA43C897"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A4FA3B1C-42DD-49DE-8FEE-E3AEFEA96B17"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:6039215C-74FB-4B4C-845A-D5442D0E2B9C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA0FDD33-D8F4-4771-9448-E19607185A58"/>
    <pav:lastSavedOn>2014-03-30 16:14:30 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:BDBA966D-9E28-4E27-B8DD-F3B30B78F601"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N32a56b46cc00439eb00a6db6763e54d2"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9399A433-5F69-4574-89FF-94B33B649AA7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:525FFE40-C3DD-4DCE-9410-EB4BB0B9086B"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:A645B5F7-D32C-4B98-801D-BB2C2141AA18"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E80D92C-B10C-4D27-B476-44F857D79289"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA3584DB-7FB6-4C4A-8A05-C3B30CCFB807"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:B5461D9D-E998-4025-9E8C-80C191B5B386</pav:previousVersion>
    <pav:createdOn>2014-03-30 15:44:05 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:3EEF4361-1F03-4790-84B6-E77AD3291191"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C9078A1D-6FE8-4636-98B6-CCFC96919368"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8666948-E618-452C-916D-D358C78832A5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B04F057A-EDC6-4235-9597-9387E928EAF6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13D60084-C2CA-4281-8A14-CDAACECA1C15">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:99E19EBA-2314-448D-B468-DBF684B5F431"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BE0AF1F-C73C-419B-BE14-2F45AC1CBE10"/>
    <pav:lineageUri>urn:domeoserver:annotation:0858AD85-F2CC-45C0-A662-E0166C1B996B</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-30 18:20:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:732E44A6-1AD6-4925-924A-8FA8916B6596"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4471F54B-10EA-4DD4-9D15-14E1E1ADAE89"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A0C4ECF8-929C-4039-8663-1B6848A1DD92</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC5A6BAE-E33A-4DAA-953F-5CA43B787BAA"/>
    <pav:createdOn>2014-03-30 18:20:31 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9532CE4-55C5-4229-AA78-50E309154F1F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B207BA64-1079-494F-82CA-2013BF09FB15">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11528DE2-DE94-43C7-8452-6A9D7E2D8160">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FA01E16-C6B6-48C5-921F-D8B7A4E05BD8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:596830B0-09FF-4D47-81E1-C30F46C57CC3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF3DBB33-6743-470A-AD73-99B2C01CA103"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:71974930-ABE4-4AAF-B76A-38A31FBED2E6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-12 21:55:28 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F4325C3-D6AE-49C2-A3CD-57FB5A2A47F9"/>
    <pav:createdOn>2014-03-12 21:55:26 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7800986F-0069-4198-97DE-02885EFD2108"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1271CD7E-1C6E-419A-95F2-CF271CE93043"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F5ED18C-4FC6-4AFC-88A6-BE6BC0AA6707"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5765E10F-47F0-4599-9FE6-2D1424A0543F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC8E662A-ABD6-44F4-8617-BA9657A07052"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:60CBE11D-C700-4D9D-BFBF-B9FA3973A847"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E638CC1-F722-47BF-B15F-70520BF73577">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1C4E402-D98B-4D88-8F6A-CFDBA7A5CCF2">
    <ao:body rdf:resource="urn:linkedspls:uuid:16E10100-4A21-4770-AA2C-E5A9412A4481"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:92E7F224-2A00-4CD6-B754-F6BEE04EB74A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:16CF406B-F959-4BEA-876F-A137D25A0189"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC344602-11EB-48A6-9847-C09CE6D0D683"/>
    <pav:createdOn>2014-03-23 23:11:08 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-23 23:10:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C99B7E72-BC6C-429E-B54E-F58DBB5C3903"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0EE680F6-120C-4D1A-AA95-B8526EFA6669"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:230B9A52-40F3-4DBE-B7FE-69F5E7013A2E">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B2D9AFB-1E55-4290-97C8-5425C9D0EA9C">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:314471DE-2B37-4A15-8B3C-84C95D91A50B">
    <ao:body rdf:resource="urn:linkedspls:uuid:800112AC-0255-439F-B416-140D248BF624"/>
    <pav:createdOn>2014-03-23 22:45:59 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:85E4C3C7-BEB9-4F8E-8B4F-3BAA7ABE4A26"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DAE7E60-BCE3-4F51-9748-431EBCF580AE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C3EEBEE6-6B9C-46A0-91E4-F89539DF24B1</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B42F7EE8-0929-4231-B90D-91E0563C291A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CB7A7AB-C4A2-4F49-BA72-C2CBE6061EC7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4752C6A1-5248-4069-B5CF-E5B8F0B04D06"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2014-03-23 22:45:49 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B46B53F9-0BE4-4C9C-8A70-2FEA5F3F02C4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:35FFE6EE-42B3-44BE-A6E6-F07D9CE93269"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:04978929-DE66-4543-ACD5-7B06C546BCCB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C42BB9E4-CF12-408E-AEB2-A886AE85A7CA">
    <ao:body rdf:resource="urn:linkedspls:uuid:3BBC6797-38DC-43B1-A086-790306EBF4C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C74B2FC9-6FD9-4416-A0AB-831E857EF34B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCE5D888-0BB9-4CB9-B165-4E8330AF1E64"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:64AF5690-7FCA-4C04-9935-2C8B572F5DEF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D502499-2D3A-41B1-9772-8C50B6783449"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25711254-2936-42CF-8E9B-834EFEC9FA6A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D888B39-8219-47F7-BE88-94F5A9DA568B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDF86D06-5D86-4A24-B735-9654D43B539A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:697B832E-6266-4E57-B97F-F121F7A0C776</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 21:14:31 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 21:14:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92D0CD32-DE29-479A-A1C9-B52F7D9F53EA">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E62D8698-C5C9-4D90-A8ED-34B080403274">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2011113-168F-413E-A516-232113392669"/>
    <pav:createdOn>2014-03-31 00:35:10 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7F5105A-3886-4258-9032-560D597BDDD1"/>
    <pav:lineageUri>urn:domeoserver:annotation:63D7E2FE-3955-457C-B316-DC74C8D3F26E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A99DF291-EDBE-490B-A5F9-A395B25AB97A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-31 00:35:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EAC3FD4-72CA-479D-8CE2-0D4BA6860CC2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA8156F2-5244-4396-8F3D-6AFED5F1971C">
    <ao:body rdf:resource="urn:linkedspls:uuid:6712D315-6869-4682-800A-3C54AE6CE580"/>
    <pav:lastSavedOn>2014-03-12 22:28:00 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D2ADC9F-5FA0-475A-A7D6-CA40D4B71B43"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A590560-5F09-4C20-88AA-6C37FDA9CEB3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CFB3F30B-1F3A-43FB-A6C1-5B6FD0303A06</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:820E9B4E-C9A0-4B1E-A63D-CAB5BD6E8691"/>
    <pav:createdOn>2014-03-12 22:27:51 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">19</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E606700-7100-4166-9850-4DAA22B9170F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3103F10-24BD-4D8C-B3B5-A693D0B395FB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0D0AE67-798F-44E4-912C-76914E545D16"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6BE8321D-0997-4EBE-A6D4-A87074093194"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:038EA0E2-9123-4C73-842E-B160587A9E0E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0983FC55-C47C-4D5F-BE45-9D49629AFEEA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFF70BB3-364D-4F0B-A650-39E747F36865"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA969F93-82C6-4BC4-9D7F-6BA7DAD7F314">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:639FE7BF-F5B9-4ADA-8B80-F40A39C4B192">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AA812FA-86B4-499B-9C15-A224E825A081">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48AEF407-1141-45D6-A133-68BBEB8BA436">
    <ao:context rdf:resource="urn:domeoclient:uuid:97733B39-74C0-4763-BD19-277B9D97F256"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:505ACF44-87C5-4A9E-A457-1E648D3969E3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E2562EB-1990-4603-8CBA-E233D59F47BA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E621FAB-09A7-4956-8D74-C2450B69C405"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E05813B-89A7-429B-A67F-CAE10B8149F8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:43F28EB4-8E1D-4DBB-8693-0D88EE7B9300"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6CED629E-0761-4325-A5C4-AAFDBEE6A710"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC1272E7-640E-45DA-A208-1C0F5533FFC6"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:6ECDB828-24C6-4DDD-B929-485E9A52DDD6"/>
    <pav:lastSavedOn>2014-03-12 22:31:53 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-12 22:31:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD1C395B-BC74-4666-B457-C81B056E575B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51C872FB-17DE-49AD-BFAB-019691A408C4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7AFAE69F-4682-4945-967E-D2DE95A1534E">
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:42854403-5CD5-4B14-9405-3A37D9EE0956"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896f4a03000b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:E1FD229B-39CC-4BAB-8D93-ECB99A7C3810"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23EEEBBF-C789-4C60-A3B7-7E63732C1737"/>
    <pav:lastSavedOn>2014-04-05 16:22:57 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:07B6B442-94F5-4541-9416-C726A6D785E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:559C0644-E2DD-42B2-BF02-24D4DE62CE3A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:31A84B76-BC19-4DF9-B0D8-7A1F05A7A87E"/>
    <pav:createdOn>2014-03-31 00:19:41 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N08198c39193c48d9819b908b5b96f973"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F8BA75B7-A26A-4146-B457-FB4621BD472A</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2B342CE-A4D1-41BE-9933-46296B0395B4"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:E62D8698-C5C9-4D90-A8ED-34B080403274"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:AFBD0952-D063-43AB-9BF8-D2765EC1F590"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:02887C31-D6D3-434D-BD70-6EA1045D8380"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2BFB965F-D1FB-464F-A5BF-ADAD50C57F44"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14933636-B0CC-4A29-8AA3-41C40B4481A2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B6B7344-5691-4A81-8539-22F0C0A83EE0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7B29D0C-ED74-476B-8E7E-E1D984A5E594"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26D588F3-41B7-406F-9D1E-4CE861B2BA80">
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26D588F3-41B7-406F-9D1E-4CE861B2BA80"/>
    <pav:createdOn>2014-03-30 17:39:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F22C0613-35DF-4B66-A47A-566B2B48B41A">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FDACEDBD-903F-4BA1-A8EA-8AAE590D4A8C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FDACEDBD-903F-4BA1-A8EA-8AAE590D4A8C"/>
    <ao:exact>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. Codeine is</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-30 16:11:15 -0400</pav:createdOn>
    <domeo:uuid>FDACEDBD-903F-4BA1-A8EA-8AAE590D4A8C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8520BBB1-AF07-4CAB-B7DB-2EC4B2E1CC35">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A609886-63C1-426A-BFD6-032F958C4B56">
    <pav:createdOn>2014-03-23 23:29:24 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:11843243-10AF-4894-A86B-8D585A2A2B67"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D125F8E7-C030-4B95-B62E-367B39C38C58"/>
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:B10C623B-444A-446E-BFEA-8DCAAA802BDC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0DB6A8E5-8AF8-46DB-8D54-04CDAC4DEC6A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:17A4C600-0031-4012-AC56-A12A2EC258C8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB6B0982-F98C-42A9-AAB9-766CDE733D95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:93EF6BAD-056C-4AE1-AEAB-83F8040CD49B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:30BE3ABA-AD95-49DC-8199-00F65722669C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76C9AA35-16FB-4216-80E4-34C205BF2995">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <rdfs:label>Not Important</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BCD3AE0-64B6-4372-9403-23F27B18E996">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4FA3B1C-42DD-49DE-8FEE-E3AEFEA96B17">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5C95A2D-96A3-4024-AD0F-11F538C15CD8"/>
    <pav:lastSavedOn>2014-03-30 15:55:04 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:76789731-3A9C-45DA-8843-ACA94A8CDA18"/>
    <pav:createdOn>2014-03-30 15:54:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5818DE13-3D3B-4F6D-841B-8FD479A495D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F53E35E3-55A2-423B-9B4C-B9508AFC99AC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E49C4E92-4E66-4887-B5CF-60F7720D7FE1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:325318F6-72EA-4720-B75B-B2013DE40BEF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A058F7BB-F374-4988-B9F1-7F5FB7E17CA4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:22BCAD85-AE77-42CE-B446-28BA6073EDFE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:F30D2122-A10A-4D9A-A79E-A76E12AC103B</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:874FE843-B328-45C6-959C-688057D5F5E8">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A2F4A09-0FB6-4B10-9A69-E9E9564CE151">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C1C0886-FD85-4371-9C72-461C413402CE">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F50F3EA8-35FA-4DF6-808B-BBC3A56A1811">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B05CC1B2-9885-4107-96E6-FC90975D9704">
    <domeo:uuid>B05CC1B2-9885-4107-96E6-FC90975D9704</domeo:uuid>
    <ao:exact>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies.</ao:exact>
    <pav:createdOn>2014-03-30 16:14:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B05CC1B2-9885-4107-96E6-FC90975D9704"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the babys doctor i</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59C749C8-D274-434F-8D8F-DA9AA137D145">
    <ao:body rdf:resource="urn:linkedspls:uuid:4481C6C3-A003-4310-83C4-78ED8D2C6ED0"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F493414B-D92A-459B-B786-4BF1B6C58AA5"/>
    <pav:lineageUri>urn:domeoserver:annotation:08B6E3CB-4696-4A13-954C-A13F2B1DBAA9</pav:lineageUri>
    <pav:createdOn>2014-03-30 18:52:38 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCE71DF7-E5F4-4726-9940-F33B07BD0A1C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:814BD1AC-4D7A-4640-90C8-1F37E6BB61A1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:023D8024-462D-4E33-B5D1-A599FEB0376B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-30 18:52:36 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4E4359B-4749-458A-AB5D-8D03E52607D3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36FF63A1-6460-4B1A-A2D9-525C2C315572">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7340A685-CA3B-4B42-A93A-04B52AEF36BA">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F27F321-E430-44D2-BD86-E4AC9391E8CC">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>TPMT</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6381DBC8-2BCD-4A87-8A3E-ED495B64A90D">
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2060FE1-CE01-4220-9066-FE2797535BAF">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DBE0930-2A4F-48F6-88C1-ABB516E50FD3">
    <ao:context rdf:resource="urn:domeoclient:uuid:C198E9AB-C699-4935-B849-980310B35971"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-23 22:41:41 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6CB6229E-1E4F-449B-9554-9CF228CE9897"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0B42AA7-C70C-40D0-B08D-41CA42B819D7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE9927F6-AE99-446B-95B8-07EBC7CE39A6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EA69C57-425F-4C6A-A016-1DC64995AF70"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:98E71879-EAF3-4F1F-B27E-D89A543CE935"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:325798BD-BBA0-4B40-83B0-547B7A7DFDBE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B722120-A648-45D2-8707-ABFCA189B87C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:C422DF83-8D3C-4A42-9612-1687B223FA33</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9E774F4-F3D4-46B4-A2B8-7A9CA74C6062"/>
    <pav:lastSavedOn>2014-03-23 22:41:30 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5321686D-5BAA-47E9-94CC-2F4421BE28DF">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE6FEF91-5B7E-47AA-9A22-83043D872EDF">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08198c39193c48d9819b908b5b96f973">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93BEAA66-B763-46A2-A2A1-F9EEB01B5E34">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:432063DE-A571-440A-AA80-F18D387C0132">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA9FC34F-025B-4188-82DA-19C543F71A47">
    <ao:body rdf:resource="urn:linkedspls:uuid:BEA71254-98F5-430C-B5BC-9F722A5A594C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B13D7D9-D25A-422E-BBEC-6D86F9228FA7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B2D9AFB-1E55-4290-97C8-5425C9D0EA9C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8113A6AE-3066-4BEF-AFBE-1BC701359D66"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DA93A1E4-36C9-441D-8720-A70DDE11E21E"/>
    <pav:createdOn>2014-03-27 10:48:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E90D65C1-2D90-48F7-9F22-70B93BC1BBEC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A679644A-F8A1-484E-8BC6-7B55AE5CC0A1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65D466AC-CFAD-42DB-8841-919234A8DB12">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:462C8AA1-56F4-4DAB-8833-C9765CCE4D3D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E044358C-165B-40CB-89A0-451D9E54F532">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DFEB95E-DD01-44E1-8ADC-DCCF6BF6A2D9">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DFEB95E-DD01-44E1-8ADC-DCCF6BF6A2D9"/>
    <pav:createdOn>2014-03-30 15:50:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <domeo:uuid>5DFEB95E-DD01-44E1-8ADC-DCCF6BF6A2D9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC0640DB-FB00-4BDD-AE6C-B8C4665F8968">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7">
    <ao:item rdf:resource="urn:domeoclient:uuid:66D7C086-7928-4B5D-954E-B3217D35FAF6"/>
    <permissions:permissions rdf:nodeID="N9a600db1ef4941f2ad8b74f810249d03"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:AA360234-8BC9-4CB9-B0C9-E9837DBAAA6D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:265CC00D-F595-4EF9-B049-EA1960301F77"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:314471DE-2B37-4A15-8B3C-84C95D91A50B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:90A210BD-44AD-4192-8EA3-6DE8C2F0EB78"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59BD910C-F161-48C6-BB1A-B4A60C6E079D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A4706763-84D4-43F5-96BA-E025F8E6EDEA"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:4C5962FF-8379-40E9-BDCA-8FA37B7E199E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:513D3C96-1A62-4B0D-A959-66B184641C3E"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-03-23 22:29:37 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C60D5D7-2E52-45C3-8A00-163F2A7D531D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6DBE0930-2A4F-48F6-88C1-ABB516E50FD3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:593B5370-4D8E-4880-8D93-1BB22CB9F410"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-23 22:52:06 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:31F8CF1D-4612-49C3-9B90-22F8C94E3AFD"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CDD04241-2616-4993-9D6E-CCC8CFEE9C87"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2111CD3C-3FD0-4344-B5AF-AD0BD3B2AC9C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70BC4B0E-82EA-47B3-A28E-AF1FAD151F53">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B920AF2-7BF3-4E68-9D5C-E77BF320A814">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56536B9A-84C4-4A27-90A6-03485E201A84">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACODYNAMICS (43681-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACODYNAMICS (43681-6)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71D67F9F-93B0-44B8-87EA-8BF46A9F22ED">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C5962FF-8379-40E9-BDCA-8FA37B7E199E">
    <ao:body rdf:resource="urn:linkedspls:uuid:BCC01BA5-BC38-4C8E-8A10-B71D0F2CCE0D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7BC1D389-097A-4877-A043-17B3182BFF4D"/>
    <pav:createdOn>2014-03-23 22:31:23 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-23 22:37:51 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:615BB512-75A0-45EA-8EE6-A4981CECD19F</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F13C1A69-A91E-4FAD-A0F4-29E21F534116"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1FC3F08-335A-4C3E-81BB-1FA0D55B9E8D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAC06436-AA19-4AB6-8952-DF7587C971B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:924B8909-93F2-4542-8FD8-2A36899A0332"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E8DC4674-2320-4409-B0D8-80574FE4D66F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C333F1D9-97BA-4943-B6A4-EDC801B9FC30"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:45828442-025F-4C91-A745-C58F6962BAEC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:432063DE-A571-440A-AA80-F18D387C0132"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:853AA7C6-D5E6-40A7-9819-3720DC95B9A5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D03700A4-6A4A-4C41-8274-1F303C3D24DC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B3B18A4-18BF-446F-A539-E1646A195DD3">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA0FDD33-D8F4-4771-9448-E19607185A58">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-30 16:00:34 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:78B326FB-1570-440D-9549-80A14728E602</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:6BA9C8A7-269D-49A9-BAB3-9246EC99DFF9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:00B8B39E-D7C5-4DC8-950A-7B67FA0171AE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BE8E2286-2A71-43A3-A53C-2F9835FEF5AF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:327F2CB7-9F4F-49C5-B05B-25C6D0858C0E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CB06ACB-5BFB-4E3A-898F-1B3BDA2301D8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:50FCA320-0FA1-4278-B518-EAF4ABD62C7D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:017280A0-99C6-46F9-8B6C-C579803765C3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B54D42D-68A4-49AC-AFBC-DD5C963A0C4E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <pav:createdOn>2014-03-30 16:00:32 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F14941D9-42B6-4F02-A883-60667BCFB049">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D6140C9-D1CB-4E50-A9D2-625B729A2697">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-23 23:12:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BBBBF84B-D648-45F7-91D4-1DB7AE1F1287"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C77F7743-813E-4911-A277-682D202D697E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC57096C-F1CB-4169-A6CA-581ADCC88DDC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C7B3200-92DC-4018-B01F-3D7003545229"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-23 23:12:33 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B75A80E7-D1B1-4675-A99F-65B4AA23350D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D9929863-E760-48E3-A8BF-570404973E36</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFB0DC70-84A8-4F8B-988B-092175789619">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>intermediate-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:265CC00D-F595-4EF9-B049-EA1960301F77">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:59DCB93D-9954-485F-9FB4-DC47DF63B223"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1367DE2A-8326-49F9-9C1B-9E60BAA5BC9C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D3B7A81-7AE3-4DF2-BACC-AD2DEF793887"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD94466E-133D-49B6-84D9-2999ABE63B60"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACB34FAD-130F-4098-A257-AAF380F439AE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:00444CA6-D837-4477-A2D4-5617C563063B"/>
    <pav:createdOn>2014-03-23 22:44:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3DD63283-6E9C-4C02-BB6E-48F818B62B72"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-23 22:44:07 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:65FB3165-FC32-4A42-97C1-59BC0C3C5328"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:02939556-27CA-4F68-9D5D-AD83C90C45E9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:11744178-0F7D-4E39-A32E-C9BA4CC843FD</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53D495A8-73C1-422D-BA5E-47262BF97FCF">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:140F95D7-520F-4FE8-8676-14E2838BBFCB">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ADE52F4-318E-44C9-99D6-9D2C7E611B16">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2ADE52F4-318E-44C9-99D6-9D2C7E611B16"/>
    <ao:suffix>One additional randomized stud</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive ( 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-30 19:15:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC344602-11EB-48A6-9847-C09CE6D0D683">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4FD1B0A7-4F88-4827-A668-6660B0ED0041">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:110BAA20-1916-4570-9902-EBECD0FBD556">
    <pav:lastSavedOn>2014-03-12 22:31:53 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:505ACF44-87C5-4A9E-A457-1E648D3969E3</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:92643846-E3C1-46F6-B186-CCB55C1B5A44"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B34B234-D3FC-4A9D-BC3F-E3741CD17BFF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0F8DDB5-4732-4500-BE21-9C24A2605993"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:322DB33A-5FE9-4090-A4F4-AF7D9F0CA353"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11528DE2-DE94-43C7-8452-6A9D7E2D8160"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:342996DB-0B46-46AE-856E-13F12749AC4F"/>
    <pav:createdOn>2014-03-12 22:30:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D5191E4-B58F-46C9-80FB-160449152002"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A9F4CD4-84CA-4390-BDAA-C971766A10C7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8A9F4CD4-84CA-4390-BDAA-C971766A10C7</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>have a liver that does not function properly. </ao:prefix>
    <pav:createdOn>2014-03-12 22:41:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A9F4CD4-84CA-4390-BDAA-C971766A10C7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFBD0952-D063-43AB-9BF8-D2765EC1F590">
    <ao:body rdf:resource="urn:linkedspls:uuid:7B9C0CF5-77BE-4351-8F4A-A03C7B56C33F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C784F374-FD0D-4D58-A395-967BCF50D373"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 00:33:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-31 00:34:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6FF595AE-67B8-49FC-9B25-8FB5728E46BE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD0D46AB-DE27-42C2-ACF0-73D745788024"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:42A10237-EFE8-4EC6-A4A2-556FF94B3F74"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E337973D-3AB5-4417-9730-A6C83967B719">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31DC1B4F-76E2-4BC0-9182-51D21B0D5162">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD0D46AB-DE27-42C2-ACF0-73D745788024">
    <ao:exact>If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD0D46AB-DE27-42C2-ACF0-73D745788024"/>
    <ao:prefix>dose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>Modify this dose based on consideration of patient-specific clinical factors. Consider lower initiation doses for elderly and/or debilitated patients (see</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-03-31 00:33:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95FA75B7-64CD-4C54-B2C8-AA44C46A9CAA">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F7452CE-6182-4F3B-AD28-A04F1E3D4178">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F7452CE-6182-4F3B-AD28-A04F1E3D4178"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>[see Clinical Pharmacology (12.5)]. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-23 23:33:39 -0400</pav:createdOn>
    <ao:suffix>[see Dosage and Administration (2.3)].</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0426F8ED-42A6-4A44-BDCC-67E4950F2DA9">
    <ao:body rdf:resource="urn:linkedspls:uuid:0ECFFFE1-DE79-4A75-B67B-2CD319736302"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A70664FC-EBAB-470A-AA3D-10BCA0659962"/>
    <pav:lastSavedOn>2014-03-23 23:04:39 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D889F217-7A08-41F3-8B7E-82C351066273"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:A52EC55E-04AD-4D91-96C6-FF619EFE1F63</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:221669A0-18A5-46A0-9458-FB576AD02A6F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:35508F03-F68C-4B43-9DE6-7B4270D23882"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:31DC1B4F-76E2-4BC0-9182-51D21B0D5162"/>
    <pav:createdOn>2014-03-23 23:01:15 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CAE67D43-C092-4EBE-BD4D-9A853CC00E7E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC407C66-02BC-455C-AC8B-6EA78DFD9A99"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:79F24D76-A347-4895-92BE-138F73B4EAAB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A8353EA-D986-4749-965E-C06DCDDF7470">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E03F6009-DF79-416C-A5F1-75843AA2E3B2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>extensive-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B93707F8-986F-49A4-BBBF-08E080D9E77E">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:01FB3168-8BEC-4DAE-A25A-B2B8E8A779C1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C79CC1E-2262-4D1D-B150-4B843A861447"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B577C610-90E5-496F-AFCD-90598AB6CCF3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 00:15:17 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD16448A-D811-436E-90B4-1314DD5EE343"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7219E9E0-E71A-4856-B7FE-4BA931BE73F9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD3208DF-A261-472A-97A1-78D5792AFDDC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-31 00:15:17 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49DA41E8-787F-4D3B-883E-602BCAF1DB44">
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-12 22:08:10 -0400</pav:createdOn>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>49DA41E8-787F-4D3B-883E-602BCAF1DB44</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49DA41E8-787F-4D3B-883E-602BCAF1DB44"/>
    <ao:suffix>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1C60409-C8C7-44AA-8133-8F301C08AA9B">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>A1C60409-C8C7-44AA-8133-8F301C08AA9B</domeo:uuid>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <pav:createdOn>2014-03-12 21:56:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A1C60409-C8C7-44AA-8133-8F301C08AA9B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A590560-5F09-4C20-88AA-6C37FDA9CEB3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A590560-5F09-4C20-88AA-6C37FDA9CEB3"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-12 22:27:51 -0400</pav:createdOn>
    <domeo:uuid>2A590560-5F09-4C20-88AA-6C37FDA9CEB3</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EF7612E-50D2-45C2-BABB-AEE63C4D5E6F">
    <poc:MedicalCondition>Whites, blacks, Chinese</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:966C255B-C6F3-40EA-8BE9-1A329E583ED6">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>SJS/TEN</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED4B82E9-E292-450B-A991-D9621C0D1014">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Complete pretreatment blood c</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED4B82E9-E292-450B-A991-D9621C0D1014"/>
    <ao:exact>For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.</ao:exact>
    <pav:createdOn>2014-03-23 22:51:43 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>ED4B82E9-E292-450B-A991-D9621C0D1014</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F41D755-4E94-4D5C-A672-02D01CB36548">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (see </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F41D755-4E94-4D5C-A672-02D01CB36548"/>
    <pav:createdOn>2014-03-19 21:39:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>2F41D755-4E94-4D5C-A672-02D01CB36548</domeo:uuid>
    <ao:exact>Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6AF04C1-87E4-4116-91BF-11F4F6030CA8">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F671322-2525-43C8-9B26-C79453DE29B6">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ADVERSE REACTIONS (34084-4)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>ADVERSE REACTIONS (34084-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACD2969B-8D6B-4A29-9EC3-48B6736E87D0">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E202F594-3D04-48CD-BA4F-2C8F8B884E31"/>
    <pav:previousVersion>urn:domeoserver:annotationset:30E4F75F-9B60-4C9C-B09B-410A9866C59B</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:728B9736-5D26-48F1-B198-1DD51E41BB71"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:65F86DB9-8AEF-4DDE-AAD6-DF5051A1356B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:createdOn>2014-03-23 23:35:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:53A6904A-3840-4524-8624-532F21C25931"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8698A1B7-D44D-4F9E-9D3F-F4A88684C6C0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E7C51BE-DB9E-45B0-A83F-979A2530FB35"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FC0B24C-0927-405A-98EB-573A96DC7704"/>
    <pav:lastSavedOn>2014-03-23 23:34:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E38AAC3-F5C6-4B40-B0AF-398DC3604757">
    <ao:body rdf:resource="urn:linkedspls:uuid:C1CEFAAB-BD67-4A5F-AB7E-BF622512BA4B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E29FBF60-B04B-4872-AA08-C0BCC8B7901A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B67DAA9-B75E-47ED-850C-E7B7B5151835"/>
    <pav:previousVersion>urn:domeoserver:annotationset:08A7DA34-EFDF-4398-8C12-7738B80E09B6</pav:previousVersion>
    <pav:lastSavedOn>2014-03-12 22:10:31 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-12 22:10:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2011359-388E-4380-BCF3-97B5FC3103EE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E02EFB6-71FF-4583-8B43-2091A457FE15"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B79CFED-63F4-434E-BB20-DA216CBE3868"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2060FE1-CE01-4220-9066-FE2797535BAF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BEEC5F59-A1BC-45C4-AA1D-B9A4A43E1829"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:017280A0-99C6-46F9-8B6C-C579803765C3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <ao:exact>Children with obstructive sleep apnea who are treated with codeine for post-tonsillectomy and/or adenoidectomy pain may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy</ao:exact>
    <domeo:uuid>017280A0-99C6-46F9-8B6C-C579803765C3</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:017280A0-99C6-46F9-8B6C-C579803765C3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-30 16:00:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A34EEA7E-FCD2-44D2-BF2E-A9CFF14C19E5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45828442-025F-4C91-A745-C58F6962BAEC">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <pav:createdOn>2014-03-23 22:35:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45828442-025F-4C91-A745-C58F6962BAEC"/>
    <ao:prefix> HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER. </ao:prefix>
    <ao:exact>STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA. PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (SEE </ao:suffix>
    <domeo:uuid>45828442-025F-4C91-A745-C58F6962BAEC</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6CB0A9BB-7F0A-482A-8B4B-42634B86C50F">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66D7C086-7928-4B5D-954E-B3217D35FAF6">
    <ao:body rdf:resource="urn:linkedspls:uuid:ACAD811C-4E46-4519-B0D8-606D5F6E45E1"/>
    <pav:lastSavedOn>2014-03-23 22:47:54 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DA4418B-534C-4739-93B9-E421A573D716"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D0DAC74-2517-4016-97B3-A56B660D5725"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:F9A4516F-DC88-4D08-8896-02EA06077140</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D745F3D-0A70-48CD-B388-ED820D7DD5CA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-23 22:47:47 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:956437DF-3040-4FE4-990F-462538B4EE77"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DBF5359-44E3-40EA-B543-3B6B08596B90"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A679644A-F8A1-484E-8BC6-7B55AE5CC0A1">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5340A9AF-11F2-4CD7-84F3-934979AA244F">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC5D1B2B-D3EE-4500-A332-7FC5314DBA35">
    <pav:createdOn>2014-03-27 10:43:16 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC5D1B2B-D3EE-4500-A332-7FC5314DBA35"/>
    <ao:suffix> Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patients CYP2C19 genotype. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>DC5D1B2B-D3EE-4500-A332-7FC5314DBA35</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> A patient with poor metabolizer status will possess two loss-of-function alleles as defined above.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDBA966D-9E28-4E27-B8DD-F3B30B78F601">
    <ao:body rdf:resource="urn:linkedspls:uuid:6FAEA418-D722-4F9C-AB66-27E29D27DDA1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:75A65ADE-85F0-4522-B219-2A71DB7F79AA"/>
    <pav:createdOn>2014-03-30 15:50:07 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDDCF997-4E90-4BAB-96B3-1800DB72CC1B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DFEB95E-DD01-44E1-8ADC-DCCF6BF6A2D9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CF0F812-D573-4458-B746-93D5FB6FB58A"/>
    <pav:lastSavedOn>2014-03-30 15:50:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA969F93-82C6-4BC4-9D7F-6BA7DAD7F314"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:629DFB8D-1FA8-4A7C-A8C9-9E0A563E11E0</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:487D741C-420F-44BB-9630-7C87B524E7AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7723C32-768B-4638-901B-E74A49E52861"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9FBDE84B-D209-4C9C-AE48-E382792E8CDC">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27F36E87-A6D6-454B-87BF-3847C7285417">
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B10C623B-444A-446E-BFEA-8DCAAA802BDC">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AFFDC03-AB18-40B8-A042-A4208215CC79">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DC57130-9078-45DC-8648-E08EC6F16DF9">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:328E2B84-107D-4F11-A6DB-189C90C32279">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2FDE0DE-8423-4B35-8195-4D7DEEF0F0D9">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2FDE0DE-8423-4B35-8195-4D7DEEF0F0D9"/>
    <pav:createdOn>2014-03-31 00:32:29 -0400</pav:createdOn>
    <ao:suffix>             </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45687D3F-E24B-49FC-B327-9E0B9FA5F7FD">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49303763-0A27-4198-8435-198F906965B4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49303763-0A27-4198-8435-198F906965B4"/>
    <domeo:uuid>49303763-0A27-4198-8435-198F906965B4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity.</ao:exact>
    <pav:createdOn>2014-03-23 23:21:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EF444C06-3764-44E8-80EF-32D87C985247">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31A84B76-BC19-4DF9-B0D8-7A1F05A7A87E">
    <pav:lastSavedOn>2014-03-31 00:32:52 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-31 00:32:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF777739-AFDC-43F3-A8B4-F58883D3836C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2FDE0DE-8423-4B35-8195-4D7DEEF0F0D9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:42437394-462B-4271-AE87-64417F6EAE21"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CB024805-C764-4CAB-A3C5-9E86E954C589</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:144D94CA-9F40-4777-95A3-126DC102C392"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86A3FEC8-D81B-4945-950B-9E2C08CD931D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:86A3FEC8-D81B-4945-950B-9E2C08CD931D"/>
    <pav:createdOn>2014-03-30 19:10:30 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estro</ao:suffix>
    <ao:prefix>ase-free survival following radical or modified radical mastectomy in postmenopausal women or women 50 years of age or older with surgically curable breast cancer with positive axillary nodes when tamoxifen was added to adjuvant cytotoxic chemotherapy.</ao:prefix>
    <ao:exact> In the Hubay study, tamoxifen was added to "low-dose" CMF (cyclophosphamide, methotrexate and fluorouracil). In the NSABP B-09 study, tamoxifen was added to melphalan [L-phenylalanine mustard (P)] and fluorouracil (F).\nIn the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC7C08EC-8538-4471-8419-AE9E97EFCD25">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8847DA0-3F9B-4A8A-98ED-9F32320D88D0">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression; death</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE35C3A5-5DB2-48D3-AC71-93E15D63676F">
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:811326F2-B052-4339-B2A4-7E07C5F6BDA7</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AEEB11F-4145-4D8F-A2B3-49B277C35CEB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67174681-E929-4017-8CEA-D035FD185AD8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B598A4B-160C-48F3-950B-69199D699A4B"/>
    <pav:createdOn>2014-03-23 23:17:54 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DBD2DEAB-C642-434F-B4B6-E048FEEA0230"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFB0DC70-84A8-4F8B-988B-092175789619"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-03-23 23:17:43 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5BCDA22-18D9-4AEF-B125-2C0DD7CE8B07"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B983002D-38CF-4BC3-B83E-A78D93513DCF">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:859A1B0C-EE52-46EC-A344-DDE415AE9B2A">
    <ao:body rdf:resource="urn:linkedspls:uuid:5B45D566-CE7D-4694-A437-6E3D96D515B1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E0F40D1-0681-4E31-A154-A349D19F785F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0776293A-51D5-419D-A524-F0AAA3469606"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D74ABAC-F090-4CCA-8C7C-5882C46A78A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2BAF4E44-2796-4A98-950E-2691827FB70A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:21638A6C-1F7D-4711-AD17-5BFE4DF3E7D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9279AC9-3248-423F-A0F7-23743468123E"/>
    <pav:createdOn>2014-03-23 23:19:53 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D487E03E-FBE5-48CA-8E8D-0492E7FAAF7B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2014-03-23 23:19:42 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A675A1D-6B1D-49EA-94BE-14512EB4982D"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0860B54B-07C7-44BC-80C1-92248FC59677</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5ECC1800-345F-4B85-8BE5-42F193C69B17">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C74B2FC9-6FD9-4416-A0AB-831E857EF34B">
    <poc:Comment>Does this talk about decreased metabolism?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCE5D888-0BB9-4CB9-B165-4E8330AF1E64">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C20E67B-BD95-43D5-98A0-35BB633C3603">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A0C7A7A-526A-4A51-8215-34375C6081DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6149E72F-574F-4685-9C85-0BB06DCDCE24">
    <ao:body rdf:resource="urn:linkedspls:uuid:2A151C25-9DF8-418D-880E-B704B7080CF1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2A998E7D-05F7-4DE6-9042-CB3547BA730B</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A1C60409-C8C7-44AA-8133-8F301C08AA9B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1119FEA-97C4-46A8-8C03-E94BAA75260C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <pav:lastSavedOn>2014-03-12 21:56:48 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:63A402CC-99C0-4136-897E-D434A9435D54"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:028BEA0F-5181-40C4-B72A-2DA8A8A5F295"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:66F355EE-B965-48F1-AE6C-8E01F41D7441"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6ABFEC3E-104C-469D-8076-BC792935BE05"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E31F02A2-601C-4204-8531-9D8B22416115"/>
    <pav:createdOn>2014-03-12 21:56:47 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B35E3F7-0914-4B29-9A4C-BA58ACE3C94F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC81A21A-A912-4A81-AC63-D62096E41180">
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A151C25-9DF8-418D-880E-B704B7080CF1">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:079F5CD8-3BB2-4045-9A1E-1DF4747FC68E">
    <ao:body rdf:resource="urn:linkedspls:uuid:86F0DEEF-AECB-4A2B-9784-1289EC654904"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A023B61-8BF0-43F9-AC73-B3F3AACE9784"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E4749D1-8233-43A6-B67D-7D9D39797DA6"/>
    <pav:lastSavedOn>2014-03-30 19:07:25 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CC74423-C0E9-4DA9-A5A6-8EFCF5514E1D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-30 19:07:28 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC866D4C-5D87-4ABE-A303-39F7C8E5E609"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A29B2292-66F3-431E-B77C-85D21F2D4906</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A0C4ECF8-929C-4039-8663-1B6848A1DD92">
    <ao:item rdf:resource="urn:domeoclient:uuid:6B9180E1-F8B0-4E45-9431-DA082CEAE63A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13D60084-C2CA-4281-8A14-CDAACECA1C15"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4044E64A-8017-4A78-94AF-9D6EE3A236EC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:934614EA-0207-42E0-98F1-ABFCA4CAD577"/>
    <permissions:permissions rdf:nodeID="N87406ff91d6c40b6814c0871287a9d1b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ADB89221-52E2-4386-BB2B-D5A0899DD249</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <pav:createdOn>2014-03-30 17:38:15 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-03-30 18:20:30 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:64546233-B868-4ACC-AC6C-C4F2AE55600A</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8134D575-2067-4D29-8061-A8454F825C41">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02887C31-D6D3-434D-BD70-6EA1045D8380">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4302688-2092-43B3-AA5A-F2E208E250B8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 00:25:15 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F127DBE1-AECA-4EBD-BEDC-B186666741B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A4274FC-E56A-4CF3-B0FF-E69ACB8124B2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:58E59978-E28B-4ADC-AB4A-815E87565940"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FF7B2C15-5977-4CEB-9F55-237750EBC451</pav:previousVersion>
    <pav:createdOn>2014-03-31 00:25:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:92D4A343-08E7-4448-A01D-A251DBEB233A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:462C8AA1-56F4-4DAB-8833-C9765CCE4D3D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:233FFCA4-79E4-4AA0-9997-EA925716C00F">
    <pav:createdOn>2014-03-12 22:14:10 -0400</pav:createdOn>
    <domeo:uuid>233FFCA4-79E4-4AA0-9997-EA925716C00F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:233FFCA4-79E4-4AA0-9997-EA925716C00F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C053A17B-E965-4611-8801-CE34B44C4A53">
    <ao:body rdf:resource="urn:linkedspls:uuid:E9119275-9781-4891-958D-4E1119AC2D53"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FFBE9EA-D06B-4805-AE3D-07508CB6A6E8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F671322-2525-43C8-9B26-C79453DE29B6"/>
    <pav:lastSavedOn>2014-03-23 23:20:42 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-23 23:20:53 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B8B1579-F063-42F2-83B1-1268058A3F61"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B983002D-38CF-4BC3-B83E-A78D93513DCF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CC578C1-8D8B-4EBA-BCC3-B93A98F483BA"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:0DF98F75-1AE6-44DA-9F46-3AEC880A7F3C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:073CA47F-0E8A-49C4-8B1B-4B1421F12204"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7A2A1B6-9673-4D0D-BD4C-7CCAAA827E9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E006CD1-9815-4CA6-9949-9A348002811A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6926D7F6-0DBB-42DA-9D4B-AC61BC569818">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6926D7F6-0DBB-42DA-9D4B-AC61BC569818"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>An INR of greater than 4.0 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding. Initial Dosage </ao:prefix>
    <ao:exact>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. The maintenance dose needed to achieve a target PT/INR is influenced by:\n\nClinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n\nGenetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <pav:createdOn>2014-03-31 00:32:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32DAA48B-4A57-46BC-8BDC-9B52724608C9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:862BA8E2-37C8-4442-9603-AF9D3E73A392"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:1542ACA9-1D1E-49E6-B097-CF4566C10FDF</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <pav:createdOn>2014-03-30 18:48:32 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:73CEE899-B4FE-4B39-803A-935FCD5883EE"/>
    <pav:lastSavedOn>2014-03-30 18:48:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:D14B40C5-DF6B-4C2E-B170-55DA97B006B7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:825D221F-84AE-4802-8BAA-915BD1F28A23"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B8D5267-546E-4B1C-996F-79A3E274839F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C876A45-36EC-4087-B118-733AC8A16CEB"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:645AED79-5CBB-4E96-8DA2-B1A4AA27F666">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:645AED79-5CBB-4E96-8DA2-B1A4AA27F666"/>
    <domeo:uuid>645AED79-5CBB-4E96-8DA2-B1A4AA27F666</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.</ao:exact>
    <ao:suffix> Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy </ao:suffix>
    <pav:createdOn>2014-03-30 16:08:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N32a56b46cc00439eb00a6db6763e54d2">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23EEEBBF-C789-4C60-A3B7-7E63732C1737">
    <ao:body rdf:resource="urn:linkedspls:uuid:58308C5D-40B5-427A-AB8A-BA9B5B593ADB"/>
    <pav:createdOn>2014-03-31 00:34:50 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:7707750B-0FB9-4270-B073-56E803B5E65A</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:FAD2B35D-163E-419F-B2EA-3B98760DD126"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:96435AEC-7FC7-476B-8A38-A7462924508D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E631115D-5EAA-48D8-9AA3-A5F848BFD320"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-31 00:35:11 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BEEC5F59-A1BC-45C4-AA1D-B9A4A43E1829">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BEEC5F59-A1BC-45C4-AA1D-B9A4A43E1829"/>
    <ao:exact>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>BEEC5F59-A1BC-45C4-AA1D-B9A4A43E1829</domeo:uuid>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:prefix>
    <pav:createdOn>2014-03-12 22:10:32 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CA5E417-AACD-4925-AAAC-931EF45B4F20">
    <rdfs:label>biomarker-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37D95355-AE9B-4454-B6DA-543CBD117D4D">
    <ao:body rdf:resource="urn:linkedspls:uuid:612A62A5-59E8-4743-BC2F-967D50CC053E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:84867383-9368-46A9-9A8E-AB299B322C1A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EFC360B-1844-43A3-BB0A-FEF39DA7EFE7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1513CF2D-BE0A-4DBC-926F-9A403B338997"/>
    <pav:lastSavedOn>2014-03-27 11:01:12 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:47128789-FCF6-4A13-BD01-045AC06E8E25</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E2A610A-170B-41FB-BA91-E698967BC64A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5FB5B5E9-2EE1-41B9-8BD4-EEC50CA96DC2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-27 11:01:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9CD3126-8090-4633-9ECE-F56AEF0EA72C">
    <ao:suffix>Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F9CD3126-8090-4633-9ECE-F56AEF0EA72C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-30 17:39:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:559C0644-E2DD-42B2-BF02-24D4DE62CE3A">
    <ao:body rdf:resource="urn:linkedspls:uuid:4A99C9B5-B169-4344-83C9-569C10A54723"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B395286B-8734-4537-8BAB-C4E0411685BF"/>
    <pav:lineageUri>urn:domeoserver:annotation:0DFDAAC7-9912-49E6-9270-5DA522B2B8DB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8402D442-202E-4308-83DA-528F027BA84F"/>
    <pav:lastSavedOn>2014-04-05 16:22:57 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:75B308C9-1DDE-449E-8E9E-9A1D909FC01B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-04-05 16:21:19 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896f4a03000b</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0FE9DAA-0CDC-4433-B1B9-90523C7903AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03C78464-2B72-4920-AEEE-1547B53F8EC8">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:382A47B7-4A81-4B30-AA8B-336379E0CDE7">
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9532CE4-55C5-4229-AA78-50E309154F1F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0681808-212F-45BC-89C8-9FAD4B49D085">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>cardiovascular events</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8127B3F2-12E4-41FD-A44F-23E96492B97D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50FCA320-0FA1-4278-B518-EAF4ABD62C7D">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4E02A39E-C080-4AA5-A578-0D1CA3F8E035">
    <pav:lineageUri>urn:domeoserver:annotationset:F2769DF7-E160-499E-96B2-621EF845FFF4</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-03-19 21:46:48 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:9F356450-F6E7-47E1-AF36-6C857B581FF1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:3AED7289-DC1B-4DFE-AB67-2390269F61BB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:04BB5F2A-93D1-42AE-808E-6E2EBC56CEFE"/>
    <permissions:permissions rdf:nodeID="Nfbfd21b005b449c08af9a1039d798a59"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B6BA9EB6-51EF-4B25-965F-6BC9D9FBAAA1</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:40F75024-E7AC-413A-8DAA-8A8A38A4225A"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:annotatesResource>
    <pav:createdOn>2014-03-19 21:34:40 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:07FDA881-59A1-4A9C-B083-8876ED57FB6E"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23941657-F490-4BE0-91D1-AE3ED266023A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E771F08C-9FFD-46F7-A737-B4CBE8363F40">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42854403-5CD5-4B14-9405-3A37D9EE0956">
    <pav:lastSavedOn>2014-03-31 00:29:06 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 00:28:41 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F6F0822-6A5A-4AC9-8FEA-E9146DEE6263"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E161E15B-D38D-44C8-ACA1-A5798BD2EA2E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DE2C2604-3963-4B66-85FC-ECCB3E6CC129</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B969AF7-491B-4B0D-9C3C-CADF2A313CEB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E638CC1-F722-47BF-B15F-70520BF73577"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2C36B0D-AE49-4B08-9DB2-0C4C2EFBF661"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4E4359B-4749-458A-AB5D-8D03E52607D3">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BBB30D8-A408-4FAA-A670-0860D0EFFF2A">
    <ao:body rdf:resource="urn:linkedspls:uuid:5076A504-0ADA-4FB6-9A8C-C39E2F39CCFA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8127B3F2-12E4-41FD-A44F-23E96492B97D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:827F9942-3331-45EB-9926-839068646646"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:25F0AFFB-94CB-4A46-8F7D-6F6DA4D0DEDE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCCD39CC-CBBF-41CA-A3BA-13FD22957DFA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:707ABC3D-A9E5-4004-B1F7-238987AA4362"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8034D576-6C73-431B-A638-082604606DA2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1892C00C-A379-423B-B6F7-998BB17E8BF8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-12 21:38:56 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DC57130-9078-45DC-8648-E08EC6F16DF9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:45687D3F-E24B-49FC-B327-9E0B9FA5F7FD"/>
    <pav:createdOn>2014-03-12 21:38:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1A8EF4C-454A-426E-B0CA-0DC18B700519">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE62DC47-0407-46E9-AD48-C8D8731F9ED0">
    <ao:body rdf:resource="urn:linkedspls:uuid:27F36E87-A6D6-454B-87BF-3847C7285417"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6256E00A-866C-41E6-9488-8C4ADF17DA5C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7340A685-CA3B-4B42-A93A-04B52AEF36BA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B9D876B-77F0-4C9C-BBF2-78234A602501"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-23 23:31:43 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:19B45175-B8B0-4F2E-9136-FC581D805D41"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3CE981CD-25A4-4DF6-8BE1-AFCBA04E8DED"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6D157E6-3137-4D39-B501-F383DFA78760"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACA8B7C8-6D94-4D8A-BF8A-A073813D2766"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D5BBD6A-3F65-42E1-9D71-195831BDCF29"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <pav:createdOn>2014-03-23 23:31:55 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:3E2FDBB4-FF77-4B35-846E-BEDD1D72656B</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E570B0B-90CB-4961-B047-C8CFCC31CDA7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0E0164C-8980-4DE9-9AE5-405F1EC1814E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFDB1CD0-A702-437D-BB2D-A0330E09AE2C">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:593B5370-4D8E-4880-8D93-1BB22CB9F410">
    <ao:body rdf:resource="urn:linkedspls:uuid:54759A36-9D88-494F-97D4-22934D98FD8D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:78C90864-4E29-4906-BC74-34F20D2DA609"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2330D2BD-123B-4912-9434-994B9B2130A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E6D74F4-3F5A-4577-9DB5-CED65F294C32"/>
    <pav:lastSavedOn>2014-03-23 22:41:30 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C422DF83-8D3C-4A42-9612-1687B223FA33</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:4DF1D6D8-CC00-4DF0-A2B6-58A4CBFA43C0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A31F3D83-D048-48ED-A4C9-D15A08D4343E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F3441C2-BD86-41C3-AB30-0F4CB875B7D8"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-23 22:40:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A5332FE-1CBC-4E26-967A-140B04F91DEC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B7A276BC-A450-4F86-80C4-A47F9BCCBD77">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:947CC237-B3E0-4A0E-9449-3B442B171949">
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-12 22:14:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:F6E36B24-41D1-4D79-939D-C2980E1C990A</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D1B480A-CB2B-4B21-98E0-4D42777E9274"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E800EF0-7C91-462C-92A5-E6C7AE789A1E"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:233FFCA4-79E4-4AA0-9997-EA925716C00F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:73E4519B-2533-4ABC-8D6D-8845FDFDD8E2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91D95F95-D5B8-4F3B-B4C6-75E40EEE4729"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E3A21EB-16F3-4394-ADCB-0315A9A1C175"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:0792F9C9-EBCB-4031-ACFC-1FF971EE10E4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-12 22:14:10 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:71D67F9F-93B0-44B8-87EA-8BF46A9F22ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7072A2DC-FEF0-4529-B45B-9BEF5809CB79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C6DC8650-91F3-4632-8727-D3702E6B25F2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11C43678-953B-4C80-9226-BCC784B9F599">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5FAF8F9F-E409-4CEF-8FFE-2F0A2A378AB3">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8917C3BF-0373-4E59-A1A1-490C0745828E">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2741CCC4-F6D7-4860-8B71-DD0FFEC41C0E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:836CED62-9EDB-4171-95B0-A8D6A56CC603"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E88C833-D05A-4612-BC1C-98D7EFFAACC2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B5D3547B-1926-4032-B1B4-D244E5751B68"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C53092CA-7954-46B8-992B-8188F5CAA62B"/>
    <pav:previousVersion>urn:domeoclient:uuid:52DCAC6B-C0BD-403C-856B-1E52D1F1135A</pav:previousVersion>
    <pav:lastSavedOn>2014-03-12 21:42:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6106A6E9-79C1-44CE-AAEC-CAAE36C6BA3E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD96F51C-16B3-42CF-BA16-5B1F8902E978"/>
    <pav:createdOn>2014-03-12 21:42:18 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5465EEC0-AD58-4E26-9CC8-356C82C92824"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B46B53F9-0BE4-4C9C-8A70-2FEA5F3F02C4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>SJS/TEN</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B7581C63-37AC-4C31-86A3-3267C1CCA382">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46A89E4B-DAD7-4E42-9430-78F606D8ABB0">
    <poc:Comment>"do not change" options need to be put?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91C4E519-31DB-49C9-9076-973C0E6E730D">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0FE9DAA-0CDC-4433-B1B9-90523C7903AE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0FE9DAA-0CDC-4433-B1B9-90523C7903AE"/>
    <ao:prefix>ties. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis ofacid residues in the proteins which are essential for biological activity. Mechanism of Action </ao:prefix>
    <domeo:uuid>F0FE9DAA-0CDC-4433-B1B9-90523C7903AE</domeo:uuid>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-05 16:21:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41A71A0C-A82C-4EFF-9B09-08E35BBCD8E7">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B45AE9C-9219-48E0-AE3B-B0BDC28794C5">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>intermediate-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6993653-7F33-4D45-B257-69BD5E9F8038">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0D29515-01BF-47A0-9735-FF49CA55FCD7">
    <pav:createdOn>2014-03-12 22:08:10 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B41029D6-0D67-4DFE-9744-03770E1121DD"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1354CA00-8626-4D27-8326-A2115FF610EF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:D3435BDA-FC2A-457B-94D1-49687251A701</pav:previousVersion>
    <pav:lastSavedOn>2014-03-12 22:08:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBFDF08D-E03B-4205-BEDA-04814DFD1C32"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:49DA41E8-787F-4D3B-883E-602BCAF1DB44"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DF8F2D5-9C7B-4654-933C-DEB4E366EC30"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8134D575-2067-4D29-8061-A8454F825C41"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:690C2D4F-B411-4529-857F-F8A02AD2E01A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D5191E4-B58F-46C9-80FB-160449152002">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DA9E5B9-EDE7-4A17-841B-40E479F483CE">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:65FD2F35-26FC-4759-B2D5-2BCC06B7C081"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:136F1ABC-4E79-49AD-8691-BDD39E57A389"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:622A02C5-0E24-4013-9FFC-6450617B8505</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:889BA00F-054D-43A9-871A-0E03E9B68495"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCE2EA7A-666F-49EC-8919-CA5EC19D8D44"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E1886B6-CFA6-4827-AF3E-32E389AAB4EE"/>
    <pav:createdOn>2014-03-23 23:43:18 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E66DD791-87AB-4AB2-B709-27A9BBBF164C"/>
    <pav:lastSavedOn>2014-03-23 23:46:11 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D61BB175-3285-410E-B6E9-47F5CE59FDFE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6D157E6-3137-4D39-B501-F383DFA78760">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-23 23:31:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The effectiveness of clopidogrel bisulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6D157E6-3137-4D39-B501-F383DFA78760"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B5C15C4-69DB-4101-A97A-F5E71FE34E31">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6A185B5-0BD2-45EC-B5F6-C88D9FCD80F1">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:584B8C60-BD97-4F4F-A18E-5CA90F22705B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39C4DA5E-F5FD-4A61-A205-BDB1588F8858">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9119275-9781-4891-958D-4E1119AC2D53">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CB377D4-FDCE-4B53-8A8E-0E31F17B3E0B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5CB377D4-FDCE-4B53-8A8E-0E31F17B3E0B"/>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM).</ao:exact>
    <pav:createdOn>2014-03-19 21:12:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>lation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic circulation. At steady-state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B7872BD-7F7F-4EF9-85A1-52FEA1C44DB0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A55FEF1E-F69C-4CE2-8851-7519EEC89FC9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A55FEF1E-F69C-4CE2-8851-7519EEC89FC9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-23 23:02:13 -0400</pav:createdOn>
    <ao:prefix>Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets. </ao:prefix>
    <domeo:uuid>A55FEF1E-F69C-4CE2-8851-7519EEC89FC9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F286ADB-3EE6-4F26-93F8-8E4FF4BE424F">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C333F1D9-97BA-4943-B6A4-EDC801B9FC30">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>SJS</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B45D566-CE7D-4694-A437-6E3D96D515B1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97733B39-74C0-4763-BD19-277B9D97F256">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97733B39-74C0-4763-BD19-277B9D97F256"/>
    <pav:createdOn>2014-03-12 22:31:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:prefix>
    <domeo:uuid>97733B39-74C0-4763-BD19-277B9D97F256</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC57394D-0D9B-4FDA-8761-EEA0BA546CBC">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:855C17ED-28CA-446A-9861-15DAAAB40AD4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>what did we decide to do about lactation?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA3584DB-7FB6-4C4A-8A05-C3B30CCFB807">
    <pav:createdOn>2014-03-30 16:04:58 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:29255FA1-9631-44F1-A1B6-5D03F3302D19"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84BD35A8-B525-428D-BD81-E61430127763"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FF71FA61-D321-4445-BCC0-D53E204784F5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:6CB0A9BB-7F0A-482A-8B4B-42634B86C50F"/>
    <pav:lastSavedOn>2014-03-30 16:05:01 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E1887DB-4AF3-49DE-B671-FFED33AC1CA4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4631A6E1-1E02-4532-B23B-CF46D78115DA</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5EEFC4B9-ABFC-4C1E-8D67-C78AB12DB61F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CDE65BB-7EFB-4688-B446-A716E7617AEF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:788C7BFA-6591-4F63-AF9A-F32923B3F607"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CB06ACB-5BFB-4E3A-898F-1B3BDA2301D8">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD790349-853C-4025-B932-4869B446E9CC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D4253A8-1C68-4605-AF78-B46AB5593CCD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 21:24:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <ao:exact>The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D4253A8-1C68-4605-AF78-B46AB5593CCD"/>
    <ao:suffix>Aripiprazole does not inhibit or induce the CYP2D6 pathway</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDC3CC31-03B5-4CD2-A38E-9C07EC86647A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CONTRAINDICATIONS (34070-3)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CONTRAINDICATIONS (34070-3)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E3A21EB-16F3-4394-ADCB-0315A9A1C175">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B4FEE1B-7D0B-46B8-AC4F-74DEDF1FF038">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED122483-7D21-41D4-AF4A-F873E8D0DDCA">
    <ao:suffix>Proton Pump Inhibitors Avoid c</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED122483-7D21-41D4-AF4A-F873E8D0DDCA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19.</ao:exact>
    <pav:createdOn>2014-03-23 23:38:54 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0C086E4-1554-493D-B74C-4A9ADBA7551F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Citalopram</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:73CEE899-B4FE-4B39-803A-935FCD5883EE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:73CEE899-B4FE-4B39-803A-935FCD5883EE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-30 18:48:32 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3470463F-AC84-496A-A953-1CA3A5A7E3E8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:F6E36B24-41D1-4D79-939D-C2980E1C990A</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E4D394E-D949-42F8-9C42-D216D10904D2"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-12 22:12:53 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:94FD81F5-C401-47DD-B5A3-6EA4CE430B95"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A42A42A-5627-40C3-8297-A112CC83960C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BCD3AE0-64B6-4372-9403-23F27B18E996"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E92EDE5E-8982-4447-B421-C0B37D5E5F6D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA75B8A1-007D-4F41-AA9A-E0CDC23D187F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A34EEA7E-FCD2-44D2-BF2E-A9CFF14C19E5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F19C0C0-60AC-49D7-8A49-6E7C501551D9"/>
    <pav:lastSavedOn>2014-03-12 22:14:10 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9FBDE84B-D209-4C9C-AE48-E382792E8CDC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94F01CB5-B665-40A4-A69B-972AEEBD57E2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DCE0D2E-8E6C-47A3-8B93-29FF0AA91F1D">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D888B39-8219-47F7-BE88-94F5A9DA568B">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B66E5587-3003-49F2-95AB-8ED4901E5D99">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>bleeding risk</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14AB543E-C90A-4554-8E9D-F595B526BA8C">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94FD81F5-C401-47DD-B5A3-6EA4CE430B95">
    <pav:createdOn>2014-03-12 22:12:53 -0400</pav:createdOn>
    <ao:exact>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94FD81F5-C401-47DD-B5A3-6EA4CE430B95"/>
    <domeo:uuid>94FD81F5-C401-47DD-B5A3-6EA4CE430B95</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EEFC4B9-ABFC-4C1E-8D67-C78AB12DB61F">
    <pav:createdOn>2014-03-30 16:04:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5EEFC4B9-ABFC-4C1E-8D67-C78AB12DB61F"/>
    <domeo:uuid>5EEFC4B9-ABFC-4C1E-8D67-C78AB12DB61F</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Codeine is secreted into human milk. </ao:prefix>
    <ao:exact>In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeines active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CD239E5-00A0-4C99-824A-5AFF50F844E0">
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-23 23:23:55 -0400</pav:createdOn>
    <domeo:uuid>8CD239E5-00A0-4C99-824A-5AFF50F844E0</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8CD239E5-00A0-4C99-824A-5AFF50F844E0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). </ao:exact>
    <ao:suffix> Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:849D5A6A-8D45-4A3D-9A88-F6CC04CA9856">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:849D5A6A-8D45-4A3D-9A88-F6CC04CA9856"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <pav:createdOn>2014-03-23 22:52:16 -0400</pav:createdOn>
    <ao:exact>For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.</ao:exact>
    <ao:suffix> Complete pretreatment blood c</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>849D5A6A-8D45-4A3D-9A88-F6CC04CA9856</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94DA12D4-8C94-453C-A186-10749AC3CA79">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A8D60F3-3042-4ACE-8A24-B8DEDB9E7E29">
    <ao:body rdf:resource="urn:linkedspls:uuid:781CFBED-4273-481E-AD79-30E79C5B5F36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8599E37-ED3D-4121-9F99-AD576994A6D8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:B77F44DE-40DB-4957-BD7D-3ED4CA6D72F5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D4E2B723-3366-477E-A046-C7778D389147"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DDAE55F6-699E-4294-AA7F-4BA101D1D6FB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4FD1B0A7-4F88-4827-A668-6660B0ED0041"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8CD239E5-00A0-4C99-824A-5AFF50F844E0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-23 23:23:42 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC57394D-0D9B-4FDA-8761-EEA0BA546CBC"/>
    <pav:createdOn>2014-03-23 23:23:55 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:862CCCD4-87E7-4B41-B0EC-0E7BE8FADCC9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8186BD4A-6862-4484-843D-9FF803CAA77C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5C1C020-584D-4069-938C-C9B2CC74B11F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:47D9C3E0-B89C-4044-90BB-A66E914CD510"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F87F4BB0-EE86-4394-AE4D-534856B88728">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <pav:createdOn>2014-03-12 22:30:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F034673-0FC4-4DF8-99D7-DE04FDF9D733"/>
    <pav:previousVersion>urn:domeoserver:annotationset:505ACF44-87C5-4A9E-A457-1E648D3969E3</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:772C5224-BCB4-40C3-9387-6490411A5527"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:45C86EFF-A82C-44D4-BACF-ED78D97FFB8E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:78097B37-4F55-49BB-8291-119FFCF8AF9A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:95FA75B7-64CD-4C54-B2C8-AA44C46A9CAA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22B5360E-BAAF-4620-A9DC-49CCCC12831F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6CF9414-F48B-4BC2-8C0E-81F5FDC14130"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-12 22:31:53 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0D1968B-059D-4E45-9A85-F6BFFE74D757">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6256E00A-866C-41E6-9488-8C4ADF17DA5C">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3A7D4FE-DF36-4022-AF9F-8E239EA508B5">
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5ADB1DCF-FC4F-4462-8DF6-CE05CA57C304">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5ADB1DCF-FC4F-4462-8DF6-CE05CA57C304"/>
    <pav:createdOn>2014-03-23 23:17:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix> Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early </ao:suffix>
    <ao:exact>Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <domeo:uuid>5ADB1DCF-FC4F-4462-8DF6-CE05CA57C304</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F2D0330-3621-43B4-80AB-6403B37102F4">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2C36B0D-AE49-4B08-9DB2-0C4C2EFBF661">
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-31 00:28:41 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2C36B0D-AE49-4B08-9DB2-0C4C2EFBF661"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>5 Similar observations have been reported in Asian patients.6,7</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B67DAA9-B75E-47ED-850C-E7B7B5151835">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7BC1D389-097A-4877-A043-17B3182BFF4D">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5034D1E8-1E2C-4493-90F2-D662231FF9CF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD5C50F3-F843-4652-9CDB-6C8E010CDCD3">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0978CC70-82ED-4575-8D0C-6F7CDA82F841">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF918CCC-C152-4418-9D73-F31EED083446">
    <pav:createdOn>2014-03-19 21:18:00 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DF918CCC-C152-4418-9D73-F31EED083446"/>
    <ao:exact>Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed</ao:exact>
    <ao:suffix> </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EAC3FD4-72CA-479D-8CE2-0D4BA6860CC2">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:622DD8C0-8911-4956-9076-01A4DB828FA9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C273F7E8-5929-4236-A018-D9EC1C328EDE">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CAE67D43-C092-4EBE-BD4D-9A853CC00E7E">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>intermediate-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D125F8E7-C030-4B95-B62E-367B39C38C58">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D125F8E7-C030-4B95-B62E-367B39C38C58"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (2.3, 5.1)</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>D125F8E7-C030-4B95-B62E-367B39C38C58</domeo:uuid>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.</ao:exact>
    <pav:createdOn>2014-03-27 10:40:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77410D4B-8063-40C2-BE7E-AE16339AAC30">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6E04BC7-676E-4E8D-A02A-FA9131F20B55">
    <ao:body rdf:resource="urn:linkedspls:uuid:8DCE0D2E-8E6C-47A3-8B93-29FF0AA91F1D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6BB7CF66-561C-4673-8E2F-375B1E3B74A6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC81A21A-A912-4A81-AC63-D62096E41180"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2BE1635E-B9CE-4C51-A731-790AA39F83C6"/>
    <pav:createdOn>2014-03-12 21:49:36 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-12 21:59:46 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:ABF47FC2-09E0-43D0-BAF8-462B1F79A261</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:39C4DA5E-F5FD-4A61-A205-BDB1588F8858"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:73668546-B71F-44AD-B671-B2C5615BEC52"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE4C453E-9913-4FCC-98D5-0EA5752E0708"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:76177A39-EF26-4215-A832-10BCEDEF4339"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A1F2384-1CD1-451E-B358-C000A704B9BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51A5D096-C4C5-48E8-B0E1-7F14E6548C3E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-23 23:21:45 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA10CA0D-A917-4C23-BCF9-D2E4B8193045"/>
    <pav:lastSavedOn>2014-03-23 23:21:33 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:E75BCD11-5B36-4E22-9C84-9AD4AAC083CE</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:02E16D41-B27B-4290-93CB-FB83EA29B5B8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:49303763-0A27-4198-8435-198F906965B4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:41A71A0C-A82C-4EFF-9B09-08E35BBCD8E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE1ABD7A-663C-436B-B453-26D0B8B247BB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E4A2D0E-018A-4EDA-9856-783BBE233B0C">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4044E64A-8017-4A78-94AF-9D6EE3A236EC">
    <ao:body rdf:resource="urn:linkedspls:uuid:5E5B9CC3-B935-42AB-BAF8-2EEE63BE2056"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:841AA996-EF35-4CFB-BF51-8D6B14F65A3E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6381DBC8-2BCD-4A87-8A3E-ED495B64A90D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:03C208F3-531B-4EEE-B812-3706BC2F6E0F</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:ADB89221-52E2-4386-BB2B-D5A0899DD249</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A0C4ECF8-929C-4039-8663-1B6848A1DD92</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A932CF6A-ED49-416F-A4DE-C90B70DF4C3A"/>
    <pav:lastSavedOn>2014-03-30 17:39:46 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-30 17:39:46 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F9CD3126-8090-4633-9ECE-F56AEF0EA72C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D2ADC9F-5FA0-475A-A7D6-CA40D4B71B43">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6106A6E9-79C1-44CE-AAEC-CAAE36C6BA3E">
    <domeo:uuid>6106A6E9-79C1-44CE-AAEC-CAAE36C6BA3E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6106A6E9-79C1-44CE-AAEC-CAAE36C6BA3E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible. </ao:exact>
    <ao:suffix>(5.1)</ao:suffix>
    <pav:createdOn>2014-03-12 21:42:18 -0400</pav:createdOn>
    <ao:prefix>Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D13A8AF-3CD3-4577-A9EA-5B07BD83E730">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22B5360E-BAAF-4620-A9DC-49CCCC12831F">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8556FCD8-8D24-4AED-8AFE-2B1A0D6AAB57">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CF0F812-D573-4458-B746-93D5FB6FB58A">
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D61BB175-3285-410E-B6E9-47F5CE59FDFE">
    <domeo:uuid></domeo:uuid>
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-23 23:43:18 -0400</pav:createdOn>
    <ao:suffix>Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D61BB175-3285-410E-B6E9-47F5CE59FDFE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0780ADEF-2787-4415-BDFB-28378B861EF8">
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB65C828-CB73-4233-B393-41AA76CB8C6F">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5DD0735-C524-4B7F-8614-0A000A3E5D23">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1271CD7E-1C6E-419A-95F2-CF271CE93043">
    <domeo:uuid>1271CD7E-1C6E-419A-95F2-CF271CE93043</domeo:uuid>
    <ao:prefix>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-12 21:55:26 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1271CD7E-1C6E-419A-95F2-CF271CE93043"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7B29D0C-ED74-476B-8E7E-E1D984A5E594">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:DE2C2604-3963-4B66-85FC-ECCB3E6CC129</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C7B0E6E-61C4-46E9-B914-A9C8A6052BE4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:991AF447-FA2E-4568-A865-00C16B645701"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F29EB7E4-5368-46FC-8E0A-46A8DEF367A5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFDBBDAE-1D40-4207-988F-1E8CEC5ADA04"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DB04C01-D293-476A-98CF-50A111D3CA0A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2014-03-31 00:29:06 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-31 00:27:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA10CA0D-A917-4C23-BCF9-D2E4B8193045">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4481C6C3-A003-4310-83C4-78ED8D2C6ED0">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E02EFB6-71FF-4583-8B43-2091A457FE15">
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <rdfs:label>Required</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E2D829B5-291B-4705-A124-C178353FC13F">
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87E915C6-DF3A-4E1C-9BB3-E366EC1817A7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBB15CB8-589E-4E27-BE01-618BEBBB10C4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA7FC0EB-CC0B-4BAF-AB43-9B0891F108E6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1EAE992-56A9-4FB0-AF29-A0F6026BAF58"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B66F8CA0-B324-4890-9E1E-AD608512C661"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D13A8AF-3CD3-4577-A9EA-5B07BD83E730"/>
    <pav:lastSavedOn>2014-03-19 21:24:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-19 21:18:00 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0852753-C453-4D54-8268-55AB9F253C00"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DF918CCC-C152-4418-9D73-F31EED083446"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07C6E7A3-1CB2-461E-A980-615D40033145"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C43B620A-1A47-4B9B-8318-726A784F9CEB"/>
    <pav:lineageUri>urn:domeoserver:annotation:F4E9F679-851C-48A2-9525-DE474FE330DE</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03D82601-ACE0-482E-A4D5-5D990F4C6B28">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CDE08EF-39A4-46FB-853C-2300AC095404">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8CDE08EF-39A4-46FB-853C-2300AC095404</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8CDE08EF-39A4-46FB-853C-2300AC095404"/>
    <ao:prefix>If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-12 22:20:03 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54759A36-9D88-494F-97D4-22934D98FD8D">
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDD04241-2616-4993-9D6E-CCC8CFEE9C87">
    <ao:body rdf:resource="urn:linkedspls:uuid:37857CA7-CAD2-4A41-A631-ED256FBC6730"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-23 22:37:51 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:34632956-EFD5-4868-9645-10BE8C5079C7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F937765-C1FF-4A98-8201-D195228605AE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A1DA3BC-4192-4E9A-B301-B64D731EF140"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:867504A6-7ABB-4807-943D-9EC28BADF976"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D292616A-93A0-47B6-BB1A-767C4E112C50"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:615BB512-75A0-45EA-8EE6-A4981CECD19F</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-23 22:34:15 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F793DBA6-9B88-4A60-A5D0-4BCD004482C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D608B4D7-D63E-4C74-B957-8721DAD3A141"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99700CC4-EF0E-4A67-9AD5-BA2ED9EFC69D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38D90118-A03F-4DFB-8B72-EF5D4C1454B7">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94F01CB5-B665-40A4-A69B-972AEEBD57E2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7775C25-95FA-4A7C-A2DB-A5D8CF10C026">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C878279-33B0-472C-8710-78F89FCE2E1A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:02C3C807-0A68-45CD-892E-4CC1DBB8D1D2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D8C6BB0-2850-4460-9D93-4339CAB541D8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:23620A66-EA8A-41A6-8908-870FCAE412CC</pav:previousVersion>
    <pav:createdOn>2014-03-27 10:51:25 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3305C361-0254-42D8-879A-56E68F3EDFD5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:45CE0CAB-7F4C-4328-9A1D-0E9079C60ED5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD1C395B-BC74-4666-B457-C81B056E575B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4FEF6F7F-2BEB-4A7B-8A94-650294ECF0C6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BB5ED28-B673-4D69-B617-5F61F5FCBA86"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3709E118-E5ED-4FB3-8F78-E7B3B21623A1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-27 10:51:51 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D83D91EF-C509-4483-8A0C-EF81CE93FF1E">
    <ao:body rdf:resource="urn:linkedspls:uuid:A6993653-7F33-4D45-B257-69BD5E9F8038"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:23941657-F490-4BE0-91D1-AE3ED266023A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E2D829B5-291B-4705-A124-C178353FC13F"/>
    <pav:createdOn>2014-03-12 22:02:29 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A4F2C04-BC76-44CD-ADC9-608CE2F78EF8"/>
    <pav:lastSavedOn>2014-03-12 22:06:01 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B2B8818-4C64-4832-90CD-03ECFEF0663D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6137586E-97D7-4E43-92B7-C9C1CC84BBCD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D0C27D59-B65D-48F1-942E-AEA6623FDFBF</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:EDC3CC31-03B5-4CD2-A38E-9C07EC86647A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:06F19C1D-3E4D-4FA6-A0FC-C0438057697A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E3B858D-9FE9-432E-95A0-BC9B20DA4518"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B57F8ABA-C546-4F23-BE5F-085C0A4C2588">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <rdfs:label>Not Important</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0B42AA7-C70C-40D0-B08D-41CA42B819D7">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3469BC10-36DD-43F6-98E3-436A610D618E">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Does this statement qualify as a "biomarker-positive" for the common test?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F6F0822-6A5A-4AC9-8FEA-E9146DEE6263">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5BCEAED0-B0FB-44BB-8A36-8513807F07BA">
    <pav:createdOn>2014-03-23 23:25:06 -0400</pav:createdOn>
    <ao:exact>Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5BCEAED0-B0FB-44BB-8A36-8513807F07BA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>5BCEAED0-B0FB-44BB-8A36-8513807F07BA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6039215C-74FB-4B4C-845A-D5442D0E2B9C">
    <ao:body rdf:resource="urn:linkedspls:uuid:AC9D2CE6-672A-4E3E-B537-BB71107CB6D6"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F657633-879C-444A-8AA2-8F98D0FF321E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:53E32812-2CFE-4097-89AA-A4E137592BF5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7B7566E1-390B-4660-A8B5-8E1001724517</pav:previousVersion>
    <pav:lastSavedOn>2014-03-30 15:52:23 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB65C828-CB73-4233-B393-41AA76CB8C6F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE3162CB-7B36-4DC3-A498-E8B58D7754B8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:15787FE5-B5C9-4688-AB1D-03ED077E7105"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:431F9DA9-900A-4963-9E24-AB4C06C74C6A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C57CCA66-6E2B-4CBB-8DF5-43543D1AE1C9"/>
    <pav:createdOn>2014-03-30 15:52:20 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F034673-0FC4-4DF8-99D7-DE04FDF9D733">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:635C6E3C-E052-4A55-A9F9-5263290E4B2A">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> (12.5) </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>635C6E3C-E052-4A55-A9F9-5263290E4B2A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-27 10:40:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:635C6E3C-E052-4A55-A9F9-5263290E4B2A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F9A8E68-8813-40B7-AC1C-31419AFC9B75">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC251B2B-04A9-4E92-8549-BD527909917D">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A4B5C2A-4303-458B-823B-94230EE0AA9D">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF777739-AFDC-43F3-A8B4-F58883D3836C">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8666948-E618-452C-916D-D358C78832A5">
    <ao:body rdf:resource="urn:linkedspls:uuid:1A0C7A7A-526A-4A51-8215-34375C6081DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8D89E8B4-53B7-4A25-98F9-DE460FCCE099"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:BD0A53D8-D315-4522-8945-C3F41DBBBDA1</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:51C872FB-17DE-49AD-BFAB-019691A408C4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:16A9F1EC-7A0B-4DC8-9C8B-AA1597EF3223"/>
    <pav:lastSavedOn>2014-03-30 15:58:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E74D5C5C-2D64-47F3-979F-D20C4375DA61"/>
    <pav:createdOn>2014-03-30 15:57:46 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE90EC35-FA29-4EE0-A7C7-70AACC8D7F13"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:20D96C9A-F90D-4509-A97C-28D2087753C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50E09AB9-8A5F-4184-ADE1-24562F02DEA6">
    <pav:lastSavedOn>2014-03-12 22:25:37 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6661B3EA-4906-4AEE-9774-F80FB5627CE6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0D1968B-059D-4E45-9A85-F6BFFE74D757"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E044358C-165B-40CB-89A0-451D9E54F532"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C273F7E8-5929-4236-A018-D9EC1C328EDE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A8F9E98-ECE1-41F5-A856-B776F13FFA28"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DC979256-C139-426B-BB71-EA7D2FCE0A65</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:849AB2CA-E399-4EF8-B314-33B1E01AFD43"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5ECC1800-345F-4B85-8BE5-42F193C69B17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3440E38A-8370-4BF3-B18F-981603FA479F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6E44E05-A5D7-4443-998F-E4F34D2AB892"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">18</pav:versionNumber>
    <pav:createdOn>2014-03-12 22:25:38 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F7C5F16-ED8A-43AA-B057-CD1C38FA8BCA">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Use specific</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:934614EA-0207-42E0-98F1-ABFCA4CAD577">
    <ao:body rdf:resource="urn:linkedspls:uuid:79A1075A-57D5-47F0-9EA8-95A310845E3F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:ADB89221-52E2-4386-BB2B-D5A0899DD249</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F45619BC-E807-4A01-BD0C-6C1558312AA2"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-30 17:38:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5321686D-5BAA-47E9-94CC-2F4421BE28DF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6D950A3-368C-4A88-AB34-BB3D04A9C6B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABC6BFA8-4207-49FE-85B6-9FE50E4520BA"/>
    <pav:lastSavedOn>2014-03-30 17:38:48 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A0C4ECF8-929C-4039-8663-1B6848A1DD92</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6E44E05-A5D7-4443-998F-E4F34D2AB892">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED6BE06A-41DA-496D-B3CD-FD0096E33793">
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:452CA95B-AEA0-4A47-B68B-350DA5AC0EAE"/>
    <pav:createdOn>2014-03-30 19:05:53 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA0483FA-0F2B-4BAF-8935-653EF7FF4E7A"/>
    <pav:lastSavedOn>2014-03-30 19:07:25 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A4B5C2A-4303-458B-823B-94230EE0AA9D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F159A80-7154-48D0-AB6C-AC0DDDF0450F"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:A29B2292-66F3-431E-B77C-85D21F2D4906</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:06CE351C-EF43-4B6E-9969-DED478D18910"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EEF4361-1F03-4790-84B6-E77AD3291191">
    <ao:body rdf:resource="urn:linkedspls:uuid:30281C67-B7E1-4405-9A6B-AB67C9A6EA0C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:230B9A52-40F3-4DBE-B7FE-69F5E7013A2E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F386F747-4791-4EA5-A022-05D5155AA999</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-30 16:11:15 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5A8BBE6-4AEF-43AC-9116-4376509F4844"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:538B2F4A-897C-4A44-8C33-A24931EF4DF3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5DD0735-C524-4B7F-8614-0A000A3E5D23"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-30 16:12:58 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FDACEDBD-903F-4BA1-A8EA-8AAE590D4A8C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CBF038B-286B-4630-8077-D2EB1C3D0C37"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6347F52F-255A-44F8-AFCF-9DCDB7E80823"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E5B9CC3-B935-42AB-BAF8-2EEE63BE2056">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5378434-D748-49C1-8365-34F51AD5E168">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59BD910C-F161-48C6-BB1A-B4A60C6E079D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-23 22:38:42 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BB86830-58D0-4AF1-97C7-936B5CC2947C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:897D7940-3B3E-4A67-AAF5-3BC2E1CBAA51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0749095D-52AD-4581-BA3C-7C5772A6673D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1A8EF4C-454A-426E-B0CA-0DC18B700519"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-23 22:38:33 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DB3914B0-920D-4BB8-BE3D-B1474CF1D742"/>
    <pav:previousVersion>urn:domeoserver:annotationset:05417EE0-0F9E-4EE9-B0BD-8DFD98D21841</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A6CEDFE-8C79-4F5D-BC54-2F83332F9C10"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:86EBC4F6-6D8E-4D23-A76B-DBA9317E0C68"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FD0CAE9-84DE-4CD6-9C22-CE662488E7CB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:19B45175-B8B0-4F2E-9136-FC581D805D41">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AEEB11F-4145-4D8F-A2B3-49B277C35CEB">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5CC1D2B-B5EF-4348-979C-3B5A68F2F002">
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D5CC1D2B-B5EF-4348-979C-3B5A68F2F002</domeo:uuid>
    <pav:createdOn>2014-03-12 22:07:02 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5CC1D2B-B5EF-4348-979C-3B5A68F2F002"/>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and shoul</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB28325D-2F76-47AB-B239-509DDABE5BC2">
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC17B331-41D8-4D1B-975F-741D01457414"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1FD15233-0A4C-4B26-AC9D-E396ABBA1EF8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7D84BC7-1B08-4D4D-AC8B-8FA9BC1F4EA5"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:93C75643-30C8-4C8E-AA08-9A2B680DDA42"/>
    <pav:createdOn>2014-03-23 23:44:55 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC5D1B2B-D3EE-4500-A332-7FC5314DBA35"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4583BABF-9093-44DF-8D39-12C4DB2ACB54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C377FA36-BC4D-4BAF-B703-F9F8FE95E2B1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C377FA36-BC4D-4BAF-B703-F9F8FE95E2B1"/>
    <ao:prefix> </ao:prefix>
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>C377FA36-BC4D-4BAF-B703-F9F8FE95E2B1</domeo:uuid>
    <pav:createdOn>2014-03-12 21:52:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D48CEAD-FDD7-4BD0-A490-369FCB0D296A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D48CEAD-FDD7-4BD0-A490-369FCB0D296A"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression.</ao:exact>
    <ao:suffix> Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-03-30 16:12:54 -0400</pav:createdOn>
    <domeo:uuid>0D48CEAD-FDD7-4BD0-A490-369FCB0D296A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FB72C9B-BB19-40D9-9885-B6FC808A8E0A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07747B94-33CD-432B-9681-4BF7B9CFF56C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:07747B94-33CD-432B-9681-4BF7B9CFF56C"/>
    <domeo:uuid>07747B94-33CD-432B-9681-4BF7B9CFF56C</domeo:uuid>
    <ao:prefix>Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. </ao:prefix>
    <pav:createdOn>2014-03-27 10:45:31 -0400</pav:createdOn>
    <ao:exact>Tests are available to determine a patients CYP2C19 genotype. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B7A8B62C-489D-4DC1-A5A8-8BF89DF166CC">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:64AF5690-7FCA-4C04-9935-2C8B572F5DEF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53455F83-7589-4904-AA1B-772F65CD01E2">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92D4A343-08E7-4448-A01D-A251DBEB233A">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16CF406B-F959-4BEA-876F-A137D25A0189">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78BC60F1-1131-4398-B38B-2CDC94D39B40">
    <ao:body rdf:resource="urn:linkedspls:uuid:B7581C63-37AC-4C31-86A3-3267C1CCA382"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0F683E1C-571E-45C0-A671-5F4139959B97</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:ED122483-7D21-41D4-AF4A-F873E8D0DDCA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAE0A0A9-B405-42BF-BC14-BE7C9DDC58D5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5DDFBA7-A6BE-44E0-90FB-A6FF287C2DFE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5789948E-7EC4-484B-82C7-46BF0845F2B6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DC2D216-2846-40C1-9F8B-815262749C5D"/>
    <pav:createdOn>2014-03-23 23:38:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-23 23:38:43 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD782267-98E9-4328-91EC-3B97CDFAFEB2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB0210B8-B6B5-4614-A7DD-D27606B343D5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:09E87A6A-EA22-4C69-87B7-6547EF5E8F74"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:31DDCF59-C246-4EDF-838D-55611368AC08"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B825C73B-E13F-4830-BB16-F900606C110C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C07DC4A-D7D4-4794-98F8-D1AC6BE5E2CC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:18756329-D495-44E8-9744-CFC6A3AAF875"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:790FD2A2-88E7-4856-9FF1-D3BAC92337AC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0681808-212F-45BC-89C8-9FAD4B49D085"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD5C50F3-F843-4652-9CDB-6C8E010CDCD3"/>
    <pav:createdOn>2014-03-23 23:27:51 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA0A95C1-EEC6-42D7-90A0-41E65CD09812">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D09554F-BACB-4D55-A9CF-D49A2D143AA6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:20D1D978-4370-4B18-A8EB-9FA2300BD2DE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:013EBECE-35C9-4801-BFEC-6845FCAC9991"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:181E4C94-00EB-42D4-B76A-251AD9BD0BCB"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-12 22:20:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1D2BA00-6FB3-4FDD-9145-5F8E591BED5B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD73B147-99E1-41E1-BEF5-00459BC2509D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8CDE08EF-39A4-46FB-853C-2300AC095404"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:36FF63A1-6460-4B1A-A2D9-525C2C315572"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8DDC681A-DB01-49D7-B458-D786189DBB9B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C643F17B-2B84-4528-9D45-34148809BB81"/>
    <pav:previousVersion>urn:domeoserver:annotationset:96F8E8B9-090A-4DB6-80B2-C4FE69D42662</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-12 22:20:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65FB3165-FC32-4A42-97C1-59BC0C3C5328">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A645B5F7-D32C-4B98-801D-BB2C2141AA18">
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:16CB55D1-C91B-48BC-8150-3F9A076D6AC8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F386F747-4791-4EA5-A022-05D5155AA999</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CE2ECE7-E64C-46D0-A002-8EAE7337E954"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-30 16:06:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A70F20E4-D873-4719-9521-16E3B3424EF2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E8536C3-4448-44A0-9F07-4C6FAF1FC04C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4291BE1-56DA-46A3-A7C7-B631356E7161"/>
    <pav:lastSavedOn>2014-03-30 16:12:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F22C0613-35DF-4B66-A47A-566B2B48B41A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BC39231-A4D1-474A-983C-D440595889F1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:645AED79-5CBB-4E96-8DA2-B1A4AA27F666"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:63645902-B328-4BF8-8B60-49696594E010"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8698A1B7-D44D-4F9E-9D3F-F4A88684C6C0">
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0749095D-52AD-4581-BA3C-7C5772A6673D">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C59693A2-324F-4A06-A787-753AB7F3C2E2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2C9A1DE-0A94-4726-870E-EE62ECD4B746"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:42949B72-C46C-41D1-BB9F-6F1BE36FC1CC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B7A8B62C-489D-4DC1-A5A8-8BF89DF166CC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2F468D5-EE6C-4455-8951-2215E73790FF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <pav:lastSavedOn>2014-03-30 18:32:07 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFB13D4F-63B0-40C5-A399-66F052E22AAE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:13AE1ED4-6994-48C8-9308-4F86F5C85E36"/>
    <pav:createdOn>2014-03-30 18:32:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:421121E1-97B7-475D-875F-D4E1DAB6FB06"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:697B832E-6266-4E57-B97F-F121F7A0C776</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:87E915C6-DF3A-4E1C-9BB3-E366EC1817A7"/>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>JHatfield
</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0CD947B9-71A0-44E6-85BB-52CCB183B3EC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDE4728E-480E-48F8-BD83-7F88F36AEE3E"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:5A4658A3-293C-4920-80E9-AE9A88D6017F</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N3dd939331bde43e9b7c5cda244c5568c"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A574DDB0-0778-4BC6-8178-DD49891131A0"/>
    <pav:createdOn>2014-03-19 21:08:37 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2014-05-05 13:25:50 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C42BB9E4-CF12-408E-AEB2-A886AE85A7CA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfbfd21b005b449c08af9a1039d798a59">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2B342CE-A4D1-41BE-9933-46296B0395B4">
    <pav:createdOn>2014-03-31 00:32:48 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB838C8F-5589-40AB-870E-B48F04B59FE0"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F7C5F16-ED8A-43AA-B057-CD1C38FA8BCA"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CB024805-C764-4CAB-A3C5-9E86E954C589</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:6926D7F6-0DBB-42DA-9D4B-AC61BC569818"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2302A2D-0E55-4B59-AD91-58549A4767D7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-31 00:32:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0388CA5E-0326-40F9-A660-1241CD189BD8">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58E59978-E28B-4ADC-AB4A-815E87565940">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D94F9B81-7F22-4FAA-A379-A66D573E58FA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:516567AB-6456-42E8-B89B-B27BE8679B0E">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:516567AB-6456-42E8-B89B-B27BE8679B0E"/>
    <pav:createdOn>2014-03-30 15:47:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix> (5.1)</ao:suffix>
    <domeo:uuid>516567AB-6456-42E8-B89B-B27BE8679B0E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F657633-879C-444A-8AA2-8F98D0FF321E">
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <domeo:uuid>8F657633-879C-444A-8AA2-8F98D0FF321E</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F657633-879C-444A-8AA2-8F98D0FF321E"/>
    <pav:createdOn>2014-03-30 15:52:20 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3AED7289-DC1B-4DFE-AB67-2390269F61BB">
    <pav:createdOn>2014-03-19 21:41:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-19 21:42:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8D3D7FEA-58C7-4DF3-832A-67A1C032C61A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:246F2575-7478-48D5-8EEC-D25E51E76525"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:46A89E4B-DAD7-4E42-9430-78F606D8ABB0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E02A39E-C080-4AA5-A578-0D1CA3F8E035</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:804BA0DB-ECE0-4D2E-B990-C7F144120BA6</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C6DC892-8D0C-4DC0-9998-5080C0455DD9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0846DFE-8249-4B82-ABB7-917D625E8EAB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94DA12D4-8C94-453C-A186-10749AC3CA79"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:F2769DF7-E160-499E-96B2-621EF845FFF4</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:367D3C7E-D6C0-4E7A-BE56-534577280FC9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B57F8ABA-C546-4F23-BE5F-085C0A4C2588"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F58A6E9-92A9-499E-9238-BE8AE64AC24A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:897D7940-3B3E-4A67-AAF5-3BC2E1CBAA51">
    <pav:createdOn>2014-03-23 22:38:42 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:897D7940-3B3E-4A67-AAF5-3BC2E1CBAA51"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>897D7940-3B3E-4A67-AAF5-3BC2E1CBAA51</domeo:uuid>
    <ao:exact>HLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans)</ao:exact>
    <ao:suffix>.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E631115D-5EAA-48D8-9AA3-A5F848BFD320">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E631115D-5EAA-48D8-9AA3-A5F848BFD320"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose.</ao:exact>
    <pav:createdOn>2014-03-31 00:34:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06CE351C-EF43-4B6E-9969-DED478D18910">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06CE351C-EF43-4B6E-9969-DED478D18910"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-30 19:05:53 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>Among women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDB38A36-093D-4F67-A73F-6746B5B82DB4">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6167F63-B759-47CE-A4B5-D9419406837C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76F61B42-B62F-42DB-93E2-94098FF5FCA6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76F61B42-B62F-42DB-93E2-94098FF5FCA6"/>
    <ao:exact>These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)</ao:exact>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>76F61B42-B62F-42DB-93E2-94098FF5FCA6</domeo:uuid>
    <pav:createdOn>2014-03-30 15:58:56 -0400</pav:createdOn>
    <ao:prefix>Data are not available for other ethnic groups. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02A65E80-FD06-4F5C-93E8-8EE7E454662F">
    <pav:createdOn>2014-03-19 21:10:56 -0400</pav:createdOn>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02A65E80-FD06-4F5C-93E8-8EE7E454662F"/>
    <ao:suffix> PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EM</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:F1C4E402-D98B-4D88-8F6A-CFDBA7A5CCF2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79C08A64-F2E5-491B-806A-9EE2DE8F4CA9"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A30188C-6347-4313-86FF-0A1E0E6A30F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C053A17B-E965-4611-8801-CE34B44C4A53"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A14345CD-ACDE-4B67-94B7-074A12C6A0CE"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:6D2EF7FB-5C82-4A66-998E-CD53BFE5A71C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:877B2B82-E7E2-4013-ACEF-BCC1941CAA47</pav:previousVersion>
    <pav:lastSavedOn>2014-03-23 23:24:54 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:51A5D096-C4C5-48E8-B0E1-7F14E6548C3E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE35C3A5-5DB2-48D3-AC71-93E15D63676F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A8D60F3-3042-4ACE-8A24-B8DEDB9E7E29"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1C739DE-B62B-4646-A3A9-45C59E793972"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:859A1B0C-EE52-46EC-A344-DDE415AE9B2A"/>
    <permissions:permissions rdf:nodeID="N78667a75e26e4c4eb8010f105e332a7b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D6140C9-D1CB-4E50-A9D2-625B729A2697"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95BE74BB-177A-4867-8D7F-FF818C787178"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:annotatesResource>
    <pav:createdOn>2014-03-23 22:59:21 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0426F8ED-42A6-4A44-BDCC-67E4950F2DA9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02C3C807-0A68-45CD-892E-4CC1DBB8D1D2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02C3C807-0A68-45CD-892E-4CC1DBB8D1D2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>02C3C807-0A68-45CD-892E-4CC1DBB8D1D2</domeo:uuid>
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:exact>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-27 10:51:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9340C2C9-029B-4D12-868B-3B2F725F4E9B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-31 00:34:18 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9340C2C9-029B-4D12-868B-3B2F725F4E9B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6CF9414-F48B-4BC2-8C0E-81F5FDC14130">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF6DF930-17C8-4F3C-AEAB-082C82AC5C3B">
    <ao:exact>The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected.</ao:exact>
    <ao:prefix>The citalopram dose should be limited in certain populations. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DF6DF930-17C8-4F3C-AEAB-082C82AC5C3B"/>
    <ao:suffix> The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures. </ao:suffix>
    <domeo:uuid>DF6DF930-17C8-4F3C-AEAB-082C82AC5C3B</domeo:uuid>
    <pav:createdOn>2014-03-19 21:46:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68363CB8-A508-4F81-92E7-54EAB5EED24A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:03D82601-ACE0-482E-A4D5-5D990F4C6B28"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A45D4405-05BF-4F00-8FD4-A206FB1ECFDB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E657DE6-AA97-4703-94A4-D6485AA96305"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9636BA00-5FDC-4143-A553-FD29374B54EB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-12 22:39:48 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:65D466AC-CFAD-42DB-8841-919234A8DB12"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FBF3B17F-C585-4A30-A038-B1C61E465887</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:55B74982-2B8D-4834-B14B-1A24634D82AF"/>
    <pav:createdOn>2014-03-12 22:39:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8188CAC-17AD-4B4F-99C1-A4BC33526BAC"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F92EF60E-B7C4-4838-89FB-5CA1589213DD"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2731F988-3D22-4BE5-BA62-612B8D82EDC0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC251B2B-04A9-4E92-8549-BD527909917D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60A2F326-9E75-4844-B196-26D3AC8A3C7D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF0D1BF8-C499-4C6B-8F6E-355B760CA8BB">
    <pav:createdOn>2014-03-19 21:22:25 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>. </ao:prefix>
    <ao:exact>The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF0D1BF8-C499-4C6B-8F6E-355B760CA8BB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Aripiprazole does not inhibit or induce the CYP2D6 pathway.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96435AEC-7FC7-476B-8A38-A7462924508D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31F8CF1D-4612-49C3-9B90-22F8C94E3AFD">
    <ao:body rdf:resource="urn:linkedspls:uuid:8B920AF2-7BF3-4E68-9D5C-E77BF320A814"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D53E7120-15FF-43EA-88CD-3DCF494C6FA8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-23 22:35:29 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B4FEE1B-7D0B-46B8-AC4F-74DEDF1FF038"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5340A9AF-11F2-4CD7-84F3-934979AA244F"/>
    <pav:createdOn>2014-03-23 22:35:40 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:22BFA5D9-BB49-43AC-B327-79212BCDB51E</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2577D553-4C25-4FA8-84E8-91352E42DAA2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D16B2F1-AD53-4D24-A8A8-9EA6B5C367F0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D96CC853-D926-47BA-97BD-9B17B70BF902"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3428274E-20B1-43B7-B003-D40CFBCD224F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:43ECB1C7-45D1-4FAA-A538-07D127816467"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61FE1D19-7E15-4A5C-908C-9EBCD9D99A5C">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:09BF6A77-DDA7-4466-AE2A-1D40A27241C7">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:525FFE40-C3DD-4DCE-9410-EB4BB0B9086B">
    <pav:lastSavedOn>2014-03-30 16:12:58 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7E852A78-D3F8-4F48-8A4D-41A29F73D1B6"/>
    <pav:createdOn>2014-03-30 16:12:54 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFDB1CD0-A702-437D-BB2D-A0330E09AE2C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DA3556D-0B0F-4C8C-9B4A-67DB213F491A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B4911D1-56E8-4B2A-8335-405058290C2A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2EEA099D-D8B1-463E-87E7-217E9570590D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E084DAEC-30B5-4035-8776-0D1CF8B30B76"/>
    <pav:previousVersion>urn:domeoserver:annotationset:F386F747-4791-4EA5-A022-05D5155AA999</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D48CEAD-FDD7-4BD0-A490-369FCB0D296A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2731D06C-AFA5-4464-BA97-511A6E6BA2F9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C854BE2C-87F1-404D-BA2F-B94E48A71323">
    <ao:body rdf:resource="urn:linkedspls:uuid:5D301A80-4A49-4750-B72B-2C43A127DB8B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B89D3B1-90F7-4906-8803-928A58587383"/>
    <pav:createdOn>2014-03-12 21:52:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:160FE20B-685B-43BF-947D-8FFD1C1B22BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9273B928-3A29-4E2B-AE1B-219844D85529"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:47FEFD9C-AFE4-42F9-A358-3CB8916AC51A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C377FA36-BC4D-4BAF-B703-F9F8FE95E2B1"/>
    <pav:lastSavedOn>2014-03-12 21:52:12 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:21CEE0B7-3DA7-4CB3-8733-455F99B3A7D9</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:45FF903A-9D80-490B-9F9E-96C737238B01"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:41057BDC-9E04-4AA3-8D2B-8830E9C8B224"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA338C65-023A-4DF3-9861-460867992280"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB838C8F-5589-40AB-870E-B48F04B59FE0">
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N07de73b6a1f24d4e912700428f76b79c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C643F17B-2B84-4528-9D45-34148809BB81">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3">
    <ao:item rdf:resource="urn:domeoclient:uuid:DA6BF0C9-4BFA-400A-BE1E-DF82AF90922D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C59693A2-324F-4A06-A787-753AB7F3C2E2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:68256107-7A03-4239-A377-8257D331C926"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:079F5CD8-3BB2-4045-9A1E-1DF4747FC68E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1A4DA464-2CD6-4840-B885-B1070CB89FCC</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N07de73b6a1f24d4e912700428f76b79c"/>
    <pav:createdOn>2014-03-30 18:31:32 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:59C749C8-D274-434F-8D8F-DA9AA137D145"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED6BE06A-41DA-496D-B3CD-FD0096E33793"/>
    <pav:lastSavedOn>2014-03-31 00:15:16 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B93707F8-986F-49A4-BBBF-08E080D9E77E"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:32DAA48B-4A57-46BC-8BDC-9B52724608C9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:D8E947C2-F0CC-4FE8-9464-2EC9438D769B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6EEA9AC-6917-49DB-ACDD-5A68069E0003">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCB82FA4-8F13-4111-8606-1FC114648522">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2731D06C-AFA5-4464-BA97-511A6E6BA2F9">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B13D7D9-D25A-422E-BBEC-6D86F9228FA7">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81EA2F09-6A53-4EFF-9949-C78B44593AF3">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE3162CB-7B36-4DC3-A498-E8B58D7754B8">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D301A80-4A49-4750-B72B-2C43A127DB8B">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00444CA6-D837-4477-A2D4-5617C563063B">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1CEFAAB-BD67-4A5F-AB7E-BF622512BA4B">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE145006-D521-4AD3-85BD-19F418544482">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44842BF2-DED7-42E6-B5D0-A90495A5D2BA">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84762B3A-A12D-46B4-98BE-4A75E451729E">
    <domeo:uuid>84762B3A-A12D-46B4-98BE-4A75E451729E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:84762B3A-A12D-46B4-98BE-4A75E451729E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-12 22:18:19 -0400</pav:createdOn>
    <ao:prefix>Following a hypersensitivity reaction to abacavir, NEVER restart ZIAGEN or any other abacavir-containing product because more severe symptoms can occur within hours and may include life-threatening hypotension and death. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>When therapy with ZIAGEN has been discontinued for reasons other than symptoms of a hypersensitivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction. If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC">
    <permissions:permissions rdf:nodeID="N20293665140445a8aead4921c18f2e40"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:1A609886-63C1-426A-BFD6-032F958C4B56"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896ed8340009"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E972F6A-F528-4242-B79C-C7832B957DE2"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <pav:lastSavedOn>2014-03-27 11:01:12 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3FFC358-5556-4074-B21C-8F1378BDF2FC"/>
    <pav:createdOn>2014-03-23 23:26:35 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:539ECE5E-F514-4036-AB23-9F30DA40D05D"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ACD2969B-8D6B-4A29-9EC3-48B6736E87D0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA336BCA-2F02-4355-9BAF-B08795A43735"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C4A5A7E-62C0-4D2C-8BB1-1F2C4357C0D5"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:35CD8A1E-7116-4119-B4B4-608CF77B37A6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9DA9E5B9-EDE7-4A17-841B-40E479F483CE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0646F913-BAFF-49A0-8F70-F023248EE27C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD782267-98E9-4328-91EC-3B97CDFAFEB2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CD06F491-C88C-461A-8FE7-4FFC80F9051F"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:37D95355-AE9B-4454-B6DA-543CBD117D4D"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA9FC34F-025B-4188-82DA-19C543F71A47"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D7775C25-95FA-4A7C-A2DB-A5D8CF10C026"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB28325D-2F76-47AB-B239-509DDABE5BC2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E71EA1DE-AD78-44B1-929E-71AC06D61540</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:78BC60F1-1131-4398-B38B-2CDC94D39B40"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE62DC47-0407-46E9-AD48-C8D8731F9ED0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD06F491-C88C-461A-8FE7-4FFC80F9051F">
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:createdOn>2014-03-23 23:28:36 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:09BF6A77-DDA7-4466-AE2A-1D40A27241C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A5D3758-F5AD-4A20-B94F-4862742E3623"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:635C6E3C-E052-4A55-A9F9-5263290E4B2A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE4B51C9-1AD0-4EBD-A7AA-AAF9B7DE763B"/>
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:65F81D64-E8F8-45B4-86EF-7D605DDAE0C0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E4D394E-D949-42F8-9C42-D216D10904D2">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E56DC4D7-A132-43DC-B9A3-0721BFA976B0">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4967FA85-A518-4BFB-81D9-51444A1F1EF8">
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4646369-10DC-4A89-8B69-EE04FF739B14">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:539ECE5E-F514-4036-AB23-9F30DA40D05D">
    <ao:body rdf:resource="urn:linkedspls:uuid:7D1C5202-0601-4F9A-9DC6-B2B97C1B39D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B207BA64-1079-494F-82CA-2013BF09FB15"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:272FCCCF-44E8-4720-B5D9-D54DF9BA77A5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-27 10:51:51 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-27 10:51:53 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C33376C6-0F22-4FC3-BDC1-75F9EAC71E8E"/>
    <pav:previousVersion>urn:domeoserver:annotationset:23620A66-EA8A-41A6-8908-870FCAE412CC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A27E1A90-B157-4865-B947-2A183E033C99"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F33C064-B479-48A7-A720-889DB228A5DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1111FFEF-E752-49D1-8D50-8F486C2C1E51"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F4624F9D-4105-4181-92E0-3CC32657B52B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0A32F5C-FBD4-4F5D-95F2-F8638897B58A">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16CB55D1-C91B-48BC-8150-3F9A076D6AC8">
    <sio:SIO_000111>USE IN SPECIFIC POPULATIONS (43684-0)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#USE IN SPECIFIC POPULATIONS (43684-0)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85E4C3C7-BEB9-4F8E-8B4F-3BAA7ABE4A26">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA360234-8BC9-4CB9-B0C9-E9837DBAAA6D">
    <pav:lastSavedOn>2014-03-23 22:37:51 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-03-23 22:38:01 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:216A8C4D-99D5-49AE-9BB1-1C508D19C692"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E985AC8-9A88-40D7-A012-AFA0FC6406F1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:615BB512-75A0-45EA-8EE6-A4981CECD19F</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A658592-62AB-44EF-BFCD-8D705DC85D46"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:50B795FF-C46C-44EF-AB7F-B77AF7CA7848"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:25714122-A100-41FA-A271-CDB397B2F724"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:11C43678-953B-4C80-9226-BCC784B9F599"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:154F5E0F-239E-4D8B-AB4B-1650282B3779"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:30B6F72E-BC8A-48B2-ABEF-584199779ECF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:327F2CB7-9F4F-49C5-B05B-25C6D0858C0E">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ADA3E8BB-56D3-4C42-B892-4E019DB266FE">
    <ao:body rdf:resource="urn:linkedspls:uuid:3200C38C-1119-4176-AB7C-1B9BEE06A1BA"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:ABF47FC2-09E0-43D0-BAF8-462B1F79A261</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C67EFA81-49F6-4EF5-93E4-0BED45C72E1C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:479239EB-1160-4AE1-A341-34816989D14B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C89D4019-418C-4943-AD5B-C36183712B8C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:282D104C-466A-4CE5-8FA9-546A361584DC"/>
    <pav:lastSavedOn>2014-03-12 21:59:46 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDA03699-F77F-466E-A772-BFFA6C8B10C9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2014-03-12 21:59:42 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A6B11192-9E06-4504-B6CB-A327A2D39237"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:256ED16B-306F-4B2E-BACA-8536BAFC8939"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4471F54B-10EA-4DD4-9D15-14E1E1ADAE89">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8188CAC-17AD-4B4F-99C1-A4BC33526BAC">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C7B0E6E-61C4-46E9-B914-A9C8A6052BE4">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:849AB2CA-E399-4EF8-B314-33B1E01AFD43">
    <pav:createdOn>2014-03-12 22:25:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>849AB2CA-E399-4EF8-B314-33B1E01AFD43</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n=1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:849AB2CA-E399-4EF8-B314-33B1E01AFD43"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47FEFD9C-AFE4-42F9-A358-3CB8916AC51A">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8186BD4A-6862-4484-843D-9FF803CAA77C">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D3B7A81-7AE3-4DF2-BACC-AD2DEF793887">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>cutaneous reactions</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F58A6E9-92A9-499E-9238-BE8AE64AC24A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 21:41:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F58A6E9-92A9-499E-9238-BE8AE64AC24A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <ao:exact>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</ao:exact>
    <domeo:uuid>9F58A6E9-92A9-499E-9238-BE8AE64AC24A</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F937765-C1FF-4A98-8201-D195228605AE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F937765-C1FF-4A98-8201-D195228605AE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2F937765-C1FF-4A98-8201-D195228605AE</domeo:uuid>
    <ao:exact>Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. </ao:exact>
    <pav:createdOn>2014-03-23 22:36:01 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix>The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86EBC4F6-6D8E-4D23-A76B-DBA9317E0C68">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60CBE11D-C700-4D9D-BFBF-B9FA3973A847">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68D3E22F-07ED-4750-98A9-E8EF201D2E54">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA648B09-F59B-4E22-8523-6401F1529B9E">
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43ECB1C7-45D1-4FAA-A538-07D127816467">
    <pav:createdOn>2014-03-23 22:35:40 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:43ECB1C7-45D1-4FAA-A538-07D127816467"/>
    <domeo:uuid>43ECB1C7-45D1-4FAA-A538-07D127816467</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.</ao:exact>
    <ao:prefix>Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F45619BC-E807-4A01-BD0C-6C1558312AA2">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A574DDB0-0778-4BC6-8178-DD49891131A0">
    <ao:body rdf:resource="urn:linkedspls:uuid:8CE35C55-5ACB-412A-9FD6-0C61497A4AA0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D4253A8-1C68-4605-AF78-B46AB5593CCD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:684043C4-99D4-48E1-89D9-91843FFEB78C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6167F63-B759-47CE-A4B5-D9419406837C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B750723B-8ABA-4370-B0BF-790B249D2FBC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F50F3EA8-35FA-4DF6-808B-BBC3A56A1811"/>
    <pav:lastSavedOn>2014-03-19 21:24:10 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A1E0F07-CFC5-4A4C-98E7-E144BAE423F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4BE273EE-7C26-4019-A132-1E01698FC686"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-19 21:24:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3428274E-20B1-43B7-B003-D40CFBCD224F">
    <rdfs:label>biomarker-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14933636-B0CC-4A29-8AA3-41C40B4481A2">
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B5C15C4-69DB-4101-A97A-F5E71FE34E31"/>
    <pav:lastSavedOn>2014-03-31 00:29:06 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:DE2C2604-3963-4B66-85FC-ECCB3E6CC129</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D769C96-B158-4628-8675-E329993925D2"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8B970845-802E-4040-B226-6A4F84B3B6B3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DBB4339-D188-4B25-BC32-0265176C1A6B"/>
    <pav:createdOn>2014-03-31 00:29:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5034D1E8-1E2C-4493-90F2-D662231FF9CF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26E678DF-4F3E-45FA-AC5D-0976318E4298">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6712D315-6869-4682-800A-3C54AE6CE580">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F491B0E9-FCF8-428E-A87C-812AB3280AB8">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A5332FE-1CBC-4E26-967A-140B04F91DEC">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E4A83A6-A990-4861-BCF6-169897B6B8D9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E4A83A6-A990-4861-BCF6-169897B6B8D9"/>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype. </ao:exact>
    <pav:createdOn>2014-03-31 00:20:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58376576-D995-4344-BBE4-2A6CC753D97C">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE331A24-968D-412B-91B8-7D4C08AF6C11">
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-30 15:56:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE331A24-968D-412B-91B8-7D4C08AF6C11"/>
    <domeo:uuid>BE331A24-968D-412B-91B8-7D4C08AF6C11</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <ao:exact>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8A88B0C-96FD-40C1-A605-C6C4636112BC">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA28E86B-78B1-490F-9DE6-39B3B705088B">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE3A70E0-BC3B-45A1-B4C5-13CC75E865C6">
    <poc:MedicalCondition>SJS/TEN</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EE64F47-E5A5-4CC9-8563-0A7E0BE6E549">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E7CDA24-C918-4533-9893-1287CCF8183F">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1FC3F08-335A-4C3E-81BB-1FA0D55B9E8D">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D2EF7FB-5C82-4A66-998E-CD53BFE5A71C">
    <ao:body rdf:resource="urn:linkedspls:uuid:64161092-B06B-40D8-B0DD-885131B35BCE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:B4B52C34-98DE-4423-B2E1-6AC6F36E84A6</pav:previousVersion>
    <pav:createdOn>2014-03-23 23:08:05 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6EEA9AC-6917-49DB-ACDD-5A68069E0003"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AEE4F635-4FDB-400A-92A6-C3F64E21DFA9"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF97874C-5EC7-4634-9036-AF1C3649F70C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:85BFB4E3-C9F4-4052-864D-F001F2FC8FC8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA8FF8BE-F672-48C5-9209-B024B62A5392"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D7D7BC8-2E63-48AD-8509-C7BE5642E054"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:31A1AEB3-0B7F-4371-B1F8-7968A6A2E248"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-23 23:07:53 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD790349-853C-4025-B932-4869B446E9CC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5A8BBE6-4AEF-43AC-9116-4376509F4844">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0D0AE67-798F-44E4-912C-76914E545D16">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CE35C55-5ACB-412A-9FD6-0C61497A4AA0">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:64161092-B06B-40D8-B0DD-885131B35BCE">
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF1F2F52-A010-4F7B-A226-1B42DC211DD5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98E71879-EAF3-4F1F-B27E-D89A543CE935">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BFB965F-D1FB-464F-A5BF-ADAD50C57F44">
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AFFDC03-AB18-40B8-A042-A4208215CC79"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE145006-D521-4AD3-85BD-19F418544482"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E7CDA24-C918-4533-9893-1287CCF8183F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:37276584-B74E-4FB5-8F92-BE77209E25DC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:6D498FF3-33DF-467B-8B8F-1BDB7ED744FD</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D15E0D1-9C28-416A-BD1F-7E1AEB24CAE5"/>
    <pav:createdOn>2014-03-31 00:22:02 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:486733A1-6BA0-491D-87AC-EA70B14043DF"/>
    <pav:lastSavedOn>2014-03-31 00:22:05 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD96F51C-16B3-42CF-BA16-5B1F8902E978">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDAED30A-05DF-4A56-9F8E-6DD05281B994">
    <pav:lastSavedOn>2014-03-12 22:34:00 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:45852E19-6CB3-4CA9-9184-70C6AC3C69C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E47C0246-9B6A-4BE6-A5D8-2ADB3920C394"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC7C08EC-8538-4471-8419-AE9E97EFCD25"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0FB9521-F95D-4205-9790-F0FBE92C424E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1FDB7FD4-1D65-46B5-BBE4-C3B05E5E33D4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:38D90118-A03F-4DFB-8B72-EF5D4C1454B7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:77410D4B-8063-40C2-BE7E-AE16339AAC30"/>
    <pav:createdOn>2014-03-12 22:34:00 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">21</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:29646A2D-EF3A-4555-940C-42CD1493859C</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCC6A986-7450-4F35-A008-C79EB76B86F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9E774F4-F3D4-46B4-A2B8-7A9CA74C6062">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C60D5D7-2E52-45C3-8A00-163F2A7D531D">
    <pav:lastSavedOn>2014-03-23 22:49:49 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC0640DB-FB00-4BDD-AE6C-B8C4665F8968"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:69A6B345-FD1B-4A9A-A62B-F220CC71A1D3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:E88042A5-290E-4A79-BB1B-56DA0D058DE0</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2516D51-A8BA-4F05-A78F-85A211CAA64B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-23 22:49:31 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC3078D1-9332-4EC6-AF69-764C06B7EB87"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:41CA07A6-5DC7-4979-B5AD-D8CC432BB53A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37586183-FFBE-4F75-9FCC-E87B8D32F621"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF2117DF-21A4-4ADC-B0D9-84511F0980DF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CB05456B-5CA0-48A2-AE72-7C5679E87FC3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DE3A70E0-BC3B-45A1-B4C5-13CC75E865C6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:924B8909-93F2-4542-8FD8-2A36899A0332">
    <rdfs:label>Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0211B005-1BBC-40DF-B279-4028894D3A11">
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4706763-84D4-43F5-96BA-E025F8E6EDEA">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:07CFF3F6-E690-4DF6-AC1A-077EB134DB5C</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AB62BB7-0B45-4E4B-8C15-EC84CC50FFF8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-23 22:52:06 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D0EA308-186E-432B-990C-BCA90E55B4A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3DB59308-0DA5-43B2-AB10-BBDA20214B95"/>
    <pav:createdOn>2014-03-23 22:51:43 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C20E67B-BD95-43D5-98A0-35BB633C3603"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:429A5667-29BB-4984-AB78-8C8370008F63"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B36538E-8738-4833-B450-26480ECF3239"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ED4B82E9-E292-450B-A991-D9621C0D1014"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95BE74BB-177A-4867-8D7F-FF818C787178">
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8331150B-687B-42BC-9FD3-909DFEB0FE8B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:811326F2-B052-4339-B2A4-7E07C5F6BDA7</pav:previousVersion>
    <pav:lastSavedOn>2014-03-23 23:17:43 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8A88B0C-96FD-40C1-A605-C6C4636112BC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <pav:createdOn>2014-03-23 23:17:31 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EE64F47-E5A5-4CC9-8563-0A7E0BE6E549"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6633FDEF-079F-449E-979D-584ECAF63B28"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5ADB1DCF-FC4F-4462-8DF6-CE05CA57C304"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:F14941D9-42B6-4F02-A883-60667BCFB049"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20D1D978-4370-4B18-A8EB-9FA2300BD2DE">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D8C6BB0-2850-4460-9D93-4339CAB541D8">
    <poc:MedicalCondition>cardiovascular events</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13AE1ED4-6994-48C8-9308-4F86F5C85E36">
    <ao:exact>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-30 18:32:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13AE1ED4-6994-48C8-9308-4F86F5C85E36"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <foafx:version>2.0alpha</foafx:version>
    <foafx:build>040</foafx:build>
    <foafx:homepage></foafx:homepage>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F4624F9D-4105-4181-92E0-3CC32657B52B">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDE4728E-480E-48F8-BD83-7F88F36AEE3E">
    <ao:body rdf:resource="urn:linkedspls:uuid:CDAA054B-E24B-48A8-A218-59FC70F32488"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 21:14:31 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-19 21:10:56 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:56536B9A-84C4-4A27-90A6-03485E201A84"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4FEBAD46-F23E-4737-A7D1-4B5D71E19C65"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:68D3E22F-07ED-4750-98A9-E8EF201D2E54"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B35E3F7-0914-4B29-9A4C-BA58ACE3C94F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:697B832E-6266-4E57-B97F-F121F7A0C776</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:02A65E80-FD06-4F5C-93E8-8EE7E454662F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F5378434-D748-49C1-8365-34F51AD5E168"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FDFC650A-05C3-4B52-A481-22A004FB3C2D">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1111FFEF-E752-49D1-8D50-8F486C2C1E51">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D394C76-09F8-414B-9A91-D92597BA034F">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>QT Prolongation</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E621FAB-09A7-4956-8D74-C2450B69C405">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07B6B442-94F5-4541-9416-C726A6D785E6">
    <ao:body rdf:resource="urn:linkedspls:uuid:06CAC201-96AF-4344-AF49-DF7E60A6D48E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:484512E9-44DD-4E7D-9CB4-DA99B2BDD0FC"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:355DB9A0-974D-4BD1-B6AA-3C439661E7B3"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lastSavedOn>2014-03-31 00:25:15 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-31 00:24:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B66E5587-3003-49F2-95AB-8ED4901E5D99"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:328E2B84-107D-4F11-A6DB-189C90C32279"/>
    <pav:previousVersion>urn:domeoserver:annotationset:FF7B2C15-5977-4CEB-9F55-237750EBC451</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B1BA362-4052-4B63-A708-937F9D8B21B8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5676C5A5-7D14-4913-93C5-5F0B5F83AFFD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1CE401E-2FEC-468E-8713-3215ED06F8B0">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A1DA3BC-4192-4E9A-B301-B64D731EF140">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E6D74F4-3F5A-4577-9DB5-CED65F294C32">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE84AE6A-738C-471C-B0E2-137314B93119">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B34B234-D3FC-4A9D-BC3F-E3741CD17BFF">
    <ao:exact>Screening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B34B234-D3FC-4A9D-BC3F-E3741CD17BFF"/>
    <domeo:uuid>9B34B234-D3FC-4A9D-BC3F-E3741CD17BFF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-12 22:30:06 -0400</pav:createdOn>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen i</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC57096C-F1CB-4169-A6CA-581ADCC88DDC">
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9188E11F-53F9-44AB-B734-844806C40192">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:853AA7C6-D5E6-40A7-9819-3720DC95B9A5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:355DB9A0-974D-4BD1-B6AA-3C439661E7B3">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>ing 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. </ao:prefix>
    <ao:exact>The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <pav:createdOn>2014-03-31 00:24:10 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:355DB9A0-974D-4BD1-B6AA-3C439661E7B3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E91D15EB-EAE8-44C3-8EC2-57447FB7B83B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAC06436-AA19-4AB6-8952-DF7587C971B0">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:031E69A8-B922-4126-B5FA-55509D1E3847">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDDCF997-4E90-4BAB-96B3-1800DB72CC1B">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FD0CAE9-84DE-4CD6-9C22-CE662488E7CB">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAE0A0A9-B405-42BF-BC14-BE7C9DDC58D5">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30B6F72E-BC8A-48B2-ABEF-584199779ECF">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55B74982-2B8D-4834-B14B-1A24634D82AF">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>biomarker-positive?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:042569B8-37CB-4D16-9AFB-DFEAFF807AC4">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D3D7FEA-58C7-4DF3-832A-67A1C032C61A">
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3BBC6797-38DC-43B1-A086-790306EBF4C7">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D502499-2D3A-41B1-9772-8C50B6783449">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACODYNAMICS (43681-6)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACODYNAMICS (43681-6)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C77F7743-813E-4911-A277-682D202D697E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42A10237-EFE8-4EC6-A4A2-556FF94B3F74">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Not change from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:509249B5-D139-492E-850E-CBD78DD46246">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21638A6C-1F7D-4711-AD17-5BFE4DF3E7D0">
    <ao:suffix>(see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21638A6C-1F7D-4711-AD17-5BFE4DF3E7D0"/>
    <ao:exact>TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets </ao:exact>
    <pav:createdOn>2014-03-23 23:19:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>21638A6C-1F7D-4711-AD17-5BFE4DF3E7D0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B6B7344-5691-4A81-8539-22F0C0A83EE0">
    <ao:body rdf:resource="urn:linkedspls:uuid:FF1F2F52-A010-4F7B-A226-1B42DC211DD5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C40C6117-12B9-4A4D-883B-2542FFC8D2B1</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2805EA8C-EF36-4F17-A3DE-0D65B57A2D91"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89C8B2C1-CB35-4D7D-8257-D11650AD37E9</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-31 00:20:28 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E4A83A6-A990-4861-BCF6-169897B6B8D9"/>
    <pav:lastSavedOn>2014-03-31 00:20:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9718231-5945-4B15-8C90-921DFE7E3D2C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6ABFEC3E-104C-469D-8076-BC792935BE05">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCE71DF7-E5F4-4726-9940-F33B07BD0A1C">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B9180E1-F8B0-4E45-9431-DA082CEAE63A">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A0C4ECF8-929C-4039-8663-1B6848A1DD92</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A78343E7-646D-44AE-804D-17E99B61E65A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:0388CA5E-0326-40F9-A660-1241CD189BD8"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A19FD79A-C725-4BDB-B026-52F32C6FBB5D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:26D588F3-41B7-406F-9D1E-4CE861B2BA80"/>
    <pav:previousVersion>urn:domeoclient:uuid:03C208F3-531B-4EEE-B812-3706BC2F6E0F</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-30 17:39:18 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AD8FE1E-C2E8-4D6D-B2BA-0522FF186938"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ADB89221-52E2-4386-BB2B-D5A0899DD249</pav:lineageUri>
    <pav:lastSavedOn>2014-03-30 17:39:46 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78C90864-4E29-4906-BC74-34F20D2DA609">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B1BA362-4052-4B63-A708-937F9D8B21B8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4E2B723-3366-477E-A046-C7778D389147">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37276584-B74E-4FB5-8F92-BE77209E25DC">
    <ao:suffix> (Table 1).2</ao:suffix>
    <ao:exact>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37276584-B74E-4FB5-8F92-BE77209E25DC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-31 00:22:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:479239EB-1160-4AE1-A341-34816989D14B">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:841AA996-EF35-4CFB-BF51-8D6B14F65A3E">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:612A62A5-59E8-4743-BC2F-967D50CC053E">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25ACCDE7-5C34-4230-8A3E-0AFC060AB38A">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdfs:label>Use specific</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50B795FF-C46C-44EF-AB7F-B77AF7CA7848">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:prefix>The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-23 22:38:01 -0400</pav:createdOn>
    <ao:exact>Across Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in &lt;1% of the population in Japan and Korea.</ao:exact>
    <domeo:uuid>50B795FF-C46C-44EF-AB7F-B77AF7CA7848</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50B795FF-C46C-44EF-AB7F-B77AF7CA7848"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A14345CD-ACDE-4B67-94B7-074A12C6A0CE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D94D39C-501C-47E1-8CF9-F788442BA615"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E233EFBB-BE1A-4A47-BDA4-CAD0F2126F85"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5BCEAED0-B0FB-44BB-8A36-8513807F07BA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7BF5B4BF-B41E-43F1-A9D3-83F0F65FCD2C"/>
    <pav:lastSavedOn>2014-03-23 23:24:54 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-23 23:25:06 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:C5EFBD3B-9932-46B9-8D94-A768E02B8A54</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8CD91A3E-F7A8-481F-BBB3-1D33A2FA2A7F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B03D7253-6A76-4467-B47F-E92D34EB9AAD"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:26E678DF-4F3E-45FA-AC5D-0976318E4298"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4BAF798F-3FAD-4BB4-9D75-C54CFE661124"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB123344-D0E1-4332-B0D4-235435FFC136"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40F75024-E7AC-413A-8DAA-8A8A38A4225A">
    <pav:lineageUri>urn:domeoserver:annotationset:F2769DF7-E160-499E-96B2-621EF845FFF4</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0E0164C-8980-4DE9-9AE5-405F1EC1814E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E02A39E-C080-4AA5-A578-0D1CA3F8E035</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8865A4EA-F8C3-487B-9A08-6A503CAF8AD1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D5B943A-FE80-4DFE-8467-184C4E893E6E"/>
    <pav:createdOn>2014-03-19 21:42:19 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-19 21:42:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA28E86B-78B1-490F-9DE6-39B3B705088B"/>
    <pav:previousVersion>urn:domeoclient:uuid:804BA0DB-ECE0-4D2E-B990-C7F144120BA6</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:33396A7B-7788-40EE-A253-C1DC4F6EC99F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:76C9AA35-16FB-4216-80E4-34C205BF2995"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:382A47B7-4A81-4B30-AA8B-336379E0CDE7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD518DD0-6A46-4E66-8F74-EAE4BE00FAB1"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:8AE9F0E0-58FA-4F77-919F-662A85A02955"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84867383-9368-46A9-9A8E-AB299B322C1A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:84867383-9368-46A9-9A8E-AB299B322C1A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Clopidogrel tablets may not work as well in people who:\nhave certain genetic factors that affect how the body breaks down clopidogrel tablets. Your doctor may do genetic tests to make sure clopidogrel tablets are right for you.</ao:exact>
    <domeo:uuid>84867383-9368-46A9-9A8E-AB299B322C1A</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>What is the most important information I should know about clopidogrel tablets? 1. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-27 11:01:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFA56C36-B17F-4540-B2AC-B71841975EA1">
    <ao:suffix> CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6,</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BFA56C36-B17F-4540-B2AC-B71841975EA1"/>
    <pav:createdOn>2014-03-23 23:42:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A78343E7-646D-44AE-804D-17E99B61E65A">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E084DAEC-30B5-4035-8776-0D1CF8B30B76">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AD8FE1E-C2E8-4D6D-B2BA-0522FF186938">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B722120-A648-45D2-8707-ABFCA189B87C">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79A1075A-57D5-47F0-9EA8-95A310845E3F">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35508F03-F68C-4B43-9DE6-7B4270D23882">
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBBBF84B-D648-45F7-91D4-1DB7AE1F1287">
    <domeo:uuid>BBBBF84B-D648-45F7-91D4-1DB7AE1F1287</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BBBBF84B-D648-45F7-91D4-1DB7AE1F1287"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-23 23:12:46 -0400</pav:createdOn>
    <ao:exact>The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C</ao:exact>
    <ao:prefix>Phenotyping and genotyping methods are commercially available. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8599E37-ED3D-4121-9F99-AD576994A6D8">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30281C67-B7E1-4405-9A6B-AB67C9A6EA0C">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CDE65BB-7EFB-4688-B446-A716E7617AEF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25F0AFFB-94CB-4A46-8F7D-6F6DA4D0DEDE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25F0AFFB-94CB-4A46-8F7D-6F6DA4D0DEDE"/>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-12 21:38:21 -0400</pav:createdOn>
    <ao:suffix>(5.1)</ao:suffix>
    <domeo:uuid>25F0AFFB-94CB-4A46-8F7D-6F6DA4D0DEDE</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:756F0451-88EE-4A2F-871E-FDC9A3A2AC61">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CBF038B-286B-4630-8077-D2EB1C3D0C37">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F5DDFBA7-A6BE-44E0-90FB-A6FF287C2DFE">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75A65ADE-85F0-4522-B219-2A71DB7F79AA">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F793DBA6-9B88-4A60-A5D0-4BCD004482C9">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0846DFE-8249-4B82-ABB7-917D625E8EAB">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Not Important</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:781CFBED-4273-481E-AD79-30E79C5B5F36">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E0F40D1-0681-4E31-A154-A349D19F785F">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18756329-D495-44E8-9744-CFC6A3AAF875">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B125C40E-C47F-4DB3-B325-E27E30FDB881">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:272FCCCF-44E8-4720-B5D9-D54DF9BA77A5">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A99DF291-EDBE-490B-A5F9-A395B25AB97A">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A99DF291-EDBE-490B-A5F9-A395B25AB97A"/>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-31 00:35:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5789948E-7EC4-484B-82C7-46BF0845F2B6">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C878279-33B0-472C-8710-78F89FCE2E1A">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2C9A1DE-0A94-4726-870E-EE62ECD4B746">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:814BD1AC-4D7A-4640-90C8-1F37E6BB61A1">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53E32812-2CFE-4097-89AA-A4E137592BF5">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45CE0CAB-7F4C-4328-9A1D-0E9079C60ED5">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8916D64D-9A5F-4535-9083-31E3FA43C897">
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. </ao:exact>
    <pav:createdOn>2014-03-12 22:06:01 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8916D64D-9A5F-4535-9083-31E3FA43C897"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Serious and sometimes fatal hypersensitivity reactions have been associated with ZIAGEN and other abacavir-containing products. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients o</ao:suffix>
    <domeo:uuid>8916D64D-9A5F-4535-9083-31E3FA43C897</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:894068D7-91D1-4766-9BF8-B43068180349">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FC0B24C-0927-405A-98EB-573A96DC7704">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5EA3F38-45AF-4BC4-B143-01BB499F5D2D">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B89D3B1-90F7-4906-8803-928A58587383">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29255FA1-9631-44F1-A1B6-5D03F3302D19">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D8E947C2-F0CC-4FE8-9464-2EC9438D769B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:606C1643-DAD6-437C-A543-80E713B209E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:70BC4B0E-82EA-47B3-A28E-AF1FAD151F53"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-30 19:15:45 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-30 19:13:22 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1BABDA90-3CD8-4CB3-A328-528C36AD52ED</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:EE84AE6A-738C-471C-B0E2-137314B93119"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:538B3F97-9F0A-47A0-9698-0BDB93EA4B56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:53455F83-7589-4904-AA1B-772F65CD01E2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54C198C9-35F0-4172-9CD4-BE50467C98EC">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D1383C8-0241-45A8-A35F-1ED51A5B8F38">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90A210BD-44AD-4192-8EA3-6DE8C2F0EB78">
    <ao:body rdf:resource="urn:linkedspls:uuid:5CA5E417-AACD-4925-AAAC-931EF45B4F20"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06252C2F-7322-410B-9938-7959BD43F9F7</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-23 22:52:16 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:CF0A7FA5-11F6-4397-B0F2-3B10082859E8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-23 22:52:06 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EB3831F-DA33-47DE-AC71-370EA008DAA6"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5EA3F38-45AF-4BC4-B143-01BB499F5D2D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:BA648B09-F59B-4E22-8523-6401F1529B9E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:849D5A6A-8D45-4A3D-9A88-F6CC04CA9856"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FB72C9B-BB19-40D9-9885-B6FC808A8E0A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:961D27CE-41BD-4A30-97DB-4AB3ACE087FD"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16A9F1EC-7A0B-4DC8-9C8B-AA1597EF3223">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>16A9F1EC-7A0B-4DC8-9C8B-AA1597EF3223</domeo:uuid>
    <ao:exact>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16A9F1EC-7A0B-4DC8-9C8B-AA1597EF3223"/>
    <pav:createdOn>2014-03-30 15:57:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Data are not available for other ethnic groups. These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at la</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97FBC6B0-D570-4F49-906E-DEA55D7EF1E7">
    <ao:context rdf:resource="urn:domeoclient:uuid:8A9F4CD4-84CA-4390-BDAA-C971766A10C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E12C5B6A-3DE2-4521-9520-42C37C001E45"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:77CC5165-709A-4280-98F9-64A95AE9C1E4"/>
    <pav:lineageUri>urn:domeoserver:annotation:EFDFEEAD-089A-4F42-8E9E-5B4412F81E06</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFCA1EBA-DD22-42C9-BA19-79E64C5DF664"/>
    <pav:createdOn>2014-03-12 22:41:28 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3AF7DCB-3E76-47B2-B616-7C19FA8EA8C2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4A848DE-556D-4C1A-A408-4D37D3B1AD1A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AA812FA-86B4-499B-9C15-A224E825A081"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-12 22:41:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC866D4C-5D87-4ABE-A303-39F7C8E5E609">
    <pav:createdOn>2014-03-30 19:07:28 -0400</pav:createdOn>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS). The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC866D4C-5D87-4ABE-A303-39F7C8E5E609"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>out 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8034D576-6C73-431B-A638-082604606DA2">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CD947B9-71A0-44E6-85BB-52CCB183B3EC">
    <pav:lastSavedOn>2014-03-19 21:14:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8556FCD8-8D24-4AED-8AFE-2B1A0D6AAB57"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D90A368-545D-414B-99DA-10D2ECADC69F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EF29D93-B708-4334-ABE0-A4F504F693F9"/>
    <pav:createdOn>2014-03-19 21:12:03 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:697B832E-6266-4E57-B97F-F121F7A0C776</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:0211B005-1BBC-40DF-B279-4028894D3A11"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAD10DE2-A5E4-4CDE-8CE2-64E7360405E3"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5CB377D4-FDCE-4B53-8A8E-0E31F17B3E0B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA0E5586-D9CF-496D-9C8D-990575E47F66"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66A3173F-9D44-4C07-BFB7-EDDA29107205">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47D3BDC7-54EA-4C97-B28C-679F896B082C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91D95F95-D5B8-4F3B-B4C6-75E40EEE4729">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C876A45-36EC-4087-B118-733AC8A16CEB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58ECC7CE-444A-452B-BBFF-D3894762B2AC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 21:36:58 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58ECC7CE-444A-452B-BBFF-D3894762B2AC"/>
    <ao:exact>In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively.</ao:exact>
    <ao:suffix> Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation (see</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>58ECC7CE-444A-452B-BBFF-D3894762B2AC</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:09E87A6A-EA22-4C69-87B7-6547EF5E8F74">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C57CCA66-6E2B-4CBB-8DF5-43543D1AE1C9">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BE0AF1F-C73C-419B-BE14-2F45AC1CBE10">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-30 18:20:31 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>9BE0AF1F-C73C-419B-BE14-2F45AC1CBE10</domeo:uuid>
    <ao:suffix>In postmenopausal women, estro</ao:suffix>
    <ao:exact>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BE0AF1F-C73C-419B-BE14-2F45AC1CBE10"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30D75678-130E-4213-AED7-CD08EE0D8776">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E31860F8-637D-427E-9017-5FE78F4A4999">
    <ao:body rdf:resource="urn:linkedspls:uuid:23A80618-FAB9-4C98-974A-150C4101638B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EF444C06-3764-44E8-80EF-32D87C985247"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E4A2D0E-018A-4EDA-9856-783BBE233B0C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F216E62E-5A04-4FB8-80E8-78AA044F91D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5676C5A5-7D14-4913-93C5-5F0B5F83AFFD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B7CA02F-D5F1-4AD1-A65E-439F0110A551"/>
    <pav:lastSavedOn>2014-03-12 22:22:35 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C6D3598E-4F9B-49F4-901D-DA73EB438AED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17865789-0D97-46CA-9402-E55D941250EF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D65A920-FF32-4C4C-8F35-AF6B9564CDD6"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:1F1B7CF2-57B9-4F48-A86C-9D60BD894A3C</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A24B4BD-71F9-4C85-91C8-68977D97EE7C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-12 22:22:36 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E2A610A-170B-41FB-BA91-E698967BC64A">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6347F52F-255A-44F8-AFCF-9DCDB7E80823">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A71CDBA-2F99-4E8A-9209-A304EB4E9DE4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A71CDBA-2F99-4E8A-9209-A304EB4E9DE4"/>
    <ao:suffix>[see Clinical Pharmacology (12.5)]. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration (2.3)].</ao:suffix>
    <pav:createdOn>2014-03-23 23:32:56 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy </ao:exact>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:429A5667-29BB-4984-AB78-8C8370008F63">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07FDA881-59A1-4A9C-B083-8876ED57FB6E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:042569B8-37CB-4D16-9AFB-DFEAFF807AC4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F9A8E68-8813-40B7-AC1C-31419AFC9B75"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CFB7832-4BF5-44E3-B77E-148FB1DC169B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F41D755-4E94-4D5C-A672-02D01CB36548"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A8353EA-D986-4749-965E-C06DCDDF7470"/>
    <pav:createdOn>2014-03-19 21:39:20 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:921E865E-412B-44C0-8B67-4CA256EE7B79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D394C76-09F8-414B-9A91-D92597BA034F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:F2769DF7-E160-499E-96B2-621EF845FFF4</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A2E65A8-DD6F-4EA5-9179-89D3C3FF6D24"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3E8A7D1-B36B-4D9D-AD4F-3242EADD49DA"/>
    <pav:lastSavedOn>2014-03-19 21:39:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:58376576-D995-4344-BBE4-2A6CC753D97C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E02A39E-C080-4AA5-A578-0D1CA3F8E035</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2741CCC4-F6D7-4860-8B71-DD0FFEC41C0E">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42437394-462B-4271-AE87-64417F6EAE21">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15200138-596B-4E19-94CA-D2A1CD7CF8E0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:154F5E0F-239E-4D8B-AB4B-1650282B3779">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5cf05de4e75a49b7a97c9a4a82f928bd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4BE273EE-7C26-4019-A132-1E01698FC686">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACODYNAMICS (43681-6)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACODYNAMICS (43681-6)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B54D42D-68A4-49AC-AFBC-DD5C963A0C4E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:221669A0-18A5-46A0-9458-FB576AD02A6F">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9399A433-5F69-4574-89FF-94B33B649AA7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:98077F2B-3233-4414-96DA-DD8B43905C68"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F491B0E9-FCF8-428E-A87C-812AB3280AB8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4A62C9A-7549-47D5-901B-7AC12A8D56C6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D94F9B81-7F22-4FAA-A379-A66D573E58FA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2014-03-30 15:58:56 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:BD0A53D8-D315-4522-8945-C3F41DBBBDA1</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:53D495A8-73C1-422D-BA5E-47262BF97FCF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E5D2475-51E1-4806-B211-B3086D8A646C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E38DADF-AA16-4501-9E06-DA6B429E04B7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:76F61B42-B62F-42DB-93E2-94098FF5FCA6"/>
    <pav:lastSavedOn>2014-03-30 15:58:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:421121E1-97B7-475D-875F-D4E1DAB6FB06">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF0D1BF8-C499-4C6B-8F6E-355B760CA8BB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6A9B411-8766-4A42-BD9E-31003583997D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B50E0C7-9351-486A-BEE3-2774F6C3F9D7"/>
    <pav:lastSavedOn>2014-03-19 21:24:10 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B07FA7C5-7086-4BFA-9FC5-C4488A865D11"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5BD05867-26DB-4074-8CFB-E72B21B26317</pav:lineageUri>
    <pav:createdOn>2014-03-19 21:22:25 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA3A4774-635D-49BF-9DDC-7764D0C66B8C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4967FA85-A518-4BFB-81D9-51444A1F1EF8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E03F6009-DF79-416C-A5F1-75843AA2E3B2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:289C513F-0EC8-4AA3-B445-BE3AE3FC5E8B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D487E03E-FBE5-48CA-8E8D-0492E7FAAF7B">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0983FC55-C47C-4D5F-BE45-9D49629AFEEA">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:657A455D-D51A-42C3-8D72-544D57C642B6">
    <ao:exact>Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>657A455D-D51A-42C3-8D72-544D57C642B6</domeo:uuid>
    <ao:suffix> Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine. TPMT genotyping or phenotyping can help identify patients who are at an increased ri</ao:suffix>
    <pav:createdOn>2014-03-23 23:08:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:657A455D-D51A-42C3-8D72-544D57C642B6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur in patients being treated with azathioprine. Severe bone marrow suppression may also occur. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D4A1B9CE-C76A-44B2-AF56-2BFE56C2DC18">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC407C66-02BC-455C-AC8B-6EA78DFD9A99">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8402D442-202E-4308-83DA-528F027BA84F">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1EAE992-56A9-4FB0-AF29-A0F6026BAF58">
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A45D4405-05BF-4F00-8FD4-A206FB1ECFDB">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:66F355EE-B965-48F1-AE6C-8E01F41D7441">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4A848DE-556D-4C1A-A408-4D37D3B1AD1A">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6D950A3-368C-4A88-AB34-BB3D04A9C6B6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6D950A3-368C-4A88-AB34-BB3D04A9C6B6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:exact>Letrozole tablet is an aromatase inhibitor indicated for:\nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> (1.1</ao:suffix>
    <pav:createdOn>2014-03-30 17:38:47 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5FB5B5E9-2EE1-41B9-8BD4-EEC50CA96DC2">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6CED629E-0761-4325-A5C4-AAFDBEE6A710">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E5D2475-51E1-4806-B211-B3086D8A646C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E29FBF60-B04B-4872-AA08-C0BCC8B7901A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B395286B-8734-4537-8BAB-C4E0411685BF">
    <sio:SIO_000338>poc:productLabelSelection</sio:SIO_000338>
    <rdfs:label>CLINICAL PHARMACOLOGY (34090-1)</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSelection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:productLabelSelection>
    <dct:description>what section of the label Pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:20D96C9A-F90D-4509-A97C-28D2087753C5">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4FEF6F7F-2BEB-4A7B-8A94-650294ECF0C6">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:790FD2A2-88E7-4856-9FF1-D3BAC92337AC">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>790FD2A2-88E7-4856-9FF1-D3BAC92337AC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:790FD2A2-88E7-4856-9FF1-D3BAC92337AC"/>
    <pav:createdOn>2014-03-27 10:39:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(12.5) </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:160FE20B-685B-43BF-947D-8FFD1C1B22BF">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>Unsure how to classify the 3 statements from this paragraph and if they should be separate or combined.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E4749D1-8233-43A6-B67D-7D9D39797DA6">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A1E0F07-CFC5-4A4C-98E7-E144BAE423F2">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>do I put \"decreased metabolism\"?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B66F8CA0-B324-4890-9E1E-AD608512C661">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B8D5267-546E-4B1C-996F-79A3E274839F">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68256107-7A03-4239-A377-8257D331C926">
    <pav:lineageUri>urn:domeoserver:annotationset:0973CCE9-67E2-46E4-ABBA-78E51BACDADA</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:1BABDA90-3CD8-4CB3-A328-528C36AD52ED</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:140F95D7-520F-4FE8-8676-14E2838BBFCB"/>
    <pav:createdOn>2014-03-30 19:10:11 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:86A3FEC8-D81B-4945-950B-9E2C08CD931D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8D396288-1083-42F4-8DF4-9C2B4AB160F8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B20082CE-01BC-44A8-985B-0F57BFABA0D6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C1C0886-FD85-4371-9C72-461C413402CE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-30 19:13:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:79086F7C-0C84-42C9-88CD-ADFABE0C30D8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F216E62E-5A04-4FB8-80E8-78AA044F91D0">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:926949F0-4D54-4C5E-9A18-E99423856F63">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E161E15B-D38D-44C8-ACA1-A5798BD2EA2E">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DAE7E60-BCE3-4F51-9748-431EBCF580AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5DAE7E60-BCE3-4F51-9748-431EBCF580AE</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:exact>Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive patients, when alternative therapies are otherwise equally acceptable.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE]). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DAE7E60-BCE3-4F51-9748-431EBCF580AE"/>
    <pav:createdOn>2014-03-23 22:45:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3DD63283-6E9C-4C02-BB6E-48F818B62B72">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3DD63283-6E9C-4C02-BB6E-48F818B62B72"/>
    <pav:createdOn>2014-03-23 22:44:18 -0400</pav:createdOn>
    <ao:exact>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE]).</ao:exact>
    <ao:prefix> experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration in determining the need for screening of genetically at-risk patients currently on Carbamazepine Extended-Release Capsules. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>3DD63283-6E9C-4C02-BB6E-48F818B62B72</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8AA3224-BEF1-4761-B5E4-E38D62375C5E">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B9C0CF5-77BE-4351-8F4A-A03C7B56C33F">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7D84BC7-1B08-4D4D-AC8B-8FA9BC1F4EA5">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CE2ECE7-E64C-46D0-A002-8EAE7337E954">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:342996DB-0B46-46AE-856E-13F12749AC4F">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCC6A986-7450-4F35-A008-C79EB76B86F8">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE90EC35-FA29-4EE0-A7C7-70AACC8D7F13">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C6D3598E-4F9B-49F4-901D-DA73EB438AED">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF3DBB33-6743-470A-AD73-99B2C01CA103">
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B598A4B-160C-48F3-950B-69199D699A4B">
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:827F9942-3331-45EB-9926-839068646646">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4583BABF-9093-44DF-8D39-12C4DB2ACB54">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:256ED16B-306F-4B2E-BACA-8536BAFC8939">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F356450-F6E7-47E1-AF36-6C857B581FF1">
    <pav:createdOn>2014-03-19 21:36:58 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:F2769DF7-E160-499E-96B2-621EF845FFF4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:AF9FE8E3-05BD-4AED-AD3E-62E34CB10483"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4E02A39E-C080-4AA5-A578-0D1CA3F8E035</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-19 21:39:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B485ED7B-BCFB-44A3-B4A6-64CF3AF7C9EC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C2C3EA2-0486-47C5-BE50-B03439581C02"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:60A2F326-9E75-4844-B196-26D3AC8A3C7D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3B6F6AF-F39A-4973-AAE2-62E73052FC26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B7A276BC-A450-4F86-80C4-A47F9BCCBD77"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:58ECC7CE-444A-452B-BBFF-D3894762B2AC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3ADA8F27-4AE2-420C-A0CC-4262BA73508E">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B07FA7C5-7086-4BFA-9FC5-C4488A865D11">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <rdfs:label>Aripiprazole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7072A2DC-FEF0-4529-B45B-9BEF5809CB79">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:991AF447-FA2E-4568-A865-00C16B645701">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the var</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:991AF447-FA2E-4568-A865-00C16B645701"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-31 00:27:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12DED5C6-4B22-4FD5-9B97-AA962F2D3E68">
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of</ao:suffix>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>12DED5C6-4B22-4FD5-9B97-AA962F2D3E68</domeo:uuid>
    <pav:createdOn>2014-03-12 21:45:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:12DED5C6-4B22-4FD5-9B97-AA962F2D3E68"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5BCDA22-18D9-4AEF-B125-2C0DD7CE8B07">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E972F6A-F528-4242-B79C-C7832B957DE2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-23 23:42:11 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F1872F36-CC24-4F65-9CE7-B0620A278F06"/>
    <pav:lineageUri>urn:domeoserver:annotation:E4C5B4E9-2F02-46B2-B74E-7E7DDB8854CD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0A32F5C-FBD4-4F5D-95F2-F8638897B58A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-23 23:46:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0978CC70-82ED-4575-8D0C-6F7CDA82F841"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BFA56C36-B17F-4540-B2AC-B71841975EA1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02E16D41-B27B-4290-93CB-FB83EA29B5B8">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1892C00C-A379-423B-B6F7-998BB17E8BF8">
    <poc:Comment>I know we discussed this at the last meeting, but I wanted to confirm if we are marking "active ingredient" for these statements. The statement refers to abacavir, so should I mark the "active ingredient" box?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A42A42A-5627-40C3-8297-A112CC83960C">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2302A2D-0E55-4B59-AD91-58549A4767D7">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:216A8C4D-99D5-49AE-9BB1-1C508D19C692">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C43B620A-1A47-4B9B-8318-726A784F9CEB">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E74D5C5C-2D64-47F3-979F-D20C4375DA61">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B04F057A-EDC6-4235-9597-9387E928EAF6">
    <ao:body rdf:resource="urn:linkedspls:uuid:1DA5E8D8-9463-4EE8-A179-6E159F87E2FB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC2B1229-C8D7-4C50-B02A-D3281A5E23EC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5FAF8F9F-E409-4CEF-8FFE-2F0A2A378AB3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E771F08C-9FFD-46F7-A737-B4CBE8363F40"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52349D35-C9A9-40FB-9457-C4D015E71E78"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-30 15:56:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABCBD09F-85BF-4BF3-91EC-46AF1E0C5138"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-30 15:56:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:CEDCB262-F29E-464A-8165-2B7C0D0905E4</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCB82FA4-8F13-4111-8606-1FC114648522"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE331A24-968D-412B-91B8-7D4C08AF6C11"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0ECFFFE1-DE79-4A75-B67B-2CD319736302">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA0E5586-D9CF-496D-9C8D-990575E47F66">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D608B4D7-D63E-4C74-B957-8721DAD3A141">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8331150B-687B-42BC-9FD3-909DFEB0FE8B">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3305C361-0254-42D8-879A-56E68F3EDFD5">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>intermediate-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C784F374-FD0D-4D58-A395-967BCF50D373">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9078A1D-6FE8-4636-98B6-CCFC96919368">
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3664A3E-9D5A-4E8E-9997-2C0DED6F5D13"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:564A5B55-1A9C-4268-A3E7-9B40281B40CA</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:39B9A890-B732-492A-85D7-C41E977B1DAA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8847DA0-3F9B-4A8A-98ED-9F32320D88D0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:618270FD-ED78-48C1-9636-6DC7186B5690"/>
    <pav:createdOn>2014-03-30 15:47:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CD80D8B-3673-4762-A7C2-01D1213A54DF"/>
    <pav:lastSavedOn>2014-03-30 15:47:51 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:698F110D-33CC-43C4-9ED3-BF931218BFB4</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:90AA8ED2-5F69-464D-A903-0114AA0E66E9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:A0EA0D96-CBC3-44B2-8239-8C450F60DFCB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:516567AB-6456-42E8-B89B-B27BE8679B0E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3188E338-4D81-45E2-84ED-62B3E2B919FE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:825D221F-84AE-4802-8BAA-915BD1F28A23">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1566EE7-9321-4FAA-A247-AEF404479CA9">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>I thought the first sentence was important to emphasize that if there was discontinuation for any reason testing should be recommended.</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCE2EA7A-666F-49EC-8919-CA5EC19D8D44">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D889F217-7A08-41F3-8B7E-82C351066273">
    <ao:exact>Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets. </ao:exact>
    <ao:prefix>nversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. </ao:prefix>
    <pav:createdOn>2014-03-23 23:02:28 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D889F217-7A08-41F3-8B7E-82C351066273"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>D889F217-7A08-41F3-8B7E-82C351066273</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:056EC7EF-FF16-45FE-B8BE-C0169E49A180">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:056EC7EF-FF16-45FE-B8BE-C0169E49A180"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8.</ao:exact>
    <pav:createdOn>2014-03-23 23:44:09 -0400</pav:createdOn>
    <ao:suffix> A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to de</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73E4519B-2533-4ABC-8D6D-8845FDFDD8E2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B41029D6-0D67-4DFE-9744-03770E1121DD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0DB6A8E5-8AF8-46DB-8D54-04CDAC4DEC6A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:028BEA0F-5181-40C4-B72A-2DA8A8A5F295">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDAA054B-E24B-48A8-A218-59FC70F32488">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2805EA8C-EF36-4F17-A3DE-0D65B57A2D91">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC3078D1-9332-4EC6-AF69-764C06B7EB87">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30BE3ABA-AD95-49DC-8199-00F65722669C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2BF08F4-7DEA-497B-B8E6-824C0106DFAE">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD73B147-99E1-41E1-BEF5-00459BC2509D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8CD91A3E-F7A8-481F-BBB3-1D33A2FA2A7F">
    <rdfs:label>intermediate-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACB34FAD-130F-4098-A257-AAF380F439AE">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4E6A196-57D8-4E55-8168-9722CB5E3D44">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2083735-0499-4324-BD13-EBC3F7678685">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16E10100-4A21-4770-AA2C-E5A9412A4481">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>TPMT</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CFB7832-4BF5-44E3-B77E-148FB1DC169B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:772C5224-BCB4-40C3-9387-6490411A5527">
    <ao:exact>Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>772C5224-BCB4-40C3-9387-6490411A5527</domeo:uuid>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-12 22:30:47 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:772C5224-BCB4-40C3-9387-6490411A5527"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweig</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AEE4F635-4FDB-400A-92A6-C3F64E21DFA9">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D769C96-B158-4628-8675-E329993925D2">
    <ao:exact>In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix> VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses.  </ao:prefix>
    <pav:createdOn>2014-03-31 00:29:05 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D769C96-B158-4628-8675-E329993925D2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:181E4C94-00EB-42D4-B76A-251AD9BD0BCB">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N20293665140445a8aead4921c18f2e40">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62264B8B-1D55-4BF4-81DD-C1160D65CF53">
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7AFAE69F-4682-4945-967E-D2DE95A1534E"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B7872BD-7F7F-4EF9-85A1-52FEA1C44DB0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3868EF78-EF7D-4EFF-AB49-6E7DB38F6F2E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A91D95F-9747-4CAA-88D8-F00BCB181669"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15200138-596B-4E19-94CA-D2A1CD7CF8E0"/>
    <pav:createdOn>2014-03-12 22:07:02 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7602BC04-8B6F-4AFE-ACCD-A7961D3B15D3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:062E98C5-D4E3-4AE7-A0C2-31F73677394E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8AA3224-BEF1-4761-B5E4-E38D62375C5E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A2F4A09-0FB6-4B10-9A69-E9E9564CE151"/>
    <pav:lastSavedOn>2014-03-12 22:07:03 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8D1383C8-0241-45A8-A35F-1ED51A5B8F38"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5CC1D2B-B5EF-4348-979C-3B5A68F2F002"/>
    <pav:previousVersion>urn:domeoserver:annotationset:00B26AA3-3B27-4803-9C31-612F3F874243</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BC39231-A4D1-474A-983C-D440595889F1">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FFBE9EA-D06B-4805-AE3D-07508CB6A6E8">
    <poc:MedicalCondition>pancytopenia</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A19FD79A-C725-4BDB-B026-52F32C6FBB5D">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65F86DB9-8AEF-4DDE-AAD6-DF5051A1356B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0646F913-BAFF-49A0-8F70-F023248EE27C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E1E0433-C665-442C-A51C-35E8F3427EEC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:AED5E825-729C-49AB-9088-0729D06BE2BC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:07747B94-33CD-432B-9681-4BF7B9CFF56C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:95E1E640-AF4A-4C6B-B3A6-60EB35E19138</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B125C40E-C47F-4DB3-B325-E27E30FDB881"/>
    <pav:lastSavedOn>2014-03-27 10:48:09 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:69C362C5-50F2-4D7D-ADFC-E6728808C39C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:81204B81-8A33-4CC1-905B-5603AE8079F2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:060C80DE-6E8A-494F-B891-E70F4BD4954E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdOn>2014-03-27 10:45:31 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5465EEC0-AD58-4E26-9CC8-356C82C92824">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA6BF0C9-4BFA-400A-BE1E-DF82AF90922D">
    <ao:body rdf:resource="urn:linkedspls:uuid:A1F50A29-97CC-4FC8-A54B-251FF1B764DE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C4C97E33-EBC1-4BA0-AD9E-0FCB9D4A5AE3</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:44842BF2-DED7-42E6-B5D0-A90495A5D2BA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4E6A196-57D8-4E55-8168-9722CB5E3D44"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8520BBB1-AF07-4CAB-B7DB-2EC4B2E1CC35"/>
    <pav:lineageUri>urn:domeoserver:annotation:8AC9E728-7931-48B7-8BA9-5B1CC092EC99</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2ADE52F4-318E-44C9-99D6-9D2C7E611B16"/>
    <pav:createdOn>2014-03-30 19:15:48 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-30 19:15:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:431F9DA9-900A-4963-9E24-AB4C06C74C6A">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0DC53070-C143-49C8-9EF1-DE9255CB3490">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06CAC201-96AF-4344-AF49-DF7E60A6D48E">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90AA8ED2-5F69-464D-A903-0114AA0E66E9">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D03700A4-6A4A-4C41-8274-1F303C3D24DC">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77CC5165-709A-4280-98F9-64A95AE9C1E4">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC9D2CE6-672A-4E3E-B537-BB71107CB6D6">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C6DC892-8D0C-4DC0-9998-5080C0455DD9">
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B734427-24D9-47B2-A3A5-D32C1ED4EE27">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:712048D1-3527-4C08-89DB-15C5DC87C2C9">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A30188C-6347-4313-86FF-0A1E0E6A30F8">
    <pav:previousVersion>urn:domeoclient:uuid:A52EC55E-04AD-4D91-96C6-FF619EFE1F63</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:92D0CD32-DE29-479A-A1C9-B52F7D9F53EA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:874FE843-B328-45C6-959C-688057D5F5E8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:45F4C49F-7B05-45AF-B153-2100A704B41B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F27F321-E430-44D2-BD86-E4AC9391E8CC"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC7B1068-9C54-42CB-8C5A-5F06348CA7E0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CA7DAB8C-C082-48C8-9540-36E5C7584A59</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:9249AAD7-3832-4D10-B845-EE5E996EE89F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BA762E3-EAE0-40CB-8FE2-544EB35D1DD9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896ed8340009</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-23 23:04:39 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:756F0451-88EE-4A2F-871E-FDC9A3A2AC61"/>
    <pav:createdOn>2014-03-23 23:04:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85B0CEE8-721A-4417-B809-CE3F5FF624B6">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBFDF08D-E03B-4205-BEDA-04814DFD1C32">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BA762E3-EAE0-40CB-8FE2-544EB35D1DD9">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EE680F6-120C-4D1A-AA95-B8526EFA6669">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0EE680F6-120C-4D1A-AA95-B8526EFA6669"/>
    <pav:createdOn>2014-03-23 23:11:08 -0400</pav:createdOn>
    <ao:suffix>Phenotyping and genotyping methods are commercially available. The most common non-functional alleles associated with reduced levels of TPMT activity are </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0EE680F6-120C-4D1A-AA95-B8526EFA6669</domeo:uuid>
    <ao:exact>It is recommended that consideration be given to either genotype or phenotype patients for TPMT. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E006CD1-9815-4CA6-9949-9A348002811A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A70664FC-EBAB-470A-AA3D-10BCA0659962">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:484512E9-44DD-4E7D-9CB4-DA99B2BDD0FC">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69A6B345-FD1B-4A9A-A62B-F220CC71A1D3">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5C95A2D-96A3-4024-AD0F-11F538C15CD8">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E1886B6-CFA6-4827-AF3E-32E389AAB4EE">
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7219E9E0-E71A-4856-B7FE-4BA931BE73F9">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B485ED7B-BCFB-44A3-B4A6-64CF3AF7C9EC">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3103F10-24BD-4D8C-B3B5-A693D0B395FB">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B77F44DE-40DB-4957-BD7D-3ED4CA6D72F5">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA3A4774-635D-49BF-9DDC-7764D0C66B8C">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACODYNAMICS (43681-6)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PHARMACODYNAMICS (43681-6)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E451B2B0-3965-44FB-ACC3-9E1A4D507002">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3709E118-E5ED-4FB3-8F78-E7B3B21623A1">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:779A75BC-3578-4F79-AFEC-3C7B452E7702">
    <domeo:uuid>779A75BC-3578-4F79-AFEC-3C7B452E7702</domeo:uuid>
    <pav:createdOn>2014-03-23 22:50:00 -0400</pav:createdOn>
    <ao:prefix>Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management.  </ao:prefix>
    <ao:exact>Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:779A75BC-3578-4F79-AFEC-3C7B452E7702"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BA7FC0EB-CC0B-4BAF-AB43-9B0891F108E6">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACODYNAMICS (43681-6)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACODYNAMICS (43681-6)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:282D104C-466A-4CE5-8FA9-546A361584DC">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:889BA00F-054D-43A9-871A-0E03E9B68495">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0776293A-51D5-419D-A524-F0AAA3469606">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>ADVERSE REACTIONS (34084-4)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ADVERSE REACTIONS (34084-4)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12275577-E2AA-4E41-8B90-7B1D504B3D24">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E233EFBB-BE1A-4A47-BDA4-CAD0F2126F85">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E05813B-89A7-429B-A67F-CAE10B8149F8">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D65A920-FF32-4C4C-8F35-AF6B9564CDD6">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EB3831F-DA33-47DE-AC71-370EA008DAA6">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73668546-B71F-44AD-B671-B2C5615BEC52">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DA5E8D8-9463-4EE8-A179-6E159F87E2FB">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34632956-EFD5-4868-9645-10BE8C5079C7">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2F468D5-EE6C-4455-8951-2215E73790FF">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92643846-E3C1-46F6-B186-CCB55C1B5A44">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D745F3D-0A70-48CD-B388-ED820D7DD5CA">
    <ao:exact>Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity. The role of other possible factors in the development of, and </ao:suffix>
    <pav:createdOn>2014-03-23 22:47:47 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0D745F3D-0A70-48CD-B388-ED820D7DD5CA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D745F3D-0A70-48CD-B388-ED820D7DD5CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:800112AC-0255-439F-B416-140D248BF624">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6137586E-97D7-4E43-92B7-C9C1CC84BBCD">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A31F3D83-D048-48ED-A4C9-D15A08D4343E">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA0483FA-0F2B-4BAF-8935-653EF7FF4E7A">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE6F9C06-B63E-417E-ACD0-A59B0522D2D2">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2330D2BD-123B-4912-9434-994B9B2130A1">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:836CED62-9EDB-4171-95B0-A8D6A56CC603">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Do not restart</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11843243-10AF-4894-A86B-8D585A2A2B67">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DBB4339-D188-4B25-BC32-0265176C1A6B">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7749190C-16B5-4A6B-8A34-DAD000CE4E93">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E92EDE5E-8982-4447-B421-C0B37D5E5F6D">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:961D27CE-41BD-4A30-97DB-4AB3ACE087FD">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B79CFED-63F4-434E-BB20-DA216CBE3868">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63A402CC-99C0-4136-897E-D434A9435D54">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8865A4EA-F8C3-487B-9A08-6A503CAF8AD1">
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <rdfs:label>Not Important</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:867504A6-7ABB-4807-943D-9EC28BADF976">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD3F6ECA-B488-48BE-B3C6-EF23440E5B29">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7745A9CF-9213-4A18-B669-937847EED031">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D1C5202-0601-4F9A-9DC6-B2B97C1B39D3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37586183-FFBE-4F75-9FCC-E87B8D32F621">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F13C1A69-A91E-4FAD-A0F4-29E21F534116">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE224250-659D-4170-907A-8D249877F63C">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71974930-ABE4-4AAF-B76A-38A31FBED2E6">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A5D3758-F5AD-4A20-B94F-4862742E3623">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1D2BA00-6FB3-4FDD-9145-5F8E591BED5B">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A058F7BB-F374-4988-B9F1-7F5FB7E17CA4">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C2C3EA2-0486-47C5-BE50-B03439581C02">
    <poc:Comment>increased metabolism?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D15E0D1-9C28-416A-BD1F-7E1AEB24CAE5">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D94D39C-501C-47E1-8CF9-F788442BA615">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AE9F0E0-58FA-4F77-919F-662A85A02955">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>8AE9F0E0-58FA-4F77-919F-662A85A02955</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8AE9F0E0-58FA-4F77-919F-662A85A02955"/>
    <ao:exact>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 21:42:19 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76177A39-EF26-4215-A832-10BCEDEF4339">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2911EA05-CD45-4AF8-ADA7-42A011B8C6D0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A70F20E4-D873-4719-9521-16E3B3424EF2">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C67EFA81-49F6-4EF5-93E4-0BED45C72E1C">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A1F2384-1CD1-451E-B358-C000A704B9BD">
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-12 21:58:07 -0400</pav:createdOn>
    <ao:suffix> Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this oc</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A1F2384-1CD1-451E-B358-C000A704B9BD"/>
    <domeo:uuid>1A1F2384-1CD1-451E-B358-C000A704B9BD</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA75B8A1-007D-4F41-AA9A-E0CDC23D187F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>variant frequency?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C7B3200-92DC-4018-B01F-3D7003545229">
    <rdfs:label>TPMT</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CCDC9ECA-E44E-42DF-AF7F-E5411C16DC2A">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA93A1E4-36C9-441D-8720-A70DDE11E21E">
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DA93A1E4-36C9-441D-8720-A70DDE11E21E"/>
    <pav:createdOn>2014-03-27 10:48:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>DA93A1E4-36C9-441D-8720-A70DDE11E21E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E2562EB-1990-4603-8CBA-E233D59F47BA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCCD39CC-CBBF-41CA-A3BA-13FD22957DFA">
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86F0DEEF-AECB-4A2B-9784-1289EC654904">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:98077F2B-3233-4414-96DA-DD8B43905C68">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FAEA418-D722-4F9C-AB66-27E29D27DDA1">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2011359-388E-4380-BCF3-97B5FC3103EE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B2B8818-4C64-4832-90CD-03ECFEF0663D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B2B8818-4C64-4832-90CD-03ECFEF0663D"/>
    <pav:createdOn>2014-03-12 22:03:19 -0400</pav:createdOn>
    <ao:exact>NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>9B2B8818-4C64-4832-90CD-03ECFEF0663D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>ZIAGEN is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products. </ao:prefix>
    <ao:suffix> </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F29EB7E4-5368-46FC-8E0A-46A8DEF367A5">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B5D3547B-1926-4032-B1B4-D244E5751B68">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B9D876B-77F0-4C9C-BBF2-78234A602501">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:707ABC3D-A9E5-4004-B1F7-238987AA4362">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E38DADF-AA16-4501-9E06-DA6B429E04B7">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CC74423-C0E9-4DA9-A5A6-8EFCF5514E1D">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:956437DF-3040-4FE4-990F-462538B4EE77">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8113A6AE-3066-4BEF-AFBE-1BC701359D66">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BEA71254-98F5-430C-B5BC-9F722A5A594C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9636BA00-5FDC-4143-A553-FD29374B54EB">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304488c4b70144896f4a03000b">
    <foafx:email>soa18@pitt.edu</foafx:email>
    <foafx:homepage></foafx:homepage>
    <foafx:title></foafx:title>
    <foafx:middlename></foafx:middlename>
    <foafx:firstname>Solomon</foafx:firstname>
    <foafx:lastname>Adams</foafx:lastname>
    <foafx:name>Solomon</foafx:name>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <rdfs:label>Solomon</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9718231-5945-4B15-8C90-921DFE7E3D2C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31A1AEB3-0B7F-4371-B1F8-7968A6A2E248">
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31A1AEB3-0B7F-4371-B1F8-7968A6A2E248"/>
    <pav:createdOn>2014-03-23 23:08:05 -0400</pav:createdOn>
    <domeo:uuid>31A1AEB3-0B7F-4371-B1F8-7968A6A2E248</domeo:uuid>
    <ao:suffix> TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine toxicity.</ao:suffix>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C07DC4A-D7D4-4794-98F8-D1AC6BE5E2CC">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:58308C5D-40B5-427A-AB8A-BA9B5B593ADB">
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3CE981CD-25A4-4DF6-8BE1-AFCBA04E8DED">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:038EA0E2-9123-4C73-842E-B160587A9E0E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:486733A1-6BA0-491D-87AC-EA70B14043DF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB123344-D0E1-4332-B0D4-235435FFC136">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD518DD0-6A46-4E66-8F74-EAE4BE00FAB1">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3868EF78-EF7D-4EFF-AB49-6E7DB38F6F2E">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7F5105A-3886-4258-9032-560D597BDDD1">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DC2D216-2846-40C1-9F8B-815262749C5D">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7A2A1B6-9673-4D0D-BD4C-7CCAAA827E9F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3ABF75A8-203E-4006-B94D-B6F3CF1F8F59">
    <poc:Comment>Which dose recommendation would you put for this? Should there be a maximum dosage option?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:69C362C5-50F2-4D7D-ADFC-E6728808C39C">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC17B331-41D8-4D1B-975F-741D01457414">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E88C833-D05A-4612-BC1C-98D7EFFAACC2">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63645902-B328-4BF8-8B60-49696594E010">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CC578C1-8D8B-4EBA-BCC3-B93A98F483BA">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43F28EB4-8E1D-4DBB-8693-0D88EE7B9300">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6A9B411-8766-4A42-BD9E-31003583997D">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CBCABF1-CAF5-41E9-9F27-45D414074DC8">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15787FE5-B5C9-4688-AB1D-03ED077E7105">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2011113-168F-413E-A516-232113392669">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25711254-2936-42CF-8E9B-834EFEC9FA6A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22BCAD85-AE77-42CE-B446-28BA6073EDFE">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67174681-E929-4017-8CEA-D035FD185AD8">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FBB31F9-83CD-4E77-9073-35E840CAFCDF">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-negative</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3dd939331bde43e9b7c5cda244c5568c">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3E8A7D1-B36B-4D9D-AD4F-3242EADD49DA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D96CC853-D926-47BA-97BD-9B17B70BF902">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F493414B-D92A-459B-B786-4BF1B6C58AA5">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0046B31A-AA6E-4C31-963B-68B292488255">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DDAE55F6-699E-4294-AA7F-4BA101D1D6FB">
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AED5E825-729C-49AB-9088-0729D06BE2BC">
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99E19EBA-2314-448D-B468-DBF684B5F431">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdfs:label>Influences Drug Response</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F3441C2-BD86-41C3-AB30-0F4CB875B7D8">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA8FF8BE-F672-48C5-9209-B024B62A5392">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A023B61-8BF0-43F9-AC73-B3F3AACE9784">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B36538E-8738-4833-B450-26480ECF3239">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:00B8B39E-D7C5-4DC8-950A-7B67FA0171AE">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75B308C9-1DDE-449E-8E9E-9A1D909FC01B">
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C906A701-35C0-4912-BDF3-E8D9DB230149">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0FB9521-F95D-4205-9790-F0FBE92C424E">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:606C1643-DAD6-437C-A543-80E713B209E7">
    <ao:exact>In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. </ao:exact>
    <ao:suffix>In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:606C1643-DAD6-437C-A543-80E713B209E7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-30 19:14:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EE9927F6-AE99-446B-95B8-07EBC7CE39A6">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DF8F2D5-9C7B-4654-933C-DEB4E366EC30">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B50E0C7-9351-486A-BEE3-2774F6C3F9D7">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>for this do I put \"increased metabolism\"?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E49C4E92-4E66-4887-B5CF-60F7720D7FE1">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A2E3C16-B3B7-4460-ABBF-BF584D1BD2FE">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:013EBECE-35C9-4801-BFEC-6845FCAC9991">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3440E38A-8370-4BF3-B18F-981603FA479F">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A658592-62AB-44EF-BFCD-8D705DC85D46">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E31F02A2-601C-4204-8531-9D8B22416115">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02939556-27CA-4F68-9D5D-AD83C90C45E9">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:073CA47F-0E8A-49C4-8B1B-4B1421F12204">
    <ao:prefix>PRECAUTIONS: Laboratory Tests ). </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:073CA47F-0E8A-49C4-8B1B-4B1421F12204"/>
    <ao:exact>Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.6, 20</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-23 23:20:53 -0400</pav:createdOn>
    <domeo:uuid>073CA47F-0E8A-49C4-8B1B-4B1421F12204</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17865789-0D97-46CA-9402-E55D941250EF">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84DD1FD1-E42A-43C2-9D8E-6E9C37BD8261">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76789731-3A9C-45DA-8843-ACA94A8CDA18">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations). </ao:exact>
    <pav:createdOn>2014-03-30 15:55:02 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76789731-3A9C-45DA-8843-ACA94A8CDA18"/>
    <domeo:uuid>76789731-3A9C-45DA-8843-ACA94A8CDA18</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2BE1635E-B9CE-4C51-A731-790AA39F83C6">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6661B3EA-4906-4AEE-9774-F80FB5627CE6">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7BF5B4BF-B41E-43F1-A9D3-83F0F65FCD2C">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1513CF2D-BE0A-4DBC-926F-9A403B338997">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:409A0EC3-91FB-4548-B12E-4379B334BE2A">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFB13D4F-63B0-40C5-A399-66F052E22AAE">
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D5B943A-FE80-4DFE-8467-184C4E893E6E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Citalopram</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99700CC4-EF0E-4A67-9AD5-BA2ED9EFC69D">
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D74ABAC-F090-4CCA-8C7C-5882C46A78A0">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:596830B0-09FF-4D47-81E1-C30F46C57CC3">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23A80618-FAB9-4C98-974A-150C4101638B">
    <poc:Comment>common test?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:728B9736-5D26-48F1-B198-1DD51E41BB71">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to increase the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#increase-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increase from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35FFE6EE-42B3-44BE-A6E6-F07D9CE93269">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:778B723C-CA30-4BEE-83B7-80E367D33A16">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79086F7C-0C84-42C9-88CD-ADFABE0C30D8">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A8F9E98-ECE1-41F5-A856-B776F13FFA28">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7723C32-768B-4638-901B-E74A49E52861">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, death, children</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B8DF96B-B8D5-4EA2-8036-D03F02D2355B">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not change the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-change-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Not change from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44B18BB4-6F45-47F5-9C2C-BBFD4EC22E1F">
    <domeo:uuid>44B18BB4-6F45-47F5-9C2C-BBFD4EC22E1F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:44B18BB4-6F45-47F5-9C2C-BBFD4EC22E1F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-27 10:42:15 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix>Tests are available to determine a patients CYP2C19 genotype. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1354CA00-8626-4D27-8326-A2115FF610EF">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E570B0B-90CB-4961-B047-C8CFCC31CDA7">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:023D8024-462D-4E33-B5D1-A599FEB0376B">
    <ao:prefix>). Women should understand that tamoxifen reduces the incidence of breast cancer, but may not eliminate risk. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:023D8024-462D-4E33-B5D1-A599FEB0376B"/>
    <pav:createdOn>2014-03-30 18:52:38 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>In women with breast cancer who are at high risk of developing a second breast cancer, treatment with about 5 years of tamoxifen reduced the annual incidence rate of a second breast cancer by approximately 50%.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41057BDC-9E04-4AA3-8D2B-8830E9C8B224">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFDBBDAE-1D40-4207-988F-1E8CEC5ADA04">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB6B0982-F98C-42A9-AAB9-766CDE733D95">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6DAFA0F-668E-4B88-8228-5995DD84BE45">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47D9C3E0-B89C-4044-90BB-A66E914CD510">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to change schedule of the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#change-schedule</poc:DoseSelectionRecommendation>
    <rdfs:label>Change schedule</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B970845-802E-4040-B226-6A4F84B3B6B3">
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D53E7120-15FF-43EA-88CD-3DCF494C6FA8">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1FDB7FD4-1D65-46B5-BBE4-C3B05E5E33D4">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B42F7EE8-0929-4231-B90D-91E0563C291A">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C33376C6-0F22-4FC3-BDC1-75F9EAC71E8E">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:144D94CA-9F40-4777-95A3-126DC102C392">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC7B1068-9C54-42CB-8C5A-5F06348CA7E0">
    <pav:createdOn>2014-03-23 23:04:50 -0400</pav:createdOn>
    <ao:suffix>.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC7B1068-9C54-42CB-8C5A-5F06348CA7E0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine tablets toxicity</ao:exact>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>AC7B1068-9C54-42CB-8C5A-5F06348CA7E0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F127DBE1-AECA-4EBD-BEDC-B186666741B2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 00:25:13 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F127DBE1-AECA-4EBD-BEDC-B186666741B2"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. </ao:prefix>
    <ao:suffix>4</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3188E338-4D81-45E2-84ED-62B3E2B919FE">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41CA07A6-5DC7-4979-B5AD-D8CC432BB53A">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E66DD791-87AB-4AB2-B709-27A9BBBF164C">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EF29D93-B708-4334-ABE0-A4F504F693F9">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2731F988-3D22-4BE5-BA62-612B8D82EDC0">
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdfs:label>Active ingredient</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E12C5B6A-3DE2-4521-9520-42C37C001E45">
    <poc:Comment>does this need to be included?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F33C064-B479-48A7-A720-889DB228A5DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>cardiovascular events</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:788C7BFA-6591-4F63-AF9A-F32923B3F607">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFF70BB3-364D-4F0B-A650-39E747F36865">
    <rdfs:label>Variant Frequency</rdfs:label>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93C75643-30C8-4C8E-AA08-9A2B680DDA42">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E90D65C1-2D90-48F7-9F22-70B93BC1BBEC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>antiplatelet effect</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N87406ff91d6c40b6814c0871287a9d1b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304488c4b70144896ed8340009">
    <foafx:lastname>Hatfield</foafx:lastname>
    <foafx:email>jocelyn.hatfield1@gmail.com</foafx:email>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:name>JHatfield</foafx:name>
    <foafx:homepage></foafx:homepage>
    <foafx:firstname>Jocelyn</foafx:firstname>
    <foafx:middlename></foafx:middlename>
    <rdfs:label>JHatfield</rdfs:label>
    <foafx:title></foafx:title>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A24B4BD-71F9-4C85-91C8-68977D97EE7C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A24B4BD-71F9-4C85-91C8-68977D97EE7C"/>
    <ao:exact>Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:prefix>Risk Factor: HLA-B*5701 Allele: </ao:prefix>
    <pav:createdOn>2014-03-12 22:22:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>7A24B4BD-71F9-4C85-91C8-68977D97EE7C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2516D51-A8BA-4F05-A78F-85A211CAA64B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2516D51-A8BA-4F05-A78F-85A211CAA64B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity. </ao:exact>
    <ao:prefix>Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management.</ao:prefix>
    <ao:suffix>The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-23 22:49:31 -0400</pav:createdOn>
    <domeo:uuid>E2516D51-A8BA-4F05-A78F-85A211CAA64B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B75A80E7-D1B1-4675-A99F-65B4AA23350D">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0100E1EA-4B4A-49F7-8DB7-CE39B674E1E2">
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DDC681A-DB01-49D7-B458-D786189DBB9B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E1887DB-4AF3-49DE-B671-FFED33AC1CA4">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17A4C600-0031-4012-AC56-A12A2EC258C8">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BE8E2286-2A71-43A3-A53C-2F9835FEF5AF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DB3914B0-920D-4BB8-BE3D-B1474CF1D742">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45852E19-6CB3-4CA9-9184-70C6AC3C69C7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>45852E19-6CB3-4CA9-9184-70C6AC3C69C7</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision-making. Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <pav:createdOn>2014-03-12 22:34:00 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45852E19-6CB3-4CA9-9184-70C6AC3C69C7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B7CA02F-D5F1-4AD1-A65E-439F0110A551">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B4911D1-56E8-4B2A-8335-405058290C2A">
    <poc:Comment>"patient counseling information" was not an option for product label section</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:136F1ABC-4E79-49AD-8691-BDD39E57A389">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:452CA95B-AEA0-4A47-B68B-350DA5AC0EAE">
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CB7A7AB-C4A2-4F49-BA72-C2CBE6061EC7">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAD2B35D-163E-419F-B2EA-3B98760DD126">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C99B7E72-BC6C-429E-B54E-F58DBB5C3903">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E8DC4674-2320-4409-B0D8-80574FE4D66F">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>the drug selection recommendation - do not start?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D29BBA81-587C-4066-A8FA-C57C38744BA3">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>VKORC1</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1119FEA-97C4-46A8-8C03-E94BAA75260C">
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:862BA8E2-37C8-4442-9603-AF9D3E73A392">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04978929-DE66-4543-ACD5-7B06C546BCCB">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B83BEC0-9ABD-44DA-8D0A-26030CBADF97">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F159A80-7154-48D0-AB6C-AC0DDDF0450F">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD3208DF-A261-472A-97A1-78D5792AFDDC">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3664A3E-9D5A-4E8E-9997-2C0DED6F5D13">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DF1D6D8-CC00-4DF0-A2B6-58A4CBFA43C0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-23 22:40:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4DF1D6D8-CC00-4DF0-A2B6-58A4CBFA43C0"/>
    <ao:exact>Prior to initiating Carbamazepine Extended-Release Capsule therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN</ao:suffix>
    <domeo:uuid>4DF1D6D8-CC00-4DF0-A2B6-58A4CBFA43C0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD94466E-133D-49B6-84D9-2999ABE63B60">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2522303D-646C-4F04-A668-FD71235C52A8">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0852753-C453-4D54-8268-55AB9F253C00">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCC01BA5-BC38-4C8E-8A10-B71D0F2CCE0D">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C79CC1E-2262-4D1D-B150-4B843A861447">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>What is the most important information I should know about using tamoxifen citrate tablets to reduce the chance of getting breast cancer? </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:exact>Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive).</ao:exact>
    <domeo:uuid>6C79CC1E-2262-4D1D-B150-4B843A861447</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C79CC1E-2262-4D1D-B150-4B843A861447"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-31 00:15:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF97874C-5EC7-4634-9036-AF1C3649F70C">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7824CDF8-8A94-4F90-A1C9-6FFA824306EC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37857CA7-CAD2-4A41-A631-ED256FBC6730">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE1ABD7A-663C-436B-B453-26D0B8B247BB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EFC360B-1844-43A3-BB0A-FEF39DA7EFE7">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E8536C3-4448-44A0-9F07-4C6FAF1FC04C">
    <rdfs:label>ultra-metabolizer-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ultra-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DBF5359-44E3-40EA-B543-3B6B08596B90">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC2B1229-C8D7-4C50-B02A-D3281A5E23EC">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CD80D8B-3673-4762-A7C2-01D1213A54DF">
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85BFB4E3-C9F4-4052-864D-F001F2FC8FC8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C53092CA-7954-46B8-992B-8188F5CAA62B">
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:732E44A6-1AD6-4925-924A-8FA8916B6596">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B577C610-90E5-496F-AFCD-90598AB6CCF3">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6BA9C8A7-269D-49A9-BAB3-9246EC99DFF9">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9273B928-3A29-4E2B-AE1B-219844D85529">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:325318F6-72EA-4720-B75B-B2013DE40BEF">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DA4418B-534C-4739-93B9-E421A573D716">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:246F2575-7478-48D5-8EEC-D25E51E76525">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F19C0C0-60AC-49D7-8A49-6E7C501551D9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4FEBAD46-F23E-4737-A7D1-4B5D71E19C65">
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7800986F-0069-4198-97DE-02885EFD2108">
    <rdfs:label>biomarker-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-negative</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0792F9C9-EBCB-4031-ACFC-1FF971EE10E4">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C31AAB9-8A63-4151-AC01-1F670DA758B2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F1872F36-CC24-4F65-9CE7-B0620A278F06">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FF71FA61-D321-4445-BCC0-D53E204784F5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3AF7DCB-3E76-47B2-B616-7C19FA8EA8C2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A675A1D-6B1D-49EA-94BE-14512EB4982D">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3200C38C-1119-4176-AB7C-1B9BEE06A1BA">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF2117DF-21A4-4ADC-B0D9-84511F0980DF">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1FD15233-0A4C-4B26-AC9D-E396ABBA1EF8">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:71AC6136-3775-476F-B9DC-5EDE88B06C69">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A932CF6A-ED49-416F-A4DE-C90B70DF4C3A">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45C86EFF-A82C-44D4-BACF-ED78D97FFB8E">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6B11192-9E06-4504-B6CB-A327A2D39237">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A6B11192-9E06-4504-B6CB-A327A2D39237</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A6B11192-9E06-4504-B6CB-A327A2D39237"/>
    <pav:createdOn>2014-03-12 21:59:42 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:81204B81-8A33-4CC1-905B-5603AE8079F2">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AF9FE8E3-05BD-4AED-AD3E-62E34CB10483">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6CB6229E-1E4F-449B-9554-9CF228CE9897">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65F81D64-E8F8-45B4-86EF-7D605DDAE0C0">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A91D95F-9747-4CAA-88D8-F00BCB181669">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DB04C01-D293-476A-98CF-50A111D3CA0A">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F92EF60E-B7C4-4838-89FB-5CA1589213DD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Your doctor can determine with a blood test if you have this gene variation. If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your doctor right away to determine if you should stop taking this medicine.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F92EF60E-B7C4-4838-89FB-5CA1589213DD"/>
    <pav:createdOn>2014-03-12 22:39:49 -0400</pav:createdOn>
    <ao:exact>Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not.</ao:exact>
    <domeo:uuid>F92EF60E-B7C4-4838-89FB-5CA1589213DD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45FF903A-9D80-490B-9F9E-96C737238B01">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E1B62F6D-4BAD-43EC-AA3E-9CDB6BE4974F">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84BD35A8-B525-428D-BD81-E61430127763">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3368ED4-4551-49AF-9456-74CC54095451">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5076A504-0ADA-4FB6-9A8C-C39E2F39CCFA">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:618270FD-ED78-48C1-9636-6DC7186B5690">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDF86D06-5D86-4A24-B735-9654D43B539A">
    <ao:exact>PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs.</ao:exact>
    <pav:createdOn>2014-03-19 21:14:28 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDF86D06-5D86-4A24-B735-9654D43B539A"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:921E865E-412B-44C0-8B67-4CA256EE7B79">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>What do you put for the dose recommendation for this?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:325798BD-BBA0-4B40-83B0-547B7A7DFDBE">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <rdfs:label>biomarker-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2577D553-4C25-4FA8-84E8-91352E42DAA2">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D7D7BC8-2E63-48AD-8509-C7BE5642E054">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BB5ED28-B673-4D69-B617-5F61F5FCBA86">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>would this be considered an increased risk for cardiovascular events (increased risk of toxicity) or a decreased efficacy for clopidogrel?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E47C0246-9B6A-4BE6-A5D8-2ADB3920C394">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A4F2C04-BC76-44CD-ADC9-608CE2F78EF8">
    <poc:Comment>Do I need to annotate this statement all 3 times that it appears?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A27E1A90-B157-4865-B947-2A183E033C99">
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:exact>
    <domeo:uuid>A27E1A90-B157-4865-B947-2A183E033C99</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A27E1A90-B157-4865-B947-2A183E033C99"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-27 10:51:53 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:prefix>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4302688-2092-43B3-AA5A-F2E208E250B8">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B20082CE-01BC-44A8-985B-0F57BFABA0D6">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D14B40C5-DF6B-4C2E-B170-55DA97B006B7">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5C1C020-584D-4069-938C-C9B2CC74B11F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:690C2D4F-B411-4529-857F-F8A02AD2E01A">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC8E662A-ABD6-44F4-8617-BA9657A07052">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:42949B72-C46C-41D1-BB9F-6F1BE36FC1CC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#biomarker-positive</poc:TestResult>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>biomarker-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6BB7CF66-561C-4673-8E2F-375B1E3B74A6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>In reference to the sentence following this statement, I felt that they were two different concepts - one for initial testing recommendations and one for future use of the medication</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDA03699-F77F-466E-A772-BFFA6C8B10C9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B03D7253-6A76-4467-B47F-E92D34EB9AAD">
    <rdfs:label>Active ingredient</rdfs:label>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <dct:description>the ingredient is active</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39B9A890-B732-492A-85D7-C41E977B1DAA">
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E606700-7100-4166-9850-4DAA22B9170F">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B8B1579-F063-42F2-83B1-1268058A3F61">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33396A7B-7788-40EE-A253-C1DC4F6EC99F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>"do not change" options?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:820E9B4E-C9A0-4B1E-A63D-CAB5BD6E8691">
    <poc:Comment>common test?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31DDCF59-C246-4EDF-838D-55611368AC08">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer-positive</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4291BE1-56DA-46A3-A7C7-B631356E7161">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53A6904A-3840-4524-8624-532F21C25931">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD16448A-D811-436E-90B4-1314DD5EE343">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:487D741C-420F-44BB-9630-7C87B524E7AB">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6BE8321D-0997-4EBE-A6D4-A87074093194">
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C89D4019-418C-4943-AD5B-C36183712B8C">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D0DAC74-2517-4016-97B3-A56B660D5725">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AB62BB7-0B45-4E4B-8C15-EC84CC50FFF8">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <rdfs:label>Required</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E6CFABA-58A9-4A7D-A950-377ED1252E26">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E7C51BE-DB9E-45B0-A83F-979A2530FB35">
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DCD89AF2-B008-4C18-9D5A-D61B8AEE8758">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D90A368-545D-414B-99DA-10D2ECADC69F">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACODYNAMICS (43681-6)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACODYNAMICS (43681-6)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E657DE6-AA97-4703-94A4-D6485AA96305">
    <poc:MedicalCondition>allergic reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78097B37-4F55-49BB-8291-119FFCF8AF9A">
    <rdfs:label>Active ingredient</rdfs:label>
    <dct:description>the ingredient is active</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE4B51C9-1AD0-4EBD-A7AA-AAF9B7DE763B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9a600db1ef4941f2ad8b74f810249d03">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4752C6A1-5248-4069-B5CF-E5B8F0B04D06">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC1272E7-640E-45DA-A208-1C0F5533FFC6">
    <rdfs:label>Required</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2BAF4E44-2796-4A98-950E-2691827FB70A">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABCBD09F-85BF-4BF3-91EC-46AF1E0C5138">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>I know we discussed lactation at some point, not sure if we need to put anything special for this?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DE4C453E-9913-4FCC-98D5-0EA5752E0708">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E3B858D-9FE9-432E-95A0-BC9B20DA4518">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAD10DE2-A5E4-4CDE-8CE2-64E7360405E3">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACAD811C-4E46-4519-B0D8-606D5F6E45E1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A2E65A8-DD6F-4EA5-9179-89D3C3FF6D24">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D287D6D4-7617-42AE-A23C-D17A2C4C821B">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07C6E7A3-1CB2-461E-A980-615D40033145">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBB15CB8-589E-4E27-BE01-618BEBBB10C4">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>does not specifically say a dose adjustment, but mentions one is needed. What do you classify \"increased exposure\" as?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:322DB33A-5FE9-4090-A4F4-AF7D9F0CA353">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3B6F6AF-F39A-4973-AAE2-62E73052FC26">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFA0A017-B8C1-4C7D-813C-C4D6120AE197">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC5A6BAE-E33A-4DAA-953F-5CA43B787BAA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59DCB93D-9954-485F-9FB4-DC47DF63B223">
    <poc:Comment>unsure what to pick on this one</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F53E35E3-55A2-423B-9B4C-B9508AFC99AC">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA338C65-023A-4DF3-9861-460867992280">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABC6BFA8-4207-49FE-85B6-9FE50E4520BA">
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93EF6BAD-056C-4AE1-AEAB-83F8040CD49B">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E985AC8-9A88-40D7-A012-AFA0FC6406F1">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5818DE13-3D3B-4F6D-841B-8FD479A495D3">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:538B3F97-9F0A-47A0-9698-0BDB93EA4B56">
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:79F24D76-A347-4895-92BE-138F73B4EAAB">
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4A62C9A-7549-47D5-901B-7AC12A8D56C6">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, signs of overdose</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A4274FC-E56A-4CF3-B0FF-E69ACB8124B2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>over anticoagulation</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7E852A78-D3F8-4F48-8A4D-41A29F73D1B6">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8B969AF7-491B-4B0D-9C3C-CADF2A313CEB">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1F50A29-97CC-4FC8-A54B-251FF1B764DE">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25714122-A100-41FA-A271-CDB397B2F724">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8D396288-1083-42F4-8DF4-9C2B4AB160F8">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6608012D-FFE0-43FE-9B53-D87FF742DA15">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45F4C49F-7B05-45AF-B153-2100A704B41B">
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C6DC8650-91F3-4632-8727-D3702E6B25F2">
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>variant frequency?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:538B2F4A-897C-4A44-8C33-A24931EF4DF3">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, sleepiness, confusion, shallow breathing</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06F19C1D-3E4D-4FA6-A0FC-C0438057697A">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3DB59308-0DA5-43B2-AB10-BBDA20214B95">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4BAF798F-3FAD-4BB4-9D75-C54CFE661124">
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D16B2F1-AD53-4D24-A8A8-9EA6B5C367F0">
    <poc:Comment>correct test?</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EA69C57-425F-4C6A-A016-1DC64995AF70">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>do not start rather than do not restart?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F5ED18C-4FC6-4AFC-88A6-BE6BC0AA6707">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>hypersensitivity reaction</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2EEA099D-D8B1-463E-87E7-217E9570590D">
    <poc:MedicalCondition>death, respiratory depression</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DA3556D-0B0F-4C8C-9B4A-67DB213F491A">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8063BEAE-A3F9-454B-8BEA-B26256A49C16">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N78667a75e26e4c4eb8010f105e332a7b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A6CEDFE-8C79-4F5D-BC54-2F83332F9C10">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0F8DDB5-4732-4500-BE21-9C24A2605993">
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>common test?</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1367DE2A-8326-49F9-9C1B-9E60BAA5BC9C">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB0210B8-B6B5-4614-A7DD-D27606B343D5">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F4325C3-D6AE-49C2-A3CD-57FB5A2A47F9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>Does this statement need annotated twice?</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52349D35-C9A9-40FB-9457-C4D015E71E78">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>death, nursing mother</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACA8B7C8-6D94-4D8A-BF8A-A073813D2766">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cardiovascular events</poc:MedicalCondition>
  </rdf:Description>
</rdf:RDF>
